sertraline profile

Sertraline is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It is used to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder, and social anxiety disorder. Sertraline works by increasing the levels of serotonin in the brain. Serotonin is a neurotransmitter that plays a role in regulating mood, sleep, appetite, and other functions. Sertraline is typically taken once daily. It can take several weeks for the full effects of sertraline to be felt. Common side effects include nausea, headache, diarrhea, dizziness, and sexual dysfunction. Sertraline is a prescription medication and should only be taken under the supervision of a doctor. It is important to talk to your doctor about any potential side effects or interactions with other medications before taking sertraline. Sertraline is one of the most widely prescribed antidepressants, and it is generally considered to be safe and effective. However, it is important to talk to your doctor about your individual needs and potential risks before taking sertraline.'

Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	68617
CHEMBL ID	809
CHEBI ID	9123
SCHEMBL ID	28701
MeSH ID	M0029930

Synonym
AC-15639
BIDD:GT0768
BIDD:PXR0193
BRD-K82036761-003-02-1
REGID_FOR_CID_68617
BPBIO1_001285
PRESTWICK3_001014
(1s,4s)-4-(3,4-dichlorophenyl)-n-methyl-tetralin-1-amine
CHEBI:9123 ,
(1s,4s)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
cis-(+)-sertraline
cp 51974
(1s-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-n-methyl-1-naphthalenamine
(+)-sertraline
(1s,4s)-sertraline
sertralinum
sertralina
1-naphthalenamine, 1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-n-methyl-, (1s-cis)-
brn 5753709
sertraline [inn:ban]
sertralina [spanish]
sertralinum [latin]
1-naphthalenamine,1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-n-methyl-, (1s-cis)-
c17h17cl2n
hsdb 7037
BSPBIO_002698
BSPBIO_001167
AB00514002
79617-96-2
C07246
sertraline
DB01104
sertraline (inn)
D02360
NCGC00092386-04
KBIO3_001918
KBIOGR_001724
SPECTRUM4_001232
SPBIO_000385
SPECTRUM3_001079
SPECTRUM2_000493
NCGC00092386-05
NCGC00092386-07
NCGC00092386-08
NCGC00092386-06
MLS001195647
smr000596516
tba-2010_sertraline_1
SRE ,
NCGC00092386-09
CHEMBL809 ,
MLS002222308
bdbm50028094
A839725
NCGC00092386-10
HMS2098K09
1-naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-, (1s,4s)-
unii-quc7nx6wmb
quc7nx6wmb ,
HMS2231I09
FT-0630872
gtpl4798
cp-519741
sertraline [who-dd]
sertraline [mi]
sertraline [inn]
sertraline [hsdb]
sertraline [vandf]
CCG-221014
SCHEMBL28701
[(1s,4s)-4-(3,4-dichlorophenyl)tetralin-1-yl]-methyl-amine;hydrochloride
bdbm79021
ncgc00092386
cid_63009
(1s,4s)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride
(1s-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-naphthalenamine
AB00514002_18
AB00514002_17
DTXSID6023577 ,
sr-01000759296
SR-01000759296-5
sertraline; 1-naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-, (1s-cis)-; (+)-sertraline; (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthalenamine; (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napht
SBI-0206734.P001
HMS3715K09
cp-51974
NCGC00092386-12
Q407617
219736-80-8
syn-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
BRD-K82036761-003-07-0
BRD-K82036761-003-20-3
SDCCGSBI-0206734.P002
NCGC00092386-27
AKOS016842914
EN300-150167
dtxcid203577
n06ab06
sertralinum (latin)

Excerpt	Reference	Relevance
"Sertraline is a selective serotonin reuptake inhibitor with specific indications in child and adolescent psychiatry. "	( Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. Antony, G; Banaschewski, T; Briegel, W; Correll, CU; Egberts, KM; Fekete, S; Fleischhaker, C; Gerlach, M; Hellenschmidt, T; Heuschmann, P; Imgart, H; Kaess, M; Karwautz, A; Kölch, M; Malzahn, U; Plener, PL; Reitzle, K; Renner, T; Reuter-Dang, SY; Rexroth, C; Rock, H; Romanos, M; Scherf-Clavel, M; Schulte-Körne, G; Smigielski, L; Taurines, R; Theisen, F; Tini, E; Unterecker, S; Walitza, S; Wewetzer, C, 2022)	2.45
"Sertraline is a commonly used SSRI antidepressant drug, metabolized by CYP2C19 and CYP2B6, that exhibits a substantial interindividual variation in clinical response, of which only a part can be attributed to known genetic variants. "	( Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population. Bråten, LS; Ingelman-Sundberg, M; Jukic, MM; Kringen, MK; Molden, E, 2022)	2.4
"Sertraline (SER) is an antidepressant and curcumin (CUR) is a natural compound with many properties."	( The effects of curcumin and sertraline on stress-induced changes in the stomach tissues of rats. Karbalay-Doust, S; Noorafshan, A; Owrang, M; Rafati, A, 2023)	1.93
"Sertraline is a selective serotonin reuptake inhibitor and a common first-line medication for the treatment of depression in adults."	( Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial. Al-Janabi, H; Au, P; Barnes, NM; Barnes, TRE; Birchwood, M; Drake, R; Giacco, D; Griffiths, SL; Husain, N; Katshu, MZUH; Major, B; Marriott, C; Ottridge, R; Palmer, ER; Patel, S; Sadiq, Z; Taylor, E; Tearne, S; Upthegrove, R; Walters, JTR; Watkins, B; Weetman, T; Woolley, R, 2023)	1.63
"Sertraline is an environmental pollutant which received magnified scientific attention due to its global presence in waters. "	( Aggression repeatability in stressed fish in response to an environmental concentration of sertraline and lunar cycle as evidenced by brain metabolomics. Douda, K; Grabic, R; Grabicová, K; Horký, P; Hubená, P; Randák, T; Slavík, O, 2023)	2.57
"Sertraline is an antidepressant medication used extensively in the therapy of depression. "	( The preventive role of wheat germ oil against sertraline-induced testicular damage in male albino rats. Hamdi, H, 2019)	2.21
"Sertraline is an (SSRI-)antidepressant metabolized by the polymorphic CYP2C19 enzyme. "	( Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Bråten, LS; Haslemo, T; Ingelman-Sundberg, M; Jukic, MM; Kringen, MK; Molden, E, 2020)	2.29
"Sertraline is an antidepressant drug that has been frequently reported in the aquatic environment and biota. "	( Determination and photodegradation of sertraline residues in aqueous environment. Gornik, T; Heath, E; Kosjek, T; Roskar, R; Trontelj, J; Vione, D; Vozic, A; Zigon, D, 2020)	2.27
"Sertraline is an antidepressant with in vitro and in vivo antifungal properties which has been recently studied as an adjuvant in the treatment of invasive infections."	( Evaluation of the expanding spectrum of sertraline against uncommon fungal pathogens. Andrade, A; Bodden-Mendoza, BA; Espinosa-Mora, JE; González, GM; Martínez-Reséndez, MF; Treviño-Rangel, RJ; Villanueva-Lozano, H, 2020)	1.55
"Sertraline hydrochloride is a commonly prescribed antidepressant medication that acts by amplifying serotonin signaling. "	( Sertraline induces DNA damage and cellular toxicity in Drosophila that can be ameliorated by antioxidants. Donlon, C; Jajoo, A; Levin, M; McVey, M; Shnayder, S, 2020)	3.44
"Sertraline is a widely prescribed antidepressant and often concomitantly applied to address negative symptoms or depression."	( Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. Gründer, G; Haen, E; Hiemke, C; Kuzin, M; Paulzen, M; Ridders, F; Schoretsanitis, G, 2020)	1.53
"Sertraline is an antidepressant drug with anticancer properties."	( Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation. Park, SY; Seol, JW; Zinnah, KMA, 2020)	1.56
"Sertraline is a widely used antidepressant that becomes an aquatic pollutant through metabolic excretion and improper disposal. "	( Sertraline inhibits top-down forces (predation) in microbial food web and promotes nitrification in sediment. Li, Y; Miao, Y; Niu, L; Wang, L; Yang, N; Zhang, H; Zhang, W, 2020)	3.44
"Sertraline is a selective serotonin reuptake inhibitor which is often used as first-line treatment for depression. "	( [Sertraline-induced chronic eosinophilic pneumonia]. Brancaleone, P; Descamps, O; Detry, G; Mignon, M; Piquet, M; Weynand, B, 2021)	2.97
"Sertraline is a safe and effective agent frequently used in the treatment of childhood depression and obsessive compulsive disorder. "	( Sertraline-Induced Amotivationel Syndrome in a 12-Year-Old Girl: A Case Report. Karayagmurlu, A; Yildiz Bayindir, B, )	3.02
"Sertraline is a well-tolerated and effective choice for treating depression in women with polycystic ovary syndrome."	( Effect of sertraline on depression severity and prolactin levels in women with polycystic ovary syndrome: a placebo-controlled randomized trial. Akhondzadeh, S; Ansari, S; Esalatmanesh, S; Ghazizadeh-Hashemi, M; Hossein Rashidi, B; Kashani, L; Masoudi, M; Noorbala, AA; Tavolinejad, H, 2021)	1.75
"Sertraline is a reasonable first-line choice in patients with IHD and depression, whereas the role of citalopram as the first-line agent should be reconsidered."	( Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. Barbui, C; Caruso, R; Gastaldon, C; Grassi, L; Hotopf, M; Ostuzzi, G; Papola, D; Rayner, L; Turrini, G, 2019)	1.24
"Sertraline (SRT) is a modern and relatively safe selective serotonin reuptake inhibitor often used in the treatment of depression. "	( Sertraline - isolation methods and quantitation in biological material. Dziurkowska, E; Wesolowski, M, 2018)	3.37
"Sertraline (SRT) is an antidepressant that has proven its activity in vitro against Cryptococcus, Coccidioides, Trichosporon and other fungi. "	( In vitro inhibitory activity of sertraline against clinical isolates of Sporothrix schenckii. Bonifaz, A; González, GM; Hernández-Rodríguez, PA; Rojas, OC; Téllez-Marroquín, R; Treviño-Rangel, RJ; Villanueva-Lozano, H, )	1.86
"Sertraline is an antidepressant drug which has been reported to cause extrapyramidal symptoms."	( Brain and liver oxidative stress after sertraline and haloperidol treatment in mice. Abdel-Salam, OM; Khadrawy, YA; Sleem, AA; Youness, ER, 2013)	1.38
"Sertraline (Zoloft) is a selective serotonin reuptake inhibitor that is a commonly prescribed drug for the treatment of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, premenstrual dysphoric disorder and post-traumatic stress disorder. "	( Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims. Angier, MK; Johnson, RD; Lewis, RJ; Williamson, KS, 2013)	2.21
"Sertraline is a widely-used antidepressant that is one of the selective serotonin reuptake inhibitors. "	( Persistence and dissipation pathways of the antidepressant sertraline in agricultural soils. Li, H; Sumarah, MW; Topp, E, 2013)	2.08
"Sertraline is an apparent non-competitive inhibitor of hPAT1-mediated transport in vitro. "	( Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro. Abdulhadi, S; Brodin, B; Frølund, S; Holm, R; Kall, MA; Langthaler, L; Nielsen, CU; Nøhr, MK; Sari, H, 2013)	3.28
"Sertraline is a selective serotonin reuptake inhibitor and curcumin is the main ingredient of turmeric with neuroprotective effects."	( Curcumin and sertraline prevent the reduction of the number of neurons and glial cells and the volume of rats' medial prefrontal cortex induced by stress. Abdollahifar, MA; Asadi-Golshan, R; Karbalay-Doust, S; Noorafshan, A; Rashidian-Rashidabadi, A, 2014)	1.49
"Sertraline is a first-line drug for breastfeeding women due to documented low levels of exposure in breastfeeding infants and very few adverse events described in case reports."	( Sertraline and breastfeeding: review and meta-analysis. Bogen, DL; Ciolino, JD; Hoxha, D; Pinheiro, E; Wisner, KL, 2015)	2.58
"Sertraline is a selective serotonin reuptake inhibitor. "	( Hypoglycemic episodes in a case of Prementrual Dysphoric Disorder on sertraline. Banerjee, P; Chaudhuri, PR; Munshi, S; Santra Dhali, R, )	1.81
"Sertraline is a selective serotonin reuptake inhibitor used as an antidepressant and antipanic agent in children and adolescents. "	( Asynchronicity of Organic and Psychiatric Symptoms in a Case of Sertraline Intoxication. Baratta, A; Marciano, S; Minnei, M; Pasini, A; Pitzianti, M, )	1.81
"Sertraline is an effective drug in reducing this complaint possibly due to its effect on reducing inflammatory cytokines."	( Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hashemi, N; Malekmakan, L; Pakfetrat, M; Tadayon, T, 2018)	2.64
"Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) widely prescribed to patients suffering from psychiatric disorders. "	( Aquatic ecotoxicity of the selective serotonin reuptake inhibitor sertraline hydrochloride in a battery of freshwater test species. Davoren, M; Hernan, R; Lyng, FM; Minagh, E; O'Rourke, K, 2009)	2.03
"Sertraline is a selective serotonin reuptake inhibitor."	( Sertraline-associated hair loss. Ghanizadeh, A, 2008)	2.51
"Sertraline is a commonly prescribed selective serotonin reuptake inhibitor drug. "	( Sertraline hepatotoxicity: report of a case and review of the literature. Gunduz, F; Ozaras, R; Tabak, F; Tabak, O; Tahan, V, 2009)	3.24
"Sertraline is a widely used antidepressant belonging to the selective serotonin reuptake inhibitor class; its efficacy has been demonstrated not only in the treatment of major depression, obsessive compulsive and panic disorders, but also for eating, premenstrual dysphoric and post-traumatic stress disorders. "	( Analytical methodologies for the determination of sertraline. Bosch, ME; Ojeda, CB; Rojas, FS; Sánchez, AJ, 2008)	2.04
"Sertraline is a selective serotonin reuptake inhibitor (SSRI) prescribed as an antidepressant. "	( Assessment of the toxicological interaction of sertraline with cholinesterase inhibiting insecticides in aquatic insects using the black fly, Simulium vittatum IS-7. Armbrust, KL; Kellock, KA; Kwon, JW; Overmyer, JP; Smith, PF, 2010)	2.06
"Sertraline is a selective serotonin reuptake inhibitor with established safety for the treatment of depression. "	( Sinus arrest due to sertraline. Eksi Duran, N; Kocabay, G; Ozkan, M; Yildiz, M, 2010)	2.13
"Sertraline is a selective serotonin reuptake inhibitor that has been used and studied extensively throughout the world and found to be safe and well tolerated in numerous patient populations, including those with either psychiatric and/or medical comorbidities. "	( An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Kamijima, K; Sheehan, DV, 2009)	2.05
"Sertraline is a selective serotonin reuptake inhibitor, which is a commonly used drug for major depressive disorder. "	( Sertraline-induced ventricular tachycardia. Golwala, H; Patel, NH; Schechter, E; Stavrakis, S, )	3.02
"Sertraline (SRT) is a widely used antidepressant whose poor solubility in water limits its oral applicability. "	( Multi-equilibrium system based on sertraline and β-cyclodextrin supramolecular complex in aqueous solution. Barreto, EA; De Almeida, WB; De Sousa, FB; Lopes, JF; Lula, IS; Passos, JJ; Sinisterra, RD, 2011)	2.09
"Sertraline is a naphthalenamine derivative which has the effect of selective serotonin reuptake inhibition. "	( Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. Cho, JY; Jang, IJ; Kim, KP; Kim, TE; Park, MK; Shin, KH; Shin, SG; Yoon, SH; Yu, KS, 2011)	2.05
"Sertraline is a commonly prescribed selective inhibitor of serotonin uptake used for the treatment of mental depression and anxiety. "	( Sertraline concentrations and postmortem redistribution. Mallett, P; McIntyre, IM, 2012)	3.26
"Sertraline is a selective serotonin reuptake inhibitor (SSRI) with well established antidepressant and anxiolytic activity. "	( Spotlight on sertraline in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	2.13
"Sertraline is an effective and well tolerated antidepressant for the treatment of major depressive disorder in patients aged > or =60 years. "	( Spotlight on sertraline in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	2.13
"Sertraline is a naphthalenamine derivative with the predominant pharmacological action of inhibiting presynaptic reuptake of serotonin from the synaptic cleft. "	( Clinical pharmacokinetics of sertraline. DeVane, CL; Liston, HL; Markowitz, JS, 2002)	2.05
"Sertraline is a basic compound and of pharmaceutical application for antidepressant treatment. "	( Analytical method for the quantitation of sertraline hydrochloride stereoisomers by electrokinetic chromatography. Foley, JP; Zhou, MX, 2004)	2.03
"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is chemically unrelated to other SSRIs, tricyclic antidepressants, and other currently available antidepressant medications. "	( A sertraline-intoxicated driver. Goodson, LJ; Rohrig, TP, )	2.3
"Sertraline hydrochloride is a selective serotonin reuptake inhibitor with demonstrated efficacy and safety for the treatment of the following disorders: major depressive, obsessive-compulsive, panic, premenstrual dysphoric, social anxiety, and posttraumatic stress. "	( Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Alderman, J, 2005)	2.09
"Sertraline is an effective antidepressant for postmenopausal women with MDD. "	( Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. Altshuler, LL; Brunhuber, MV; Dunkin, J; Elman, S; Fairbanks, L; Rapkin, A; Rasgon, NL; Troung, C; Wroolie, TE, )	1.88
"Sertraline hydrochloride is a highly potent and selective inhibitor of serotonin (5HT). "	( Ab initio and density functional computations of the vibrational spectrum, molecular geometry and some molecular properties of the antidepressant drug sertraline (Zoloft) hydrochloride. Bayari, SH; Kandemirli, F; Sagdinc, S, 2007)	1.98
"Sertraline seems to be an effective, well-tolerated treatment for pruritus due to chronic liver disease. "	( Sertraline as a first-line treatment for cholestatic pruritus. Getachew, Y; Handem, I; Jacobe, H; Mayo, MJ; Rush, AJ; Saldana, S, 2007)	3.23
"Sertraline is an effective antidepressant acting as a selective serotonin reuptake inhibitor. "	( Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. Busto, U; Kaplan, HL; Sellers, EM; Zawertailo, LA, 1995)	2.02
"Sertraline is a highly specific, potent inhibitor of serotonin reuptake. "	( The role of sertraline in the management of depression. Shelton, RC, )	1.95
"Sertraline is a potent inhibitor of serotonin reuptake in the central nervous system and is used clinically to treat depression and obsessive-compulsive behavior. "	( Distribution of sertraline in postmortem cases. Jenkins, AJ; Levine, B; Smialek, JE, 1994)	2.08
"Sertraline is a new antidepressant that has potent and selective inhibition of neuronal serotonin reuptake."	( Sertraline intoxication in a child. Kaminski, CA; Robbins, MS; Weibley, RE, 1994)	2.45
"Sertraline is a serotonin reuptake inhibitor that has been approved for use in the treatment of depression. "	( Sertraline: a new antidepressant. Auster, R, 1993)	3.17
"Sertraline is an antidepressant which selectively inhibits the neuronal uptake of serotonin in the central nervous system. "	( Hemodialyzability of sertraline. Schwenk, MH; Verga, MA; Wagner, JD, 1995)	2.05
"Sertraline is an antidepressant for which preliminary data suggest a low inherent toxicity. "	( Analysis of sertraline-only overdoses. Anderson, B; Klein-Schwartz, W, 1996)	2.12
"Sertraline is a member of the newest class of antidepressants, the selective serotonin reuptake inhibitors. "	( Orthostatic hypotension induced by sertraline withdrawal. Amsden, GW; Georgian, F, )	1.85
"Sertraline is a serotonin reuptake inhibitor. "	( Influence of liver cirrhosis on sertraline pharmacokinetics. Angebaud, P; Coates, P; Démolis, JL; Funck-Brentano, C; Grangé, JD; Jaillon, P, 1996)	2.02
"Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity."	( Sertraline for the treatment of depression in Parkinson's disease. Hauser, RA; Zesiewicz, TA, 1997)	2.46
"Sertraline (Zoloft) is a selective serotonin reuptake inhibitor that is commonly used in adults in the treatment of mood and anxiety disorders. "	( Pediatric sertraline overdose. Catalano, G; Catalano, MC; Cooper, DS; Guttman, JM, )	1.98
"Sertraline appears to be a useful agent in the pharmacological treatment of premature ejaculation."	( Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. McMahon, CG, 1998)	2.01
"Sertraline is an effective and well-tolerated treatment for patients with panic disorder."	( Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Clary, CM; Pohl, RB; Wolkow, RM, 1998)	3.19
"Sertraline appears to be a useful agent in the pharmacological treatment of premature ejaculation."	( Treatment of premature ejaculation with sertraline hydrochloride. McMahon, CG, 1998)	2.01
"Sertraline is a selective serotonin reuptake inhibitor (SSRI) for which marketing approval has been obtained recently in Germany. "	( Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Arató, M; Bauer, H; Gallinat, J; Hegerl, U; Janka, Z; Möller, HJ; Pflug, B, 1998)	2
"Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder."	( Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. Biederman, J; Cook, EH; Cutler, NR; Dominguez, R; Ferguson, J; March, JS; Mardekian, J; Muller, B; Riesenberg, R; Rosenthal, M; Safferman, A; Sallee, FR; Steiner, H; Wagner, KD; Wolkow, R, 1998)	3.19
"Sertraline is a selective serotonin reuptake inhibitor that is approved by the U.S. "	( Sertraline-induced panic attacks. Catalano, G; Catalano, MC; Hakala, SM, )	3.02
"Sertraline is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. "	( The effect of sertraline on routine blood chemistry values. Catalano, G; Catalano, MC; Kanfer, SN; Stock, SL; Taylor, WD; Toner, LC, )	1.93
"Sertraline is an effective treatment for patients with generalized social phobia."	( Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Bowen, RC; Chokka, PR; Goldner, EM; Hadrava, V; Johnston, DG; Lane, RM; Lavallee, YJ; Nandy, S; Pecknold, JC; Swinson, RP; Van Ameringen , MA; Walker, JR, 2001)	3.2
"5. Sertraline was found to be a safe, well-tolerated, and effective as an antidepressant in elderly patients suffering from hypertension and other forms of vascular comorbidity."	( Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. Clary, CM; Doraiswamy, PM; Krishnan, KR, 2001)	1.02
"Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI), and is an effective antidepressant agent."	( Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Gurbel, PA; O'Connor, CM; Serebruany, VL, 2001)	1.34
"Sertraline is a widely used serotonin reuptake inhibitor that has been shown to have both antidepressant and antianxiety effects."	( The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. Born, L; MacQueen, G; Steiner, M, 2001)	1.29
"Sertraline is an effective treatment for generalised social phobia. "	( Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Blomhoff, S; Haug, TT; Hellström, K; Holme, I; Humble, M; Madsbu, HP; Wold, JE, 2001)	2.01
"Sertraline is a selective serotonin reuptake inhibitor (SSRI) and an effective antidepressant."	( Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. Hwang, O; Kim, SW; Park, SY, 2002)	1.26
"Sertraline is a selective serotonin reuptake inhibitor (SSRI) with well established antidepressant and anxiolytic activity. "	( Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	3.2
"Sertraline is an effective and well tolerated antidepressant for the treatment of major depressive disorder in patients aged > or =60 years. "	( Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	3.2
"Sertraline is a selective inhibitor of central serotonin reuptake. "	( Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. McTavish, D; Murdoch, D, 1992)	3.17
"Sertraline is a non-tricyclic, potent and selective serotonin reuptake inhibitor (SSRI) which is currently approved for the treatment of depression in several countries, including the UK and the USA. "	( Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Chouinard, G, 1992)	3.17
"Sertraline hydrochloride is a new naphthylamino compound that specifically blocks neuronal reuptake of serotonin. "	( Sertraline: a new specific serotonin reuptake blocker. Guthrie, SK, 1991)	3.17
"Sertraline is a new, selective serotonin (5HT) uptake inhibitor with antidepressant activity. "	( Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. Breeding, M; Knoth, K; Sanders-Bush, E; Tsutsumi, M, 1989)	3.16
"Sertraline is a member of a new class of psychotherapeutic agents that selectively inhibit serotonin reuptake in the brain. "	( Pharmacology of sertraline: a review. Heym, J; Koe, BK, 1988)	2.06

Excerpt	Reference	Relevance
"Sertraline has a low potential for drug interactions at the level of the cytochrome P450 enzyme system."	( Spotlight on sertraline in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	1.41
"Sertraline has a secondary amine group; therefore, we predicted that it may react with formalin to give N-methyl derivatives."	( Conversion of sertraline to N-methyl sertraline in embalming fluid: a forensic implication. Sai Prakash, PK; Suma, R, )	1.21
"Sertraline has a linear pharmacokinetic profile and a half-life of about 26 h."	( The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. Born, L; MacQueen, G; Steiner, M, 2001)	1.29
"Sertraline has a low potential for drug interactions at the level of the cytochrome P450 enzyme system."	( Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	2.48
"Sertraline has a proved efficacy in post-traumatic stress disorder (PTSD), but it is unknown which symptoms respond or in what sequence this occurs. "	( Characterizing the effects of sertraline in post-traumatic stress disorder. Clary, CM; Davidson, JR; Farfel, GM; Landerman, LR, 2002)	2.05
"Sertraline has been shown to ameliorate the effects of CMS-induced depression."	( Does Sertraline Affect Hypothalamic Food Intake Peptides in the Rat Experimental Model of Chronic Mild Stress-Induced Depression? Gormus, ZIS; Gunes, CE; Koca, RO; Kutlu, S; Solak, H, 2022)	1.96
"Sertraline has been shown to be effective in the treatment of depression. "	( Selection of the optimal dose of sertraline for depression: A dose-response meta-analysis of randomized controlled trials. Chen, Y; Li, J; Liu, Y; Luo, X; Ren, M; Si, T; Zhu, D, 2023)	2.63
"Sertraline has in vitro and in vivo activity against Cryptococcus and is synergistic with fluconazole in mice."	( Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. Bangdiwala, AS; Boulware, DR; Hullsiek, KH; Kirumira, P; Meya, DB; Nalintya, E; Naluyima, R; Namanda, S; Nikweri, Y; Rajasingham, R; Rutakingirwa, MK; Skipper, CP; Turya, F, 2020)	1.67
"Sertraline hydrochloride has low solubility and undergoes first-pass metabolism resulting in low bioavailability. "	( Preparation and Optimization of Sertraline Hydrochloride Tablets with Improved Dissolution Through Crystal Modification. Al-Nimry, SS; Jaber, MA, 2017)	2.18
"Sertraline has been studied less extensively, and there have been a few studies concerning SSRIs that report follow-up data at more than 12 weeks of follow-up."	( A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Brustolin, A; Campisi, S; Fassino, S; Lavagnino, L; Leombruni, P; Pierò, A, 2008)	1.33
"Sertraline has been used as a treatment for anxiety disorders since the mid 1990s and has proven itself an effective, well-tolerated and economically viable treatment for panic disorder (PD) when used in the range of 50 to 175 mg per day. "	( Sertraline in the treatment of panic disorder. Clayton, AH; Hobgood, CD, 2009)	3.24
"Sertraline has a low potential for drug interactions at the level of the cytochrome P450 enzyme system."	( Spotlight on sertraline in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	1.41
"Sertraline has minimal inhibitory effects on the major cytochrome P450 enzymes, and few drug-drug interactions of clinical significance have been documented."	( Clinical pharmacokinetics of sertraline. DeVane, CL; Liston, HL; Markowitz, JS, 2002)	1.33
"Sertraline has shown promise in the treatment of dialysis-associated hypotension (DAH) in a limited number of end-stage renal disease patients. "	( Addition of sertraline to other therapies to reduce dialysis-associated hypotension. Abu-Alfa, AK; Brewster, UC; Ciampi, MA; Perazella, MA, 2003)	2.14
"Sertraline has a secondary amine group; therefore, we predicted that it may react with formalin to give N-methyl derivatives."	( Conversion of sertraline to N-methyl sertraline in embalming fluid: a forensic implication. Sai Prakash, PK; Suma, R, )	1.21
"Sertraline has not been associated with sedating or anticholinergic effects, psychomotor impairment, or cardiovascular toxicity."	( The role of sertraline in the management of depression. Shelton, RC, )	1.23
"Sertraline has dose-proportional changes in plasma concentrations, in contrast to fluoxetine and paroxetine."	( Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Preskorn, S, 1994)	1.22
"Sertraline treatment has negative effects on sexual function and performance in both sexes, while nefazodone has none."	( Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Feiger, A; Kiev, A; Shrivastava, RK; Wilcox, CS; Wisselink, PG, 1996)	1.35
"Sertraline use has been increasing secondary to its efficacy and its more tolerable side effect profile than the tricyclic antidepressants."	( Pediatric sertraline overdose. Catalano, G; Catalano, MC; Cooper, DS; Guttman, JM, )	1.26
"Sertraline has been tested extensively in the treatment of panic and obsessive-compulsive disorders."	( Sertraline in the treatment of anxiety disorders. Hirschfeld, RM, 2000)	2.47
"Sertraline has a linear pharmacokinetic profile and a half-life of about 26 h."	( The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. Born, L; MacQueen, G; Steiner, M, 2001)	1.29
"Sertraline has been shown to blunt postprandial hyperglycemia in rats and to potentiate the hypoglycemic effects of sulfonylurea agents in humans. "	( Sertraline-induced hypoglycemia. Fraser, AD; Mukherjee, SD; Pollak, PT, 2001)	3.2
"Sertraline (SRT) has been shown to be an effective antidepressant in extensive clinical trial programs but data on plasma concentrations regarding clinical outcome and tolerability are lacking. "	( Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. Boscati, L; Cerveri, G; Laini, V; Malvini, L; Manfré, S; Mauri, MC; Panza, G; Regispani, F; Scalvini, ME; Volonteri, LS, 2002)	2.03
"Sertraline has a low potential for drug interactions at the level of the cytochrome P450 enzyme system."	( Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	2.48
"Sertraline has a proved efficacy in post-traumatic stress disorder (PTSD), but it is unknown which symptoms respond or in what sequence this occurs. "	( Characterizing the effects of sertraline in post-traumatic stress disorder. Clary, CM; Davidson, JR; Farfel, GM; Landerman, LR, 2002)	2.05
"Sertraline has minimal anticholinergic activity, is essentially devoid of cardiovascular effects, has a wide therapeutic index and may be administered to elderly patients or those with underlying cardiovascular disorders."	( Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. McTavish, D; Murdoch, D, 1992)	2.45
"Sertraline has been found to be superior to placebo and equivalent to amitriptyline in treatment of depression."	( Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Grimsley, SR; Jann, MW, 1992)	1.38

Excerpt	Reference	Relevance
"Sertraline led to an increase in fish aggression and more repeatable/consistent behaviour compared to control fish."	( Aggression repeatability in stressed fish in response to an environmental concentration of sertraline and lunar cycle as evidenced by brain metabolomics. Douda, K; Grabic, R; Grabicová, K; Horký, P; Hubená, P; Randák, T; Slavík, O, 2023)	1.85
"Only sertraline was able to increase transepithelial electrical resistance in the rat colon both when used in an ex vivo (0.8 μg/mL, 180 min) or in vivo (30 mg/kg p.o., 20 days) fashion. "	( Sertraline and Citalopram Actions on Gut Barrier Function. Beltrán, CJ; Bravo, JA; Escobar-Luna, J; Eyzaguirre-Velásquez, J; González-Arancibia, C; González-Toro, MP; Julio-Pieper, M, 2021)	2.58
"Sertraline could inhibit cell proliferation and induce apoptosis. "	( [Experimental Study on Apoptosis of Kasumi-1 Cells Induced by Sertraline and Its Molecular Mechanism]. Pan, XR; Tong, JH; Xia, D; Yan, WW; Zhang, YT, 2015)	2.1
"Sertraline had lower total costs per QALY than venlafaxine (34,788 Baht vs."	( Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial. Leelahanaj, T, 2012)	1.47
"Sertraline did not produce a significant decline in vigilance performance, presumably due to its concomitant effects on dopamine activity, counteracting the negative effects of serotonin on dopamine neurotransmission."	( Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. Kruizinga, MJ; Ramaekers, JG; Riedel, WJ; Schmitt, JA; van Boxtel, MP; Vuurman, EF, 2002)	1.04
"Sertraline may produce dual neurotransmitter effects similar to the serotonin-norepinephrine reuptake inhibitors (SNRIs); however, it has been tested against an SNRI in only 1 previous study, and never at an optimal dose. "	( A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. Dunner, DL; Haman, KL; Hirschfeld, RM; Kiev, A; Lydiard, RB; Rapaport, MH; Shelton, RC; Smith, WT; Zajecka, JM, 2006)	2.03
"Sertraline was found to inhibit weight gain and decrease food intake without affecting locomotion in rats and genetically obese (ob/ob) mice. "	( Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Chapin, DS; Johnson, JL; Nielsen, JA; Torgersen, LK, 1992)	3.17

Excerpt	Reference	Relevance
"Sertraline treatment reduced TCTP expression in BC cell lines, significantly impacting cell viability, clonogenicity, and migration."	( Sertraline as a potential cancer therapeutic approach: Biological relevance of TCTP in breast cancer cell lines and tumors. Baldissera, AB; Basílio, ABC; Boia-Ferreira, M; Castro, MAA; Chaim, OM; Gremski, LH; Resende, JSS; Senff-Ribeiro, A; Veiga, SS, 2023)	3.07
"Sertraline in the treatment of Major Depressive Disorder (MDD) in South Korean participants."	( Effects of transcranial direct current stimulation using miniaturized devices vs sertraline for depression in Korea: A 6 week, multicenter, randomized, double blind, active-controlled study. Choi, WJ; Kim, B; Kim, S; Kim, WJ; Park, JY; Park, S; Roh, D; Son, SJ, 2020)	1.51
"Sertraline treatments improved larval survival and health index score, especially at doses of 10 and 15 mg/kg. "	( In vivo evaluation of the antifungal activity of sertraline against Aspergillus fumigatus. Becerril-García, MA; González, GM; Méndez-Galomo, KS; Montoya, AM; Robledo-Leal, ER; Solís-Villegas, EM; Treviño-Rangel, RJ; Villanueva-Lozano, H, 2019)	2.21
"Sertraline treatment resulted in up-regulation of brain BDNF, phospho-ERK and Bcl-2 that may be involved in the pro-cognitive effect of sertraline."	( Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Gil-Ad, I; Miron, O; Taler, M; Weizman, A, 2013)	1.37
"In sertraline-treated cells, the induction of apoptosis and cell death was shown to be the result of activation of JNK, but not ERK1/2 or p38 in the mitogen-activated protein kinase (MAPK) pathway."	( Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Chen, S; Couch, L; Dobrovolsky, VN; Guo, L; Lin, H; Mei, N; Wan, L; Xuan, J, 2014)	2.36
"Sertraline treatment led to a significant increase in brain-RSA covariation for patients compared with controls, despite a lack of improvement in mean RSA."	( Partial Amelioration of Medial Visceromotor Network Dysfunction in Major Depression by Sertraline. Allen, JJ; Lane, RD; Mercado, RA; Schafer, SM; Thayer, JF; Wager, TD, 2015)	1.36
"Sertraline treatment prevented increases in body weight, fat, insulin, and HOMA-IR (all p<0.05), without significantly altering activity levels."	( Sertraline inhibits increases in body fat and carbohydrate dysregulation in adult female cynomolgus monkeys. Appt, SE; Carr, JJ; Clarkson, TB; Jones, SR; Kritchevsky, SB; Register, TC; Shively, CA; Silverstein-Metzler, MG, 2016)	2.6
"Sertraline might be a treatment for patients with ESRD who do not respond to other routine drugs."	( Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hashemi, N; Malekmakan, L; Pakfetrat, M; Tadayon, T, 2018)	2.64
"In sertraline-treated rats, E(2) decreased 5-HT(2A) receptor mRNA, and E(2)-withdrawal increased 5-HT(1A), 5-HT(2A) and 5-HT(2C) receptor mRNA."	( Estradiol-sertraline synergy in ovariectomized rats. Craft, RM; Cunningham, KA; Seitz, PK; Sell, SL; Stutz, SJ; Thomas, ML, 2008)	1.26
"Sertraline treatment significantly reduced the BDI score as compared with both baseline and placebo."	( Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Angeloni, L; Costa, GM; Fontana, F; Mancini, S; Manzoli, L; Pizzi, C, 2009)	1.07
"Sertraline treatment reduces MSNA at rest and during mental challenge in depressed patients, which may have prognostic implications in this group."	( Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline. Azul, JB; Kuniyoshi, FH; Laterza, MC; Lotufo-Neto, F; Negrão, CE; Pullenayegum, EM; Rondon, MU; Scalco, AZ; Scalco, MZ; Trombetta, IC; Wajngarten, M, 2009)	1.3
"Sertraline treatment improved BDI score of patients with depression (P < 0.001)."	( Sertraline treatment is associated with an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. Atalay, H; Biyik, M; Biyik, Z; Guney, I; Solak, Y; Tonbul, HZ; Turk, S; Uguz, F; Yeksan, M, 2010)	2.52
"Sertraline-treated patients experienced more adverse events, most notably gastrointestinal and respiratory, than placebo-treated patients."	( Sertraline for the treatment of depression in Alzheimer disease. Drye, LT; Frangakis, C; Lyketsos, CG; Martin, BK; Meinert, CL; Mintzer, JE; Munro, CA; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Weintraub, D, 2010)	2.52
"Sertraline treatment is not associated with delayed improvement between 12 and 24 weeks of treatment and may not be indicated for the treatment of depression of AD."	( Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Drye, LT; Frangakis, C; Lyketsos, CG; Martin, BK; Meinert, CL; Mintzer, JE; Munro, CA; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Weintraub, D, 2010)	3.25
"Sertraline treatment for depression."	( Prodromal dementia with lewy bodies manifesting as sertraline-induced parkinsonism: a case report. Kim, I; Kim, JH; Kim, YJ; Lee, BC; Ma, HI; Park, J; Yu, KH, )	1.83
"Sertraline treatment reduced the depression-like effect in EC and SC, but not in IC."	( Effects of sertraline on behavioral alterations caused by environmental enrichment and social isolation. Erol, K; Ulupinar, E; Yildirim, E, 2012)	1.49
"Sertraline treatment."	( Cognitive improvement following treatment in late-life depression: relationship to vascular risk and age of onset. Barch, DM; Doraiswamy, PM; DʼAngelo, G; Garcia, KS; Gersing, K; Pieper, C; Sheline, YI; Taylor, W; Welsh-Bohmer, K; Wilkins, CH, 2012)	1.82
"sertraline-treated cells."	( Accumulation of an antidepressant in vesiculogenic membranes of yeast cells triggers autophagy. Chen, J; Korostyshevsky, D; Lee, S; Perlstein, EO, 2012)	1.1
"The sertraline-treated rats showed a significant reduction in clinical arthritis compared to controls, at all doses given, accompanied by a significant increase in interleukin 10 and a decrease in tumor necrosis factor-α levels and cycloxygenase-2 production, without lymphotoxicity. "	( Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis. Baharav, E; Bar, M; Gil-Ad, I; Karp, L; Taler, M; Weinberger, A; Weizman, A, 2012)	1.23
"Sertraline treatment did not modify the symptoms, which may suggest different mechanisms with regard to different antidepressant drug discontinuation syndromes."	( Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. Berney, P; Curtin, F; Kaufmann, C, 2002)	1.04
"Sertraline treatment produced a lower total withdrawal symptom score and less irritability, anxiety, craving, and restlessness than placebo. "	( A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Covey, LS; Glassman, AH; Rivelli, S; Stage, K; Stetner, F, 2002)	2.07
"Sertraline treatment of Candida spp."	( Interaction of sertraline with Candida species selectively attenuates fungal virulence in vitro. Dierich, MP; Fuchs, A; Fuchs, D; Kacani, L; Lass-Flörl, C; Ledochowski, M; Speth, C; Würzner, R, 2003)	1.39
"Sertraline treatment decreased the symptoms of PTSD; however this was not accompanied by a significant increase in neopterin production."	( Neopterin production in posttraumatic stress disorder before and after pharmacotherapy. Atmaca, M; Kuloglu, M; Onal, S; Tezcan, E, 2003)	1.04
"Sertraline-treated patients showed a significant improvement on the anxiety/ depression subscale of the BPRS on ITT analysis (F = 10.1, p = 0.004)."	( A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. Cooper, SJ; King, DJ; Lynch, G; Mulholland, C, 2003)	1.3
"The sertraline-treated group had greater improvements in the scores for the Cornell Scale for Depression in Dementia (P =.002) and Hamilton Depression Rating Scale (P =.01), and a statistical trend toward less decline in activities of daily living on the Psychogeriatric Depression Rating Scale-activities of daily living subscale (P =.07)."	( Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Baker, AS; Brandt, J; DelCampo, L; Frangakis, C; Lyketsos, CG; Miles, Q; Munro, C; Rabins, PV; Sheppard, JM; Steele, CD; Steinberg, M, 2003)	1.04
"Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P =.001; overall mean change, -22.84 vs -20.19, respectively; P =.007). "	( Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Ambrosini, P; Childress, A; Deas, D; Donnelly, C; Greenbaum, MS; Rynn, M; Wagner, KD; Wohlberg, C; Yang, R, 2003)	2.14
"Sertraline-treated patients in the comorbid group had similar adverse events and discontinuations when compared to those in the noncomorbid group."	( Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. Burt, T; Cassidy, EL; Clary, CM; Doraiswamy, PM; Holland, PJ; Hornig, M; Mandel, FS; Salomon, RM; Sheikh, JI, 2004)	1.32
"More sertraline-treated subjects reported improved functioning in the domains of family relationships, social activities, and sexual activity."	( Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Freeman, EW; Polansky, M; Rickels, K; Sondheimer, SJ; Xiao, S, 2004)	1.05
"Sertraline is the only treatment for major depressive disorder studied in a placebo-controlled trial of patients with ACS and found to be safe and effective."	( Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Glassman, AH; Harrison, DJ; O'Connor, CM, 2005)	1.34
"Sertraline treatment of major depressive disorder following hospitalization for a recent myocardial infarction or unstable angina appears to be a cost-effective strategy."	( Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Glassman, AH; Harrison, DJ; O'Connor, CM, 2005)	2.06
"Sertraline-treated participants with less severe alcohol dependence and early-onset PTSD had significantly fewer drinks per drinking day (p < 0.001)."	( Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Anton, RF; Back, SE; Brady, KT; Randall, CL; Simpson, K; Sonne, S, 2005)	2.49
"Sertraline treatment demonstrated efficacy for both the psychic and somatic anxiety symptoms of GAD."	( Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Allgulander, C; Austin, C; Burt, T; Dahl, AA; Kutcher, SP; Ravindran, A, 2005)	3.21
"Both sertraline treatment and symptomatic recovery from depression were associated with increased HRV compared with placebo-treated and nonrecovered post-ACS control groups, respectively, but this results primarily from decreased HRV in the comparison groups."	( Heart rate variability in acute coronary syndrome patients with major depression: influence of sertraline and mood improvement. Bigger, JT; Gaffney, M; Glassman, AH; Van Zyl, LT, 2007)	1.01
"Sertraline treatment improved the motor performance in R6/2 mice, but did not affect nontransgenic mice."	( The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Duan, W; Jiang, M; Li, Q; Masuda, N; Peng, Q; Ross, CA; Zhao, M, 2008)	1.4
"Sertraline-treated patients demonstrated a significant improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) severity scores compared with placebo-treated patients, while dothiepin-treated patients did not show significant improvement compared with placebo."	( Management of depression in real-life settings: knowledge gained from large-scale clinical trials. Thompson, C, 1994)	1.01
"For sertraline-treated patients with depression included on their computerized medical problem list, the mean daily dose was 57 +/- 25 mg for the first prescription and 110 +/- 65 mg for the ninth."	( Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Coons, SJ; Gregor, KJ; McDonald, RC; Overhage, JM, )	0.61
"Sertraline treatment decreased apomorphine-induced hypothermia by almost half in FSLs, whereas slight hyperthermia was induced in FRL rats instead."	( Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Overstreet, DH; Pucilowski, O, 1993)	1.01
"Sertraline treatment has negative effects on sexual function and performance in both sexes, while nefazodone has none."	( Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Feiger, A; Kiev, A; Shrivastava, RK; Wilcox, CS; Wisselink, PG, 1996)	1.35
"Sertraline treatment increases average expenditures for physician visits ($21.74; P < or = 0.05), psychiatric visits ($56.79; P < or = 0.05), laboratory tests ($1.21; P < or = 0.05), hospitalizations ($70.59; P < or = 0.05), psychiatric hospitalizations ($95.75; P < or = 0.05), and antidepressant pharmacotherapy ($69.85; P < or = 0.05), for a total per capita increase in health service use of $315.96 (P < or = 0.05), compared with treatment with fluoxetine."	( Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. Buesching, DP; Galin, RS; Hughes, TE; Legg, RF; Morgan, M; Nemec, NL; Robison, LM; Sclar, DA; Skaer, TL, )	1.08
"Sertraline treatment produced significant improvements relative to placebo in time to ejaculation and number of successful attempts at intercourse, as well as overall clinical judgements of improvement."	( Sertraline treatment for premature ejaculation. Camera, A; Mendels, J; Sikes, C, 1995)	2.46
"Sertraline treatment did not affect Kd and Bmax of [3H]CGP12177 and [3H]ketanserin bindings or cAMP, accumulation by norepinephrine, isoproternol, 5'-guanylylimidodiphosphate [Gpp(NH)p] and forskolin in the cortical membrane compared with vehicle-treated rats."	( Behavioral stimulation without alteration of beta and 5-HT receptors and adenylate cyclase activity in rat brain after chronic sertraline administration. Kamijima, K; Kiuchi, Y; Nara, K; Oguchi, K; Tadokoro, C; Yamazaki, Y, 1997)	1.22
"Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01)."	( Sertraline in diabetic neuropathy: preliminary results. Goodnick, PJ; Jimenez, I; Kumar, A, 1997)	2.46
"Sertraline treatment was ineffective in reducing consumption during the stressful period of home-cage reunion, a period characterized by high levels of aggressive behavior."	( The serotonin reuptake inhibitor sertraline reduces excessive alcohol consumption in nonhuman primates: effect of stress. Hasert, M; Higley, J; Linnoila, M; Suomi, S, 1998)	1.3
"Sertraline-treated patients also showed greater improvement that was statistically significant on several ratings of panic disorder symptomatology and functioning."	( Methodologies and outcomes from the sertraline multicenter flexible-dose trials. Clary, CM; Rapaport, MH; Wolkow, RM, 1998)	1.3
"Sertraline-treated patients also had significantly more improvement than placebo-treated patients in scores on the Quality of Life Enjoyment and Satisfaction Questionnaire, patient global evaluation, and Clinical Global Impression severity of illness and global improvement scales."	( Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Clary, CM; Pohl, RB; Wolkow, RM, 1998)	2.46
"Sertraline-treated patients exhibited significantly greater improvement (P=.01) at end point than did patients treated with placebo for the primary outcome variable, panic attack frequency. "	( Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Manfro, GG; Otto, MW; Pollack, MH; Wolkow, R; Worthington, JJ, 1998)	3.19
"Sertraline treatment had a significantly more positive effect, when compared to nortriptyline, across almost all associated measures of cognitive function, energy, anxiety, and quality of life and was better tolerated than nortriptyline, with a lower attrition rate/side effect burden."	( Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Clary, CM; Finkel, SI; Richter, EM, 1999)	1.3
"Sertraline treatment was associated with clinical improvement and was well tolerated in >85% of the patients in this open-label treatment trial for patients with major depression after myocardial infarction. "	( An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Baker, B; Dorian, P; Frasure-Smith, N; Glassman, AH; Harrison, W; Jiang, JW; Lespérance, F; O'Connor, CM; Shapiro, PA, 1999)	2.02
"Sertraline treatment effectively reduces the clinical symptoms and functional impairments associated with dysthymia. "	( Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Anisman, H; Bialik, RJ; Charbonneau, Y; Ellis, J; Griffiths, J; Merali, Z; Ravindran, AV; Telner, J; Wiens, A, 1999)	1.75
"Sertraline-treated patients showed statistically greater cognitive improvement on several measures."	( A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. Batzar, ED; Clary, CM; Doraiswamy, PM; Krishnan, KR; Newhouse, PA; Richter, EM, 2000)	1.32
"Sertraline treatment seemed to provide an advantage in reducing drinking in alcohol-dependent patients without lifetime depression, illustrated best with a measure of drinking frequency during treatment."	( Double-blind clinical trial of sertraline treatment for alcohol dependence. Cnaan, A; Kranzler, HR; Luck, G; Pettinati, HM; Rukstalis, MR; Volpicelli, JR, 2001)	1.32
"4. Sertraline treatment yielded comparable levels of response in all 3 groups (response criterion: CGI-much or very much improved) at treatment endpoint on both a completer analysis (HTN, 86%; VASC, 89%; NoVASC, 77%) and significantly higher response rates on a 12-week endpoint analysis (HTN, 74%; VASC, 69%; NoVASC, 58%; p < 0.05)."	( Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. Clary, CM; Doraiswamy, PM; Krishnan, KR, 2001)	1.02
"Sertraline treatment was well tolerated, with a 9% discontinuation rate because of adverse events, compared with 5% for placebo."	( Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Davidson, JR; Farfel, GM; Rothbaum, BO; Sikes, CR; van der Kolk, BA, 2001)	1.3
"Sertraline-treated patients were significantly more improved than non-sertraline-treated patients (chi(2)=12.53, P<0.001; odds ratio=0.534; 95% Cl 0.347-0.835). "	( Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Blomhoff, S; Haug, TT; Hellström, K; Holme, I; Humble, M; Madsbu, HP; Wold, JE, 2001)	2.01
"Sertraline, as drug for treatment, has been chosen since its clinical uses range from treatment of depression to that of many other psychiatric clinical conditions so that it has been thought to be a good candidate to this type of study."	( A neural network approach to the outcome definition on first treatment with sertraline in a psychiatric population. Bellodi, L; Franchini, L; Politi, E; Rossini, D; Smeraldi, E; Spagnolo, C, 2001)	1.26
"Sertraline treatment was associated with marked improvement on all QOL/functional measurements: at the end of the acute treatment phase, 58% of responders on treatment with sertraline had achieved Q-LES-Q total scores within 10% of community norms."	( Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Clary, CM; Endicott, J; Rapaport, MH, 2002)	1.26
"Sertraline treatment of chronic PTSD is associated with rapid improvement in quality of life that is progressive and sustained over the course of more than 1 year of treatment."	( Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Clary, CM; Endicott, J; Rapaport, MH, 2002)	1.99
"Sertraline treatment also resulted in a higher proportion of remissions than fluoxetine (defined as a CGI-I	( Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. Austin, C; Bergeron, R; Chaput, Y; Goldner, E; Hadrava, V; Ravindran, AV; Swinson, R; van Ameringen, MA, 2002)	2.48
"Sertraline treatment was well tolerated, with a 13% discontinuation rate as a result of adverse events."	( Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Amital, D; Austin, C; Bleich, A; Kotler, M; Lane, RM; Miodownik, C; Zohar, J, 2002)	1.29
"Treatment with sertraline with or without ketoprofen significantly reduced the baseline levels of all biomarkers to levels which were in the normal range (IDO, TGF-β1, and IL-4) or still somewhat higher than in controls (IFN-γ)."	( Plasma Indoleamine-2,3-Dioxygenase (IDO) is Increased in Drug-Naï ve Major Depressed Patients and Treatment with Sertraline and Ketoprofen Normalizes IDO in Association with Pro-Inflammatory and Immune- Regulatory Cytokines. Al-Dujaili, AH; Al-Hakeim, HK; Maes, M; Twayej, AJ, 2020)	1.11
"Treatment with sertraline was then commenced with an objective improvement of his cognitive and behavioral status."	( Efficacy of sertraline in a patient with Neuro-Beçhet's disease. Bruno, G; Canevelli, M; Letteri, F; Tosto, G, 2013)	1.11
"Pretreatment with sertraline, previously shown to prevent hypoglycemia-associated glucoregulatory failure, did not prevent blunting of hypoglycemia-induced CPP prevention by recurrent hypoglycemia."	( Orexin signaling is necessary for hypoglycemia-induced prevention of conditioned place preference. Dunn-Meynell, A; Levin, BE; Otlivanchik, O; Sanders, NM, 2016)	0.76
"Treatment with sertraline (mean dose 66.0 +/- 29.8 mg) resulted in improvement in all UPDRS domains along with a significant decrease of the HADS scores. "	( Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. García-Sánchez, C; Gironell, A; Kulisevsky, J; Martínez-Corral, M; Pagonabarraga, J; Pascual-Sedano, B, 2008)	1.02
"Treatment with sertraline (5 and 10 mg/kg) significantly reversed behavioral, biochemical and mitochondrial enzyme dysfunctions in 3-nitropropionic acid treated group."	( Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Kumar, A; Kumar, P, 2009)	1.03
"Treatment with sertraline improves depressive symptoms and reduces plasma markers of oxidative stress in depressed CHF patients."	( Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. Andreadou, I; Antonellos, N; Douzenis, A; Ikonomidis, I; Kremastinos, D; Lykouras, E; Markantonis-Kiroudis, S; Michalakeas, CA; Nikolaou, M; Paraskevaidis, I; Parissis, JT; Varounis, C, 2011)	1.1
"Treatment with sertraline significantly reduced all these parameters (respectively: +19.8 ± 6.9%, -3.3 ± 2 mmHg, -13.1 ± 10.8 bpm, -9.8 ± 5.7 cpm) and serum 5-HT level dropped to 634 ± 69 ng/mL (P < 0.05)."	( Sertraline inhibits formalin-induced nociception and cardiovascular responses. Abreu, GR; Futuro Neto, HA; Gonçalves, WL; Gouvea, SA; Pires, JG; Santuzzi, CH; Tiradentes, RV, 2012)	2.16
"Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo."	( Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Drye, LT; Frangakis, CE; Longmire, CF; Lyketsos, CG; Martin, BK; Meinert, CL; Mintzer, JE; Munro, CA; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Weintraub, D, 2012)	0.73
"Treatment with sertraline was associated with substantially less release of platelet/endothelial biomarkers than was treatment with placebo."	( Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Califf, RM; Finkel, MS; Gaffney, M; Glassman, AH; Harrison, W; Krishnan, KR; Malinin, AI; Musselman, DL; Nemeroff, CB; O'Connor, CM; Serebruany, VL; van Zyl, LT, 2003)	0.87
"Treatment with sertraline in depressed post-ACS patients is associated with reductions in platelet/endothelial activation despite coadministration of widespread antiplatelet regimens including aspirin and clopidogrel. "	( Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Califf, RM; Finkel, MS; Gaffney, M; Glassman, AH; Harrison, W; Krishnan, KR; Malinin, AI; Musselman, DL; Nemeroff, CB; O'Connor, CM; Serebruany, VL; van Zyl, LT, 2003)	0.88
"Treatment with sertraline was associated with less depression at the end of treatment in female subjects compared with female subjects who received placebo."	( Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. Anton, RF; Durazo-Arvizu, R; Latham, PK; Moak, DH; Voronin, KE; Waid, RL, 2003)	2.1
"Treatment with sertraline resulted in significantly greater last observation carried forward (LOCF)-endpoint improvement than placebo on both the HAM-A psychic and somatic anxiety factors. "	( Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Allgulander, C; Austin, C; Burt, T; Dahl, AA; Kutcher, SP; Ravindran, A, 2005)	2.12
"Treatment with sertraline also resulted in greater worsening of scores on the Medical Outcomes Study (MOS) Short Form 36 standardized physical component and the global Female Sexual Function Index."	( Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Cohen, B; Grady, D; Kristof, M; Olyaie, A; Sawaya, GF; Tice, J, 2007)	1.01
"Treatment with sertraline did not improve hot flush frequency or severity in generally healthy perimenopausal and postmenopausal women, but was associated with bothersome side effects."	( Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Cohen, B; Grady, D; Kristof, M; Olyaie, A; Sawaya, GF; Tice, J, 2007)	1.02
"Treatment with sertraline for 26 days increased the area under the mean prothrombin time vs time curve by 145 sec h (7.9%), compared with a decrease of 17 sec h (-1.0%) in the placebo group."	( Effect of sertraline on protein binding of warfarin. Apseloff, G; Gerber, N; Tremaine, LM; Wilner, KD, 1997)	1.04
"Treatment with sertraline was nearly as effective and had a lower incidence of side effects."	( Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Kim, SC; Seo, KK, 1998)	0.92
"Treatment with sertraline, with or without group cognitive behavior therapy, reduced the functional impairment of depression. "	( Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Anisman, H; Bialik, RJ; Charbonneau, Y; Ellis, J; Griffiths, J; Merali, Z; Ravindran, AV; Telner, J; Wiens, A, 1999)	0.66
"Treatment with sertraline was initiated in February 1998."	( Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. Nace, DA; Towers, AL; Verrico, MM, 2000)	0.88
"Treatment with sertraline for 4 weeks increased plasma cortisol levels, while 24 weeks of sertraline treatment increased plasma T(3) levels in depressed patients."	( Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Jakovljević, M; Korsić, M; Mihaljević-Peles, A; Mück-Seler, D; Pivac, N; Sagud, M, 2002)	1.04
"Pretreatment with sertraline (1-32 mg/kg IP) did not affect the total amount of spontaneous locomotor activity during 50 min following administration of cocaine (15-40 mg/kg IP)."	( Sertraline and cocaine-induced locomotion in mice. I. Acute studies. Fischette, CT; Reith, ME; Wiener, HL, 1991)	2.05

Excerpt	Reference	Relevance
" The side-effect profile of sertraline was similar in young and old, and individual side effects did not make a notable contribution to the discontinuation rate."	( Toleration and safety of sertraline: experience worldwide. Doogan, DP, 1991)	0.88
" In an attempt to circumvent these adverse effects, many antidepressants were prescribed at less than therapeutic doses, resulting in a high probability of inadequate treatment, relapse, or recurrence."	( Striking a balance between safety and efficacy: experience with the SSRI sertraline. Casey, DE, 1994)	0.52
" The incidence of adverse events was similar for both treatments; 40."	( Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Aguglia, E; Bolino, F; Casacchia, M; Cassano, GB; Faravelli, C; Ferrari, G; Giordano, P; Pancheri, P; Ravizza, L; Trabucchi, M, 1993)	0.54
" The fates of SSRI-associated sexual adverse effects and clinical managements of restoring these side effects were described."	( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Hsu, JH; Shen, WW, 1995)	0.29
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."	( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Hsu, JH; Shen, WW, 1995)	0.29
"To study the adverse drug reaction (ADR) profile of selective serotonin re-uptake inhibitors (SSRI) in Belgium and the Netherlands."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.29
"All adverse reactions of fluoxetine, fluvoxamine, paroxetine and sertraline, reported between the moment of registration of these drugs and January 1st 1995, were assessed for causality."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.53
"At the national monitoring centres of Belgium and of the Netherlands adverse reactions were reported 78 and 537 times, respectively."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.29
" More adverse reactions were reported in the Netherlands than in Belgium."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.29
" We have addressed the question of whether there is a 'serotonin withdrawal syndrome' by analysis of spontaneous reports of suspected adverse drug reactions (ADRs) associated with four SSRIs."	( A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. MacKay, AV; Price, JS; Waller, PC; Wood, SM, 1996)	0.29
" Overall, 27% of the SSRI-treated patients had no adverse sexual side effects; in contrast, 86% of patients treated with bupropion had no adverse sexual effects, and 77% of bupropion-treated patients reported at least one aspect of heightened sexual functioning."	( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997)	0.53
"SSRI-induced adverse sexual effects appear to be the rule rather than the exception and may be substantially underreported unless patients are specifically asked about the effects of these medications on various aspects of sexual function."	( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997)	0.53
"Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants."	( Lamotrigine toxicity secondary to sertraline. Gerner, R; Kaufman, KR, 1998)	0.58
" Extrapyramidal adverse effects have been reported with the selective serotonin re-uptake inhibitor (SSRI) antidepressants, particularly fluoxetine and paroxetine."	( Extrapyramidal adverse effects associated with sertraline. Lambert, MT; Petty, F; Trutia, C, 1998)	0.56
"English-language articles identified through MEDLINE (1985 through 1997), and case reports from the American Association of Poison Control Centers (AAPCC) (1987 through 1996) and United States Food and Drug Administration (FDA) adverse event database (through 1997) that describe findings of fatal and nonfatal overdoses involving SSRIs alone or in combination with other ingestants were reviewed."	( SSRI safety in overdose. Barbey, JT; Roose, SP, 1998)	0.3
" At very high doses (> 75 times the common daily dose), more serious adverse events, including seizures, electrocardiogram (ECG) changes, and decreased consciousness may occur."	( SSRI safety in overdose. Barbey, JT; Roose, SP, 1998)	0.3
"There were no clinically significant cardiovascular adverse events in any of the subjects enrolled in the study."	( Absence of cardiovascular adverse effects of sertraline in children and adolescents. Biederman, J; Faraone, SV; Fine, CS; Geller, D; March, JS; Millstein, RB; Spencer, TJ; Wilens, TE; Wolkow, R, 1999)	0.56
" Sertraline was well tolerated, with insomnia the only adverse effect reported significantly more often than placebo (16."	( Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. Asnis, GM; Baker, D; Brady, K; Farfel, GM; Pearlstein, T; Rothbaum, B; Sikes, CR, 2000)	1.53
" There were more withdrawals due to adverse events in the clomipramine group than in the sertraline group (17% versus 12%)."	( A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. Blashko, C; Goger, J; Kosolowski, J; Lane, RM; Lépine, JP; Moles, MF; Probst, C; Scharfetter, B, 2000)	0.78
" All-cause adverse events were recorded in 35 patients (42."	( An open, baseline controlled evaluation of sertraline safety and efficacy in the treatment of depression in Thai patients. , 2001)	0.57
" These results indicate that imipramine and sertraline are equally effective for the treatment of major depression in later life, although adverse reactions are more frequent among subjects treated with imipramine than with sertraline."	( Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Almeida, OP; Forlenza, OV; Hirata, ES; Stoppe, A, 2001)	0.83
" This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.52
" A measure of side-effect intensity distinguished paroxetine from the other antidepressants on a measure of sexual dysfunction."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.52
"These results confirm the clinical utility of the TSES as a simple, clinician-administered antidepressant side-effect scale."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.52
" All Adverse Events (AEs) during follow-up were recorded by the psychiatrists for the duration of SSRI treatment until discontinuation or until at least 12 months."	( Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Heerdink, ER; Leufkens, HG; Meijer, WE; van Eijk, JT, 2002)	0.61
"In this study we found that almost three out of four patients reported an adverse event."	( Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Heerdink, ER; Leufkens, HG; Meijer, WE; van Eijk, JT, 2002)	0.61
"Major depression affects about 25% of the patients who have Alzheimer disease and has serious adverse consequences for patients and caregivers."	( Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Baker, AS; Brandt, J; DelCampo, L; Frangakis, C; Lyketsos, CG; Miles, Q; Munro, C; Rabins, PV; Sheppard, JM; Steele, CD; Steinberg, M, 2003)	0.56
" Safety monitoring indicated few differences in adverse effects between the 2 treatment groups."	( Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Baker, AS; Brandt, J; DelCampo, L; Frangakis, C; Lyketsos, CG; Miles, Q; Munro, C; Rabins, PV; Sheppard, JM; Steele, CD; Steinberg, M, 2003)	0.56
" Adverse events were monitored and recorded systematically during the trial."	( Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Datto, CJ; DiFilippo, S; Katz, IR; Oslin, DW; Streim, JE; Ten Have, TR; Weintraub, D, 2003)	0.53
"Twelve subjects were discontinued due to serious adverse events (SAE), 5 were discontinued due to other significant side effects, and 2 withdrew consent."	( Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Datto, CJ; DiFilippo, S; Katz, IR; Oslin, DW; Streim, JE; Ten Have, TR; Weintraub, D, 2003)	0.53
"In this frail elderly population, venlafaxine was less well tolerated and, possibly, less safe than sertraline without evidence for an increase in efficacy."	( Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Datto, CJ; DiFilippo, S; Katz, IR; Oslin, DW; Streim, JE; Ten Have, TR; Weintraub, D, 2003)	0.75
" However, subtle differences in improvements in PTSD symptom clusters, physiologic reactivity, and reported adverse events were identified."	( Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Burgin, C; Jones, DE; Masters, BK; Parker, DE; Potter-Kimball, R; Tucker, P; Wyatt, DB, 2003)	0.53
" Sertraline-treated patients in the comorbid group had similar adverse events and discontinuations when compared to those in the noncomorbid group."	( Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. Burt, T; Cassidy, EL; Clary, CM; Doraiswamy, PM; Holland, PJ; Hornig, M; Mandel, FS; Salomon, RM; Sheikh, JI, 2004)	1.5
" Sertraline was safe and well tolerated by patients with or without medical illness."	( Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. Burt, T; Cassidy, EL; Clary, CM; Doraiswamy, PM; Holland, PJ; Hornig, M; Mandel, FS; Salomon, RM; Sheikh, JI, 2004)	1.5
" Safety was evaluated by physical and laboratory evaluations and the monitoring of adverse events (AEs)."	( Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Cullen, EI; Kumar, D; Nagy, CF; Perdomo, CA; Pratt, RD; Wason, S, 2004)	0.58
"For treatment of depressive disorders in routine outpatient settings, sertraline is safe and efficacious."	( Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients. Bair, MJ; Göbel, C; Löwe, B; Schenkel, I, 2005)	0.81
" Their use is frequently associated with dose-limiting adverse effects."	( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I, )	0.13
" For detecting side effect liability (ataxia, sedation, impairment of voluntary motor functions), (1) the rota-rod test, (2) measurement of spontaneous motility, (3) the weight-lifting test and (4) the thiopental sleep test were used."	( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I, )	0.13
"Therapeutic indices calculated from the results of these in vivo experiments for the clinically used muscle relaxants are in agreement with their adverse effect profiles in humans."	( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I, )	0.13
" Only one patient, in the reboxetine group, dropped out due to a side effect (constipation)."	( [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. Akgöz, S; Akkaya, C; Eker, SS; Kirli, S; Sarandöl, A, 2005)	0.62
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control."	( Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007)	1.78
" The treatment response was assessed at baseline, week 4 and week 12, with hospital anxiety and depression scale (HADS) and Montgomery Asberg depression rating scale (MADRS), to rate depression and anxiety; mini mental adjustment to cancer scale (Mini-MAC), to assess the psychological response to the diagnosis of cancer; clinical global impression (CGI) to evaluate severity of illness; dosage record and treatment emergent symptom scale (DOTES), to assess the adverse effects of the clinical treatments and their possible relation with the drug used; and QL index to rate quality of life."	( Sertraline effectiveness and safety in depressed oncological patients. Caldera, P; Siri, I; Torta, R, 2008)	1.79
" No severe adverse effects were observed."	( Sertraline effectiveness and safety in depressed oncological patients. Caldera, P; Siri, I; Torta, R, 2008)	1.79
" Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4."	( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)	0.35
" The presented results indicate that sertraline hydrochloride adversely affects aquatic organisms at levels several orders of magnitude higher than that reported in municipal effluent concentrations, however adverse effects may result from lower concentration exposures, further research into chronic toxicity is therefore advocated."	( Aquatic ecotoxicity of the selective serotonin reuptake inhibitor sertraline hydrochloride in a battery of freshwater test species. Davoren, M; Hernan, R; Lyng, FM; Minagh, E; O'Rourke, K, 2009)	0.86
"Because of the high prevalence of depression and its significant adverse impact on prognosis of patients with ischemic heart disease (IHD) and HF, the Safety and Efficacy of Sertraline for Depression in Patients with Chronic Heart Failure (SADHART-CHF) trial aims to assess the effects of sertraline on response of depression as well as on the cardiac prognosis of patients with HF."	( Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Arias, RM; Callwood, DD; Cuffe, MS; Henke, E; Jiang, W; Krishnan, R; Kuchibhatla, M; O'Connor, C; Silva, SG; Zakhary, B, 2008)	0.85
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
"Sertraline was safe in patients with significant HF."	( Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. Arias, RM; Callwood, DD; Cuffe, MS; Jiang, W; Krishnan, R; Kuchibhatla, M; O'Connor, CM; Rivelli, SK; Silva, SG; Stough, WG; Zakhary, B, 2010)	2.11
" Also, with the aim to evaluate the antidepressant effect of its iodine product we demonstrated for this compound the toxic effect towards the male Wistar rats."	( Sertraline and its iodine product: experimental and theoretical vibrational studies: potential in vitro anti-thyroid activity of sertraline and iodine product toxicity with respect to male Wistar rats. Escudero, GE; Ferraresi Curotto, V; Ferrer, EG; Laino, CH; Pis Diez, R; Williams, PA, 2013)	1.83
"Cisplatin is a widely used chemotherapeutic agent, but its ototoxicity side effect can occur in the majority of patients."	( Possible protective effect of sertraline against cisplatin-induced ototoxicity: an experimental study. Erdogan, S; Iseri, M; Ozturk, M; Sarı, F; Topdag, M; Ucar, S, 2013)	0.68
"Tandospirone is safe and effective and appears non-inferior to sertraline for SAD in youths."	( Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial. Gan, JJ; Huang, X; Ji, JL; Li, C; Li, WH; Luo, YL; Wang, B; Zhang, W, 2013)	0.86
" Simvastatin was the most toxic tested compound for zebrafish embryo, followed by diclofenac."	( Toxicity screening of diclofenac, propranolol, sertraline and simvastatin using Danio rerio and Paracentrotus lividus embryo bioassays. Martins, R; Ribeiro, S; Santos, MM; Torres, T, 2015)	0.67
"To evaluate the frequency of adverse events (AEs) across 4 treatment conditions in the Child/Adolescent Anxiety Multimodal Study (CAMS), and to compare the frequency of AEs between children and adolescents."	( Child/Adolescent anxiety multimodal study: evaluating safety. Albano, AM; Birmaher, B; Chrisman, A; Compton, SN; Iyengar, S; Keeton, C; Kendall, PC; March, JS; McCracken, J; Piacentini, J; Riddle, MA; Rynn, MA; Sakolsky, DJ; Shen, S; Sherrill, JT; Walkup, JT; Waslick, B, 2015)	0.42
" The aim of this study was to examine the features and prevalence of adverse effects of paroxetine and sertraline in breastfed infants."	( Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. Arpaci, N; Uguz, F, 2016)	0.92
"The prevalence rate of adverse events in the infants was 12."	( Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. Arpaci, N; Uguz, F, 2016)	0.71
"The results suggest that the prevalence rate of adverse events in the infants exposed to sertraline or paroxetine is relatively low and mostly mild."	( Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. Arpaci, N; Uguz, F, 2016)	0.93
" Iopamidol was not toxic at concentrations up to 101 mg/L."	( The effects of pharmaceuticals on a unionid mussel (Lampsilis siliquoidea): An examination of acute and chronic endpoints of toxicity across life stages. Bendo, NA; de Solla, SR; Giacomin, M; Gillis, PL; Gilroy, ÈAM; King, LE; Salerno, J, 2017)	0.46
" The adverse events in this chart review were consistent with the known safety profile of sertraline."	( Dosage, effectiveness, and safety of sertraline treatment for posttraumatic stress disorder in a Japanese clinical setting: a retrospective study. Hoshino, Y; Kamo, T; Kato, H; Kuribayashi, K; Maeda, M; Oe, M; Shigemura, J, 2016)	0.93
"This study was conducted to clarify the toxic effects of sertraline (SRT) on the reproductive system of male rats and to elucidate the underlying mechanisms."	( Sertraline-induced reproductive toxicity in male rats: evaluation of possible underlying mechanisms. Atli, O; Aydogan-Kilic, G; Baysal, M; Ilgin, S; Karaduman, B; Kilic, V; Ucarcan, S, )	1.82
" This study aimed to evaluate sertraline efficacy and adverse events in Chinese patients with PTSD over 12 weeks."	( Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. Li, BL; Li, W; Ma, YB; Meng, QG; Yang, Q; Zhang, Y, 2017)	1.06
" Impact of Event Scale-Revised subscores constituted the primary outcome, with Clinical Global Impression Scale-Severity scores and adverse events as secondary outcomes."	( Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. Li, BL; Li, W; Ma, YB; Meng, QG; Yang, Q; Zhang, Y, 2017)	0.77
" The most common adverse event was nausea, which occurred in 12 (33."	( Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. Li, BL; Li, W; Ma, YB; Meng, QG; Yang, Q; Zhang, Y, 2017)	0.77
" Significantly lower adverse event rate was observed in the Shugan Jieyu group."	( Clinical efficacy and safety of the Shugan Jieyu capsule in patients with acute myocardial infarction and depression. Liu, W; Qin, J, 2016)	0.43
"Although sertraline is widely prescribed as relatively safe antidepressant drug, hepatic toxicity was reported in some patients with sertraline treatment."	( In vivo investigation on the chronic hepatotoxicity induced by sertraline. Almansour, MI; Jarrar, BM; Jarrar, YB, 2018)	1.14
" The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache."	( Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D, 2019)	0.51
"Our case adds to the existing literature by demonstrating that patients may experience adverse medication effects despite lamotrigine levels that are normally considered to be in the therapeutic range, highlighting the importance of clinical correlation when obtaining medication levels."	( Delirium Secondary to Lamotrigine Toxicity. Catalano, G; Catalano, MC; Fusick, AJ; Gunther, SR; Hernandez, MJ; Sanchez, DL; Sullivan, GA, 2020)	0.56
" Therefore, BoNT/A could be a safe and effective option for the treatment of depression."	( The safety and efficacy of botulinum toxin A on the treatment of depression. Cao, C; Chen, LH; Fan, Y; Hu, H; Jiang, C; Li, Y; Liu, J; Liu, T; Luo, W; Tang, Z; Wu, W; Xu, Y; Zhang, Q, 2021)	0.62
" These medications alleviate symptoms and restore function for many youths; however, they are associated with a distinct adverse effect profile, and their tolerability may complicate treatment or lead to discontinuation."	( Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Croarkin, PE; Mills, JA; Poweleit, EA; Ramsey, LB; Strawn, JR, 2023)	0.91
", weight gain) adverse effects of SSRIs and some SNRIs in pediatric patients."	( Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Croarkin, PE; Mills, JA; Poweleit, EA; Ramsey, LB; Strawn, JR, 2023)	0.91
"We provide a framework for discussing SSRI/SNRI tolerability with patients and their families and describe the pharmacologic basis, course, and predictors of adverse events in youth."	( Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Croarkin, PE; Mills, JA; Poweleit, EA; Ramsey, LB; Strawn, JR, 2023)	0.91
"SSRI/SNRIs are associated with both early-emerging (often transient) and late-emerging adverse effects in youth."	( Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Croarkin, PE; Mills, JA; Poweleit, EA; Ramsey, LB; Strawn, JR, 2023)	0.91

Excerpt	Reference	Relevance
"The pharmacokinetic properties of the newer specific serotonin (5-HT) reuptake inhibitors are reviewed."	( Pharmacokinetics of the selective serotonin reuptake inhibitors. DeVane, CL, 1992)	0.28
" From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme."	( Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Baumann, P; Rochat, B, 1995)	0.48
"The pharmacokinetic interactions of sertraline and fluoxetine with the tricyclic antidepressant desipramine were studied in 18 healthy male volunteers phenotyped as extensive metabolizers of dextromethorphan."	( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994)	0.81
" Samples for pharmacokinetic analyses were obtained on Days 15 and 32; trough plasma concentrations of carbamazepine and its principal metabolite, carbamazepine-10, 11-epoxide (CBZ-E), were determined daily beginning on Day 13."	( Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Dewland, PM; Muirhead, DC; Rapeport, WG; Tanner, T; Wesnes, K; Williams, SA, 1996)	0.66
"There were no significant differences between the sertraline and placebo groups in any of the pharmacokinetic parameters for carbamazepine or CBZ-E."	( Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Dewland, PM; Muirhead, DC; Rapeport, WG; Tanner, T; Wesnes, K; Williams, SA, 1996)	0.92
"There were no significant differences between the sertraline group and the placebo group in the pharmacokinetic parameters of phenytoin."	( Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Cross, M; Muirhead, DC; Rapeport, WG; Wesnes, K; Williams, SA, 1996)	0.87
"7-fold increase in Cmax and a significant prolongation in elimination half-life in hepatically impaired patients."	( Influence of liver cirrhosis on sertraline pharmacokinetics. Angebaud, P; Coates, P; Démolis, JL; Funck-Brentano, C; Grangé, JD; Jaillon, P, 1996)	0.58
"A nonblinded study was conducted to compare the pharmacokinetic properties of the selective serotonin reuptake inhibitor sertraline in 22 young (aged 18 to 45 years) and 22 elderly (> 65 years) volunteers, of whom half were male and half were female."	( Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Ronfeld, RA; Tremaine, LM; Wilner, KD, 1997)	0.83
" The pharmacokinetic analyses were based on data from 20 individuals."	( Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Baris, BA; Gardner, MJ; Preskorn, SH; Wilner, KD, 1997)	0.7
" There were no significant treatment effects on the mean area under the plasma concentration-time curve (AUC), mean peak plasma sertraline concentration (Cmax), mean time to reach Cmax (tmax), mean terminal elimination half-life, or the mean elimination rate constant in either study."	( Sertraline. Chronopharmacokinetics and the effect of coadministration with food. Baris, BA; Ronfeld, RA; Wilner, KD, 1997)	1.95
" An approximately 10-fold increase in the Cmax and AUC(24) of paroxetine and an approximately 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concentration changes."	( Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Alderman, J; Allison, J; Chung, M; Greenblatt, DJ; Harrison, W; Penenberg, D; Preskorn, SH, 1997)	0.74
"To examine the pharmacokinetic interaction between the selective serotonin reuptake inhibitor sertraline and the tricyclic antidepressants desipramine or imipramine in 12 healthy male subjects."	( The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997)	0.88
"Multiple-dose, but not single-dose, treatment with sertraline significantly reduced apparent plasma clearance (CL/F) and prolonged the half-life of desipramine relative to baseline."	( The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997)	0.91
"This pharmacokinetic interaction is likely the result of an inhibition of CYP2D6 tricyclic metabolism by sertraline."	( The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997)	0.87
"Mean area under the plasma concentration-time curve (AUC), peak plasma concentration (Cmax), and elimination half-life (t1/2) for sertraline and desmethylsertraline were similar to previously reported adult values."	( Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. Alderman, J; Chung, M; Johnston, HF; Wolkow, R, 1998)	1.95
" They differ, however, in their pharmacokinetic properties."	( Pharmacokinetics of selective serotonin reuptake inhibitors. Härtter, S; Hiemke, C, 2000)	0.31
"05) and terminal elimination half-life values of sertraline (35."	( Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Chen, XP; He, N; Liu, ZQ; Shu, Y; Wang, JH; Wang, W; Zhou, HH, 2001)	0.89
"The mean steady-state half-life of 50 mg was significantly shorter (15."	( Sertraline pharmacokinetics and dynamics in adolescents. Axelson, DA; Birmaher, B; Brent, DA; Bridge, J; Nuss, S; Perel, JM; Rudolph, GR, 2002)	1.76
"The half-life of sertraline 50 mg becomes significantly shorter from the initial dose to steady-state, and many adolescents may benefit from twice-per-day dosing."	( Sertraline pharmacokinetics and dynamics in adolescents. Axelson, DA; Birmaher, B; Brent, DA; Bridge, J; Nuss, S; Perel, JM; Rudolph, GR, 2002)	2.1
" The present study reports the pharmacokinetic results of up to eight serum samples per patient."	( Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Aberg-Wistedt, A; Agren, H; Akerblad, AC; Bengtsson, F; Höglund, P; Reis, M, 2004)	0.64
"The co-administration of once-daily oral donepezil HCl 5 mg for 15 days and once-daily oral sertraline HCl (50 mg for 5 days increased to 100 mg for 10 days) did not result in any clinically meaningful pharmacokinetic interactions, and no unexpected AEs were observed."	( Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Cullen, EI; Kumar, D; Nagy, CF; Perdomo, CA; Pratt, RD; Wason, S, 2004)	0.8
"The goal of this study was to determine whether there is a pharmacokinetic interaction, as shown by plasma concentrations and electrocardiographic evidence of QTc intervals, between sertraline 200 mg QD and cisapride 10 mg QID, and between sertraline 200 mg QD and pimozide (single 2-mg dose)."	( Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Alderman, J, 2005)	0.84
" Coadministration of sertraline and pimozide resulted in statistically significant increases of 35% and 37% in pimozide Cmax and AUC(0-infinity), respectively, compared with pimozide alone."	( Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Alderman, J, 2005)	0.97
" A pharmacokinetic analysis was performed using both traditional compartmental modeling and a population pharmacokinetic approach."	( Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. DeVane, CL; Donovan, JL; Gibson, BB; Markowitz, JS; Wang, JS; Zhu, HJ, 2006)	0.55
" It increased the plasma AUC and elimination half-life (T1/2e) of desmethyl-SERT 12."	( Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. DeVane, CL; Donovan, JL; Gibson, BB; Markowitz, JS; Wang, JS; Zhu, HJ, 2006)	0.55
"These results suggest that pharmacokinetic interactions exist among these three psychoactive drugs involving inhibition of drug metabolizing enzymes and/or P-gp and other drug transporters present in the BBB."	( Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. DeVane, CL; Donovan, JL; Gibson, BB; Markowitz, JS; Wang, JS; Zhu, HJ, 2006)	0.55
" Blood samples were collected for pharmacokinetic analysis of ADTs."	( The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K, 2010)	0.36
" For each sampling period for SER, area under the serum concentration versus time curve, maximal serum concentration (Cmax), and the time at which Cmax occurred (Tmax) were determined."	( Pharmacokinetics of sertraline across pregnancy and postpartum. Anthony, M; Davis, MF; Fankhauser, M; Freeman, MP; Fried, K; Moreno, F; Nolan, PE; Woosley, RL, 2008)	0.67
" Putatively the co-administration of bupropion and sertraline could lead to a significant pharmacokinetic drug-drug interaction."	( Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. Hassan, HE; Molnari, JC; Myers, AL, 2012)	1.02
" This study was performed to evaluate the pharmacokinetic (PK) characteristics after the administration of low dose sertraline for the purpose of exploring an application of microdosing methods in PK studies."	( Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. Cho, JY; Jang, IJ; Kim, KP; Kim, TE; Park, MK; Shin, KH; Shin, SG; Yoon, SH; Yu, KS, 2011)	0.82
" In this process, particular attention is paid to the pharmacokinetic characteristics of the drug and its safety in clinical use."	( Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety. Mandrioli, R; Mercolini, L; Raggi, MA, 2013)	0.63
" The calculated half-life of sertraline following overdose was 28 h (IQR 19."	( The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. Cooper, JM; Duffull, SB; Isbister, GK; Saiao, AS, 2015)	1.02
" We characterized the impact of sertraline co-administration on olanzapine clearance in psychotic depression using population pharmacokinetic methods."	( The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Bies, RR; Davies, SJ; Flint, AJ; Kirshner, MM; Meyers, BS; Mulsant, BH; Pollock, BG; Rothschild, AJ; Sorisio, D; Whyte, EM, 2015)	1.06
" We used NONMEM (Version VII) for population pharmacokinetic analysis, assessing effects of the covariates sex, African American origin, smoking, age, and sertraline co-administration."	( The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Bies, RR; Davies, SJ; Flint, AJ; Kirshner, MM; Meyers, BS; Mulsant, BH; Pollock, BG; Rothschild, AJ; Sorisio, D; Whyte, EM, 2015)	0.98
"Population pharmacokinetic analysis comprised 336 samples from 175 individuals."	( The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Bies, RR; Davies, SJ; Flint, AJ; Kirshner, MM; Meyers, BS; Mulsant, BH; Pollock, BG; Rothschild, AJ; Sorisio, D; Whyte, EM, 2015)	0.78
" This fully validated method was successfully applied to the pharmacokinetic study after an oral administration of 100 mg sertraline to 20 Chinese healthy male volunteers."	( Determination of Sertraline in Human Plasma by UPLC-MS/MS and its Application to a Pharmacokinetic Study. Tian, DD; Wang, Z; Ye, Q; Yue, XH; Zhang, JW; Zhu, K, 2016)	0.98
" Half-life and sex effect on sertraline apparent clearance (males averaging 50% higher (p < 0."	( SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Bies, RR; Davies, SJ; Flint, AJ; Kirshner, MM; Meyers, BS; Mulsant, BH; Pollock, BG; Rothschild, AJ; Sorisio, D; Whyte, EM, 2016)	0.97
"This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling."	( Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help? Chen, Y; Lin, J; Mao, J; Peters, S; Shebley, M; Templeton, IE; Varma, MV; Yu, H, 2016)	0.43
" The study objectives were to develop a physiologically-based pharmacokinetic (PBPK) model of sertraline and estimate the probability of achieving effective concentrations in various human tissues."	( Physiologically-Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target Tissues. Alhadab, AA; Brundage, RC, 2020)	1.03
" The aim of our study was to evaluate pharmacokinetic interactions between clozapine and sertraline analysing a therapeutic drug monitoring database of 1644 clozapine-medicated patients."	( Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. Gründer, G; Haen, E; Hiemke, C; Kuzin, M; Paulzen, M; Ridders, F; Schoretsanitis, G, 2020)	1.03
" The study objective was to characterize sertraline pharmacokinetics by developing and validating a sertraline population pharmacokinetic (PK) model in healthy subjects using published clinical PK data."	( Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysis. Alhadab, AA; Brundage, RC, 2020)	1.11
" We aimed to develop a physiologically based pharmacokinetic (PBPK) model that allows gestational-age dependent prediction of sertraline dosing in pregnancy."	( Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. Beitz, J; Crentsil, V; George, B; Lumen, A; Nguyen, C; Wang, J; Wesley, B, 2020)	1
" A pharmacokinetic modeling virtual clinical trials approach was implemented to: (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 phenotypes, and (ii) identify appropriate dose titration strategies to stabilize sertraline levels within a defined therapeutic range throughout gestation."	( The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study. Almurjan, A; Badhan, RKS; Macfarlane, H, 2021)	1.08
" These results indicate P-gp-mediated pharmacokinetic interaction increases pimozide accumulation in AC16 cells, and the subsequent elevated pimozide levels within the cells may result in an increased risk of hERG channel inhibition."	( P-Glycoprotein-Mediated Pharmacokinetic Interactions Increase Pimozide hERG Channel Inhibition. Ito, MA; Mizoi, K; Morishita, H; Ogihara, T; Perera, LMB; Yano, K; Zhang, X, 2022)	0.72
"Sertraline is one of the most prescribed antidepressants, but its pharmacokinetic (PK) properties are still not completely characterized."	( Population Pharmacokinetic Modeling to Inform Sertraline Dosing Optimization in Patients with Depression. Ilic, N; Jankovic, SM; Milovanovic, J; Nikolic, VN; Popovic, D; Stoiljkovic, M; Vujovic, M, 2023)	2.61

Excerpt	Reference	Relevance
" Ice packs combined with a cooling blanket and dantrolene 80 mg iv were administered to control fever and rigidity, respectively."	( Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Graber, MA; Hoehns, TB; Perry, PJ, 1994)	1.73
"Selective serotonin reuptake inhibitor antidepressants should not be combined with monoamine oxidase inhibitor antidepressants because of the risk of serotonin syndrome."	( Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Graber, MA; Hoehns, TB; Perry, PJ, 1994)	1.73
" To minimize the potential for an adverse event, the practitioner must remember the drug-drug interactions, and possible consequences when one of these antidepressants is being prescribed."	( Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Richelson, E, 1997)	0.3
" In the present study, the effect of gabapentin (GBP) on seizure score and memory is evaluated when it is given alone and in combination with some antidepressants, such as sertraline (SERTR) and alprazolam (ALP)."	( Effects of gabapentin and antidepressant drug combinations on convulsions and memory in mice. Ali, A; Dua, Y; Pal, SN; Pillai, KK; Rizwan, AN, )	0.33
"Accumulating evidence indicates that modulation of the activity of cytochrome P450 (CYP) enzymes and the multidrug resistance transporter P-glycoprotein (P-gp) is responsible for many drug-drug interactions."	( Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. DeVane, CL; Donovan, JL; Gibson, BB; Markowitz, JS; Wang, JS; Zhu, HJ, 2006)	0.55
"The potential interaction of risperidone (RISP), which is metabolized by 2D6 and transported across the blood brain barrier (BBB) by P-gp, was studied in combination with bupropion (BUP) and also with sertraline (SERT)."	( Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. DeVane, CL; Donovan, JL; Gibson, BB; Markowitz, JS; Wang, JS; Zhu, HJ, 2006)	0.74
" Linezolid is a weak monoamine oxidase inhibitor and has been reported to interact with selective serotonin reuptake inhibitors (SSRIs)."	( Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Andrus, MR; Byrd, DC; Clark, DB, 2006)	0.55
"Patients taking antidepressants are more likely to also be taking multiple medications, increasing the risk of adverse drug-drug interactions (DDIs)."	( The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. Choi, J; Golbeck, AL; Neff, M; Preskorn, SH; Shah, R, 2007)	0.54
"Our data, showing that ziprasidone in combination with sertraline lead to a decrease of prolonged P3 latencies, are in line with previous studies showing a decrease of prolonged P3 latencies by antidepressant treatment."	( The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features. Arolt, V; Baune, BT; Dannlowski, U; Deckert, J; Evers, S; Hetzel, G; Moeller, O; Nguyen, DH, 2007)	0.85
"The potential of metabolites to contribute to drug-drug interactions (DDIs) is not well defined."	( Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Fujioka, Y; Hachad, H; Isoherranen, N; Levy, RH; Yeung, CK, 2011)	0.37
" Our aims were to prospectively assess the antiviral efficacy and safety of this drug combination in chronic hepatitis C (CHC) patients."	( Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. Altmeyer, R; Cheng, CW; Chopra, N; Lawitz, E; Lim, SG; McHutchison, JG; Patel, K; Randle, JC; Tillmann, HL, 2011)	0.59
" Using data from a recent factorial, double-blinded, placebo-controlled trial applying tDCS-alone and combined with sertraline to treat 120 depressed outpatients over 6 wk (Brunoni et al."	( Differential improvement in depressive symptoms for tDCS alone and combined with pharmacotherapy: an exploratory analysis from the Sertraline vs. Electrical Current Therapy for Treating Depression Clinical Study. Benseñor, IM; Brunoni, AR; Fregni, F; Júnior, RF; Kemp, AH; Lotufo, PA, 2014)	0.82
" In addition, we aimed to explore differences in drug-drug interactions across multiple GBM-derived cell cultures and predict such differences by use of transcriptional biomarkers."	( Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B, 2013)	0.39
"We performed a screen in which we quantified drug-drug interactions for 465 drug pairs in each of the 5 GBM cell lines U87MG, U343MG, U373MG, A172, and T98G."	( Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B, 2013)	0.39
"In this study we report on potential drug-drug interactions between drugs occurring in patient clinical data."	( Using semantic predications to uncover drug-drug interactions in clinical data. Cairelli, MJ; Fiszman, M; Kilicoglu, H; Melton, GB; Pakhomov, SV; Rindflesch, TC; Rosemblat, G; Zhang, R, 2014)	0.4
" In addition, in an aggressive and highly resistant human ovarian xenograft mouse model the use of sertraline in combination with Doxil® generated substantial reduction in tumor progression, with extension of the median survival of tumor-bearing mice."	( Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Bitcover, R; Drinberg, V; Peer, D; Rajchenbach, W, 2014)	0.88
"To observe the clinical effectiveness of Qilin Pills combined with sertraline in the treatment of secondary non-consolidated kidney qi premature ejaculation (PE)."	( [Efficacy of Qilin Pills combined with sertraline in the treatment of secondary non-consolidated kidney qi premature ejaculation]. Li, JX; Lu, QG, 2015)	0.92
"Qilin Pills combined with sertraline has a definite efficacy in the treatment of secondary non-consolidated kidney qi PE and therefore deserves wide clinical application."	( [Efficacy of Qilin Pills combined with sertraline in the treatment of secondary non-consolidated kidney qi premature ejaculation]. Li, JX; Lu, QG, 2015)	0.99
"To observe the clinical effect of Shugan Yiyang Capsules combined with sertraline in the treatment of premature ejaculation (PE)."	( [Efficacy of Shugan Yiyang Capsules combined with sertraline on premature ejaculation]. Wu, XW; Zeng, YY, 2015)	0.9
"Shugan Yiyang Capsules combined with sertraline have a definite and lasting effect on premature ejaculation."	( [Efficacy of Shugan Yiyang Capsules combined with sertraline on premature ejaculation]. Wu, XW; Zeng, YY, 2015)	0.94
"To investigate the clinical effectiveness of sertraline hydrochloride combined with four-spot caress in the treatment of primary premature ejaculation (PE)."	( [Sertraline hydrochloride combined with four-spot caressing for primary premature ejaculation]. Bian, TS; Huang, J; Liu, ZJ; Wang, JS; Yue, J; Zeng, QQ; Zhu, Y, 2015)	1.59
"Sertraline hydrochloride combined with four-spot caressing, with its definite efficacy and rare adverse reactions, deserves wide clinical application in the treatment of primary PE."	( [Sertraline hydrochloride combined with four-spot caressing for primary premature ejaculation]. Bian, TS; Huang, J; Liu, ZJ; Wang, JS; Yue, J; Zeng, QQ; Zhu, Y, 2015)	2.77
" Our results show the therapeutic potential of chlorpromazine and sertraline in combination with amphotericin B against neurocryptococcosis."	( In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii. Alves, SH; Chassot, F; Loreto, ÉS; Rossato, L; Santurio, JM; Zanette, RA, 2016)	0.92
"This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling."	( Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help? Chen, Y; Lin, J; Mao, J; Peters, S; Shebley, M; Templeton, IE; Varma, MV; Yu, H, 2016)	0.43
"The study was a randomised pragmatic trial comparing venlafaxine and sertraline in combination with psychotherapy and social counselling."	( Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study. Bech, P; Carlsson, J; Elklit, A; Mortensen, EL; Sonne, C, 2016)	0.91
" Limited resources and information on significant drug-drug interactions with dietary supplements and prescription medications have contributed to associated complications and unexpected events."	( Dietary Supplement-Drug Interaction-Induced Serotonin Syndrome Progressing to Acute Compartment Syndrome. Marzella, N; Patel, YA, 2017)	0.46
"5mA; electrode 3,5×7cm) combined with 50mg/day of sertraline were performed."	( Transcranial direct current stimulation of 20- and 30-minutes combined with sertraline for the treatment of depression. Bocharnikova, EN; Druzhkova, TA; Gersamia, AG; Gotovtseva, GN; Gudkova, AA; Guekht, AB; Menshikova, AA; Pavlova, EL; Semenov, RV, 2018)	0.96
"tDCS of 20- or 30-minutes combined with sertraline are efficient for the treatment of mild and moderate depression; the effect of 30min stimulation exceeds the one obtained from 20min."	( Transcranial direct current stimulation of 20- and 30-minutes combined with sertraline for the treatment of depression. Bocharnikova, EN; Druzhkova, TA; Gersamia, AG; Gotovtseva, GN; Gudkova, AA; Guekht, AB; Menshikova, AA; Pavlova, EL; Semenov, RV, 2018)	0.98
"To compare the clinical effects of acupuncture combined with sertraline hydrochloride and simple sertraline hydrochloride on tumor-related depression."	( [Clinical observation of acupuncture combined with sertraline hydrochloride tablets on tumor-related depression]. Deng, XY; Xu, TS, 2019)	1.01
"The efficacy of antidepressant drugs combined with psychotherapy is controversial; hence, this meta-analysis was conducted to assess the efficacy of the combination therapy."	( Efficacy of Sertraline Combined with Cognitive Behavioral Therapy for Adolescent Depression: A Systematic Review and Meta-Analysis. Li, G; Liu, W; Wang, C; Wang, X; Yang, L, 2021)	1
" We included the literature on the comparison of the sertraline combined with cognitive behavioral therapy (CBT) and each treatment alone for adolescent depression published in 2000-2021."	( Efficacy of Sertraline Combined with Cognitive Behavioral Therapy for Adolescent Depression: A Systematic Review and Meta-Analysis. Li, G; Liu, W; Wang, C; Wang, X; Yang, L, 2021)	1.25
"Although the number of comparative trials is small, this study shows that sertraline is effective for adolescent depression, but sertraline combined with CBT is more effective."	( Efficacy of Sertraline Combined with Cognitive Behavioral Therapy for Adolescent Depression: A Systematic Review and Meta-Analysis. Li, G; Liu, W; Wang, C; Wang, X; Yang, L, 2021)	1.23
" This 24-week randomized, double-blinded, controlled clinical trial randomly allocated 452 FEDN SCZ patients to receive a usual dose of ziprasidone (control group) or half the dose of ziprasidone in combination with sertraline (ZS group)."	( Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial. Guan, X; Kosten, TR; Liu, J; Wang, Y; Wu, F; Xiu, M; Zhang, X; Zhu, C, 2022)	1.17
" We hypothesized that a low dose of risperidone in combination with sertraline would reduce serious adverse effects without decreasing treatment response."	( Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023)	1.4
"A total of 230 patients with FEMN SZ were randomly assigned to receive low-dose risperidone in combination with sertraline (RS group) or regular-dose risperidone (control group)."	( Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023)	1.37
"Our study suggests that low-dose risperidone in combination with sertraline was more effective for psychotic symptoms and psychosocial functioning, with significantly fewer adverse effects in patients with FEMN SZ."	( Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023)	1.4
" Potential drug-drug interactions (DDIs) were assessed by Lexi-Interact ver."	( Potential Drug Interactions in Terminally-Ill Cancer Patients, a Report from the Middle East. Mahzoni, H; Moghaddas, A; Momenzadeh, M; Naghsh, E; Sharifi, M, 2023)	0.91
" Our findings highlight that rTMS in combination with antidepressants is a rapid method of symptom improvement in patients with somatic pain with MDD and is helpful for cognitive impairment and anxiety."	( Rapid improvements and subsequent effects in major depressive disorder patients with somatic pain using rTMS combined with sertraline. Lei, F; Sun, Y; Zheng, Z; Zou, K, 2023)	1.12

Excerpt	Reference	Relevance
" They are well absorbed orally but exhibit an extensive first-pass extraction in the liver."	( Pharmacokinetics of the selective serotonin reuptake inhibitors. DeVane, CL, 1992)	0.28
" Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism that is partially saturable."	( The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Johnson, AM; Tulloch, IF, 1992)	0.28
" The results of these 2 studies show that the bioavailability and elimination of sertraline tablets are not influenced by the time of administration or administration with or without food."	( Sertraline. Chronopharmacokinetics and the effect of coadministration with food. Baris, BA; Ronfeld, RA; Wilner, KD, 1997)	1.97
"To compare the bioavailability of 2 sertraline tablets formulations (Tolrest from Laboratórios Biosintética, and Zoloft from Laboratórios Pfizer, Brazil) in 24 healthy volunteers of both sexes (12 male and 12 female) who received a single 50 mg dose of each sertraline formulation."	( Comparative bioavailability of two sertraline tablet formulations in healthy human volunteers after a single dose administration. Corso, G; De Nucci, G; Frota Bezerra, FA; Lerner, FE; Moraes, ME; Moraes, MO; Perozin, M; Sucupira, M, 1998)	0.85
"Since the 90% CI for both Cmax and AUC(0-96h) mean ratio were within the 80-125% interval proposed by the Food and Drug Administration, it was concluded that Tolrest was bioequivalent to Zolof for both extent and rate of absorption in a single dose administration."	( Comparative bioavailability of two sertraline tablet formulations in healthy human volunteers after a single dose administration. Corso, G; De Nucci, G; Frota Bezerra, FA; Lerner, FE; Moraes, ME; Moraes, MO; Perozin, M; Sucupira, M, 1998)	0.58
"The study was designed to evaluate the bioavailability of two sertraline (CAS 79617-96-2) formulations."	( Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. Alpan, RS; Erenmemisoglu, A; Koytchev, R; Ozalp, Y; van der Meer, MJ, 2004)	0.82
"An open-label, randomised, crossover single dose study, using 2 periods x 2 sequences, with a minimum washout period of 4 weeks, was conducted in order to assess the comparative bioavailability of two formulations of sertraline hydrochloride (CAS 79617-96-2) 100 mg tablets."	( Comparative bioavailability/ bioequivalence of two different sertraline formulations: a randomised, 2-period x 2-sequence, crossover clinical trial in healthy volunteers. Almeida, S; Caturla, MC; Cea, E; Filipe, A; Portolés, A; Terleira, A, 2005)	0.76
"To compare the bioavailability of two sertraline tablet (50 mg) formulations (Serlift from Ranbaxy Laboratories Ltd."	( Comparative bioavailability of two sertraline tablet formulations after single-dose administration in healthy Thai volunteers. Gaysonsiri, D; Kanchanawat, S; Khuroo, A; Kittiwattanagul, K; Monif, T; Panigrahy, BK; Paupairoj, P; Reyar, S; Tassaneeyakul, W; Tippabhotla, SK; Vannaprasath, S, 2008)	0.89
"The following recommendations are made regarding intubation studies: (i) no intubation study is recommended for compounds with high permeability, since these compounds are likely to be well absorbed from the colon; (ii) compounds with moderate permeability may require an intubation study if the dog colon and in silico models predict a marginally acceptable CR concentration-time profile; (iii) use a dose that approximates 1 h of the intended CR delivery rate; (iv) use the smallest volume possible; (v) define and record tubing placement; (vi) use a thermodynamically stable solution or/and suspension."	( The use of gastrointestinal intubation studies for controlled release development. Sutton, SC, 2009)	0.35
"To determine the bioavailability of 50 mg sertraline tablets between the test product (Zotaline, M&H Manufacturing Co."	( Bioequivalence study of 50 mg sertraline tablets in healthy Thai volunteers. Chatsiricharoenkul, S; Kongpatanakul, S; Niyomnaitham, S; Pongnarin, P; Sathirakul, K, 2009)	0.91
" Self-report indices of mood and personality, and genotype (5-HTTLPR) and sertraline bioavailability were assessed."	( Mood and personality effects in healthy participants after chronic administration of sertraline. Allen, NB; Simmons, JG, 2011)	0.82
" Genotype and bioavailability of sertraline did not moderate these findings, however gender did."	( Mood and personality effects in healthy participants after chronic administration of sertraline. Allen, NB; Simmons, JG, 2011)	0.87
" Hence, sertraline could alter the bioavailability of drugs absorbed via PAT1."	( Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro. Abdulhadi, S; Brodin, B; Frølund, S; Holm, R; Kall, MA; Langthaler, L; Nielsen, CU; Nøhr, MK; Sari, H, 2013)	2.27
"Human serum albumin (HSA)-drug binding is an important factor to determine half life and bioavailability of drugs."	( Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Ashrafi-Kooshk, MR; Khodarahmi, R; Nowroozi, A; Rahimi, B; Sadrjavadi, K; Shahlaei, M, 2015)	0.7
" Poor bioavailability (around 44%) of hydrochloride salt is considered to be conversion of salts to free base in the gastrointestinal tract which retard it's absorption."	( Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats. Harwansh, RK; Iqbal, Z; Rahman, MA, 2019)	0.81
" Hence, the SLN can be used as a potential carrier for successful delivery of poorly water-soluble drugs associated with poor oral bioavailability like sertraline."	( Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats. Harwansh, RK; Iqbal, Z; Rahman, MA, 2019)	1.01
" plasma concentration data then absorption and bioavailability were optimized from oral data."	( Physiologically-Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target Tissues. Alhadab, AA; Brundage, RC, 2020)	0.82
" The steroid structure was chemically altered to improve bioavailability and create an oral dosage form."	( Neuroactive steroids - new possibilities in the treatment of postpartum depression. Adamičková, A; Gažová, A; Hrubá, O; Massarová, P; Vranecová, K; Žigová, L, 2022)	0.72

Excerpt	Relevance	Reference
"The pharmacology and pharmacokinetics, adverse effects, drug interactions, efficacy, and dosage and administration of the new selective serotonin reuptake inhibitors paroxetine, sertraline, and fluvoxamine are reviewed."	( Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Grimsley, SR; Jann, MW, 1992)	0.86
" Furthermore, the SSRIs generally do not require dosage escalation for most patients and evidence indicates that they are effective in the treatment of depression associated with anxiety and insomnia."	( Bridging the gap between psychiatric practice and primary care. Thompson, C, 1992)	0.28
" The first of these studies of a flexible dosing design showed that sertraline, given for eight weeks in daily dosages of 50-200 mg, was a safe and effective treatment for OCD, and superior to placebo."	( Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Chouinard, G, 1992)	1.96
" There was no evidence for tolerance to the hypophagic and weight-loss effects of sertraline during either of the chronic dosing studies."	( Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Chapin, DS; Johnson, JL; Nielsen, JA; Torgersen, LK, 1992)	1.95
" Once-daily dosing is recommended, with steady state being reached after about 7 days."	( Clinical implications of the pharmacology of sertraline. Warrington, SJ, 1991)	0.54
" The incidence of side effects was related to both dosage and dosage regimen."	( Toleration and safety of sertraline: experience worldwide. Doogan, DP, 1991)	0.58
" The primary adverse events associated with serotonin reuptake inhibitors involve the gastrointestinal system, although side effects may be less frequent at lower dosage levels."	( Clinical overview of serotonin reuptake inhibitors. Rickels, K; Schweizer, E, 1990)	0.28
" After a 2-week titration period in which the once-daily sertraline dose was increased from 50 mg/day to a maximum of 200 mg/day, dosage was maintained until the end of the eighth week, then patients were titrated off medication over the next 2 weeks."	( Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Bick, PA; Chouinard, G; Gaffney, M; Goodman, W; Greist, J; Hackett, E; Jenike, M; Rasmussen, S; White, K, 1990)	0.75
" Chronic dosing produces down-regulation of beta-adrenergic receptors."	( Sertraline: a new antidepressant. Caillard, V; Doogan, DP, 1988)	1.72
" Acute and repeated dosing of sertraline decreased serotonin content of whole blood."	( Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. Browne, RG; Koe, BK; Weissman, A; Welch, WM, 1983)	2
" Outpatients at a Veterans Affairs mental health clinic who were being treated with fluoxetine were randomly assigned to receive either 50 or 75 mg of sertraline hydrochloride for every 20 mg of fluoxetine (as the hydrochloride salt) or to continue to receive their current dosage of fluoxetine."	( Clinical effect of converting antidepressant therapy from fluoxetine to sertraline. Christenson, JL; Cushing, AG; Haider, A; Miller, DR; Station, RD, 1995)	0.72
" The current study examined the efficacy, safety, and optimal dosing strategy of sertraline in patients with OCD."	( Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Chouinard, G; DuBoff, E; Greist, J; Halaris, A; Kim, SW; Koran, L; Liebowitz, M; Lydiard, RB; Rasmussen, S; White, K, 1995)	0.77
" The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."	( A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Bennie, EH; Martindale, JJ; Mullin, JM, 1995)	0.87
" Its pharmacologic profile permits once-daily dosing while allowing plasma drug levels to equilibrate within 1 week."	( The role of sertraline in the management of depression. Shelton, RC, )	0.51
" At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment."	( Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Preskorn, S, 1994)	0.5
" Case study reports suggest that elderly persons are responsive to selective serotonin uptake inhibitors, although medication selection and dosage may need to be adjusted as a result of the medical conditions sometimes present in the elderly."	( Treatment of obsessive compulsive disorder in the elderly: a review and case example. Calamari, JE; Faber, SD; Hitsman, BL; Poppe, CJ, 1994)	0.29
" The Regenstrief Medical Record System was used to analyze the dosing of SSRIs in the outpatient population of an urban teaching hospital."	( Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Coons, SJ; Gregor, KJ; McDonald, RC; Overhage, JM, )	0.13
"Eleven patients meeting DSM-III-R criteria for at least one personality disorder were treated with sertraline in an open clinical trial with a flexible dosing schedule."	( An open trial of sertraline in personality disordered patients with impulsive aggression. Coccaro, EF; Kavoussi, RJ; Liu, J, 1994)	0.84
" Concentrations in plasma were determined after 7 days of desipramine (50 mg/day) dosing alone, during the 21 days of desipramine and selective serotonin reuptake inhibitor (SSRI) coadministration (fluoxetine, 20 mg/day; sertraline, 50 mg/day), and for 21 days of continued desipramine administration after SSRI discontinuation."	( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994)	0.72
" In keeping with previous data obtained with other sigma receptor ligands, low doses of sertraline and of clorgyline potentiated selectively with a bell-shaped dose-response curve the effect of N-methyl-D-aspartate (NMDA) on pyramidal neurons in the CA3 region of the rat dorsal hippocampus."	( Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands. Bergeron, R; De Montigny, C; Debonnel, G, 1993)	0.51
" Bruxism remitted in all patients after a decrease in antidepressant dosage (N = 1) or addition of buspirone (N = 3)."	( SSRI-associated nocturnal bruxism in four patients. Ellison, JM; Stanziani, P, 1993)	0.29
" In addition, they suggest that a decrease in SSRI dosage or the addition of buspirone may relieve SSRI-associated nocturnal bruxism."	( SSRI-associated nocturnal bruxism in four patients. Ellison, JM; Stanziani, P, 1993)	0.29
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."	( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Hsu, JH; Shen, WW, 1995)	0.29
" Side effects increased with increasing dosage but were usually mild and well tolerated."	( Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Abuzzahab, FS; Amin, M; Claghorn, JL; Dubé, S; Fabre, LF; Mendels, J; Petrie, WM; Small, JG, 1995)	1.73
"The results of this study suggest that dosing adjustments of digoxin may not be necessary in patients receiving concomitant sertraline administration."	( Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. Coates, PE; Dewland, PM; Forster, PL; Rapeport, WG, 1996)	0.87
" Cognitive function testing was performed on Day 1 before carbamazepine dosing (baseline), Day 15 (carbamazepine alone), and Day 32 (carbamazepine plus sertraline or placebo)."	( Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Dewland, PM; Muirhead, DC; Rapeport, WG; Tanner, T; Wesnes, K; Williams, SA, 1996)	0.86
" The plasma phenytoin concentration-time profile was determined on Day 7 before the start of sertraline or placebo dosing and at the end of dosing on Day 24."	( Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Cross, M; Muirhead, DC; Rapeport, WG; Wesnes, K; Williams, SA, 1996)	0.83
" Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25."	( Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. Oliver, SD; Rapeport, WG; Wesnes, K; Williams, SA, 1996)	0.61
" Indeed, planned pharmacokinetic drug interactions at the level of P450s have been proposed to reduce cyclosporine dosage requirements, to reduce variability of TCA levels, and to manipulate the contribution of alternative metabolic pathways to minimize toxic effects."	( Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. Harvey, AT; Preskorn, SH, 1996)	0.29
"1 for protocols 1 and 2, respectively) in stimulating the 5-HTP-induced HTR and produced a bell-shaped dose-response curve."	( The stimulatory and inhibitory components of cocaine's actions on the 5-HTP-induced 5-HT2A receptor response. Darmani, NA; Reeves, SL, 1996)	0.29
" The tramadol dosage had recently been increased, resulting in what was believed to be serotonergic syndrome."	( Possible serotonin syndrome associated with tramadol and sertraline coadministration. Blackburn, KH; Mason, BJ, 1997)	0.54
"Serotonin syndrome is a toxic hyperserotonergic state that develops soon after initiation or dosage increments of the offending agent."	( Possible serotonin syndrome associated with tramadol and sertraline coadministration. Blackburn, KH; Mason, BJ, 1997)	0.54
" In this study, sertraline was administered at a dosage of 200mg once daily (the maximum recommended daily dosage) for 21 days after upward dosage titration from 50 mg/day over a 9-day period."	( Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Ronfeld, RA; Tremaine, LM; Wilner, KD, 1997)	0.97
" There was a small but statistically significant decrease (16%) in the clearance of tolbutamide in patients receiving the maximum recommended dosage of sertraline."	( A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Preskorn, SH; Tremaine, LM; Wilner, KD, 1997)	0.77
" These results suggest that sertraline at the maximum recommended dosage under steady-state conditions, and demethylsertraline, the principal metabolite of sertraline, are unlikely to exert significant inhibitory effects on the CYP2C19 and CYP3A3/4 hepatic isoenzymes responsible for the metabolism of diazepam."	( Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Baris, BA; Gardner, MJ; Preskorn, SH; Wilner, KD, 1997)	0.99
" The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition."	( Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Meier, E; Sánchez, C, 1997)	0.3
"With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy."	( Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997)	0.3
"A sustained-release formulation of bupropion (bupropion SR), developed with an improved pharmacokinetic profile to permit less frequent dosing than the immediate-release form, has not been evaluated in active comparator trials."	( Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. Ascher, JA; Hughes, AR; Johnston, JA; Kavoussi, RJ; Segraves, RT, 1997)	0.54
" The dosage of sertraline ranged from 25 to 150 mg/day (93."	( The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM; Shulman, RW, 1998)	0.87
" In case 2, a 25 mg reduction in the total daily dose of sertraline resulted in halving of the lamotrigine blood level even though the lamotrigine dosage was increased by 33%."	( Lamotrigine toxicity secondary to sertraline. Gerner, R; Kaufman, KR, 1998)	0.82
" The purpose of this study was to assess whether there was a difference in expenditures during the first 90 days of SSRI therapy with paroxetine or sertraline versus fluoxetine in patients who were also receiving a stable dosage of a nonpsychiatric drug also metabolized by the CYP-450 2D6 or 3A4 isoenzyme systems."	( Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system. Croghan, TW; Crown, WH; Hylan, TR; Melfi, CA; Meneades, LM; Ozminkowski, RJ; Robinson, RL, )	0.33
"Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued to receive this dosage of medication for 8 more weeks."	( Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. Biederman, J; Cook, EH; Cutler, NR; Dominguez, R; Ferguson, J; March, JS; Mardekian, J; Muller, B; Riesenberg, R; Rosenthal, M; Safferman, A; Sallee, FR; Steiner, H; Wagner, KD; Wolkow, R, 1998)	3.19
" Sixteen patients who did not respond to the traditional antipsychotics after 2 weeks of treatment with a certain dosage of haloperidol were administered with 50 mg of sertraline for a period of 2 weeks."	( Co-administration of sertraline and haloperidol. Han, CS; Kim, SH; Lee, MS; You, YW, 1998)	0.81
"Evidence that serotonergic antidepressants are effective for treating premenstrual syndrome (PMS) raises the question of whether dosing only in the symptomatic premenstrual phase is effective for this disorder."	( Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. Arredondo, F; Freeman, EW; Kao, LC; Pollack, SE; Rickels, K; Sondheimer, SJ, 1999)	0.3
" Cost, number of prescriptions, and dosage strength data is also presented."	( Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities. Voris, JC, 1999)	0.3
" administration, sertraline is slowly absorbed with peak plasma concentrations at 6 - 8 h, and has a terminal elimination half-life of approximately 26 h, indicating once-daily dosing is available."	( Bioequivalence evaluation of two sertraline tablet formulations in healthy male volunteers after a single dose administration. Chen, LM; Qu, ZW; Wu, JF; Zhang, JT; Zhu, CJ, 1999)	0.92
"To test the efficacy of late-luteal phase dosing of sertraline hydrochloride in women with moderate-to-severe premenstrual dysphoric disorder."	( Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Jermain, DM; Kuehl, TJ; Preece, CK; Sulak, PJ; Sykes, RL, )	0.75
" The flexible dosage range was 50 to 150 mg/d."	( Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Freeman, EW; Polansky, M; Rickels, K; Sondheimer, SJ, 1999)	0.3
" If there was an insufficient response, the dose was titrated upwards to a maximum of 200 mg/day, with 2 weeks at each dosage level."	( An open study of sertraline in patients with major depression who failed to respond to moclobemide. Chiu, E; George, T; Hokin, A; Krapivensky, N; Theodoros, MT; Tiller, JW, 1999)	0.64
" The proposed methods were applied successfully to the determination of the cited drugs either in pure or dosage forms with good accuracy and precision."	( Spectrophotometric determination of fluoxetine and sertraline using chloranil, 2, 3 dichloro-5, 6 dicyano benzoquinone and iodine. Bebawy, LI; El-Kousy, N; Shokry, M; Suddik, JK, 1999)	0.56
" However, there is no data on the dosage of selective serotonin uptake inhibitors (SSRIs) required to maintain symptom resolution in women treated for major depression during pregnancy."	( Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Hostetter, A; Llewellyn, A; McLaughlin, E; Stowe, ZN; Strader, JR, 2000)	0.31
"6 kg, and their mean sertraline dosage was 55 mg/d."	( The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Buffum, J; Bui, BC; Chan, WK; Harralson, AF; Lee, AJ, 1999)	0.9
"Fifty-seven highly recurrent unipolar patients, excluded from previous long-term studies with selective serotonin reuptake inhibitors (SSRIs) after they experienced a new recurrence, were acutely treated with the full dosage of the SSRIs they were on."	( Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes? Bongiorno, F; Franchini, L; Rossini, D; Smeraldi, E; Spagnolo, C; Zanardi, R, 2000)	0.31
" All three sertraline doses produced significant efficacy compared to placebo, with no consistent evidence of a dose-response effect."	( The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Clary, CM; Fayyad, R; Londborg, P; Sheikh, JI, 2000)	1.04
" Clinical effects from the medications were measured in relation to and shown to be a function of dosage level."	( Therapeutic effects and long-term efficacy of antidepressant medication for persons with developmental disabilities. Behavioral assessment in two cases of treatment-resistant aggression and self-injury. Blew, P; Luiselli, JK; Thibadeau, S, 2001)	0.31
" A 34 year-old male patient experienced visual hallucinations and severe tremor after dramatically increasing his dosage of oxycodone while on stable amounts of sertraline and cyclosporin."	( Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. Flockhart, DA; Rosebraugh, CJ; Woosley, RL; Yasuda, SU, 2001)	0.77
"2 per cent of patients the final sertraline dosage was 50 mg."	( An open, baseline controlled evaluation of sertraline safety and efficacy in the treatment of depression in Thai patients. , 2001)	0.85
" While some patients clearly benefit from higher doses, the results of the current study are consistent with the lack of any evidence for a dose-response curve with sertraline in the treatment of depression."	( The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Demartinis, N; García-España, F; Mandos, LA; Rickels, K; Rynn, M; Schweizer, E, 2001)	0.8
" To determine whether selective serotonin reuptake inhibitors (SSRI) induced hypomania is secondary to medication effects, we examined the dose-response relationship of SSRI-induced hypomania in two patients with depressive disorder."	( Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Ramasubbu, R, 2001)	0.31
" However, the time course for maximum inhibition to occur or for inhibition to dissipate when dosing is discontinued, requires clarification."	( Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. Boulton, DW; DeVane, CL; Goldman, J; Liston, HL; Markowitz, JS; Risch, SC, 2002)	0.54
" This raises the important question of whether once-weekly enteric-coated fluoxetine, 90 mg, is effective for maintenance of response in patients whose depressive symptoms have responded to daily dosing with selective serotonin reuptake inhibitors (SSRIs) such as citalopram, paroxetine, or sertraline."	( Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002)	0.74
" Patients with a DSM-IV diagnosis of OCD and a Y-BOCS greater or equal to 16 were randomly assigned to receive one of the two dosing regimens; an upper target dose of 150 mg/day was selected on the basis of a review of mean dosages used in flexible-dose sertraline studies."	( Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Albert, U; Bogetto, F; Maina, G, 2002)	1.94
" In addition, no dosage adjustments are warranted for elderly patients solely based on age."	( Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	1.76
"For paroxetine and fluoxetine, plasma concentrations and dosage strongly influence the magnitude of enzyme inhibition."	( CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J, 2002)	0.31
" In addition, no dosage adjustments are warranted for elderly patients solely based on age."	( Spotlight on sertraline in the management of major depressive disorder in elderly patients. Muijsers, RB; Noble, S; Plosker, GL, 2002)	0.68
"Cognitive and psychomotor performance are not altered in healthy humans receiving multiple dosing with sertraline."	( Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Grossmann, J; Kirch, W; Mück-Weymann, M; Siepmann, M, 2003)	0.92
" We review the pharmacology, the adverse effects, the dosing guidelines, as well as the indications of sertraline."	( The antidepressant sertraline: a review of its uses in a range of psychiatric and medical conditions. Emes, R; Gill, T; Khouzam, HR; Raroque, R, 2003)	0.86
" Drug dosage was maintained at levels that achieved remission."	( Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. Abou-Saleh, MT; Ashworth, L; Mottram, PG; Wilson, KC, 2003)	0.55
"Sertraline at therapeutic dosage does not provide significant protection against recurrence."	( Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. Abou-Saleh, MT; Ashworth, L; Mottram, PG; Wilson, KC, 2003)	2
" The heterocyclic agent trazodone significantly inhibited paw oedema by 46 and 41% at 1 and 2h after dosing at the highest dose (40 mg kg(-1)) examined."	( Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Abdel-Salam, OM; El-Shenawy, SM; Nofal, SM, 2003)	0.32
" The authors report the outcome of extended, high-dosage sertraline treatment in a sample of nursing home residents experiencing residual significant depressive symptoms after 10 weeks of treatment with sertraline at a final dosage of 100 mg/day."	( Effect of increasing the dose and duration of sertraline trial in the treatment of depressed nursing home residents. Datto, CJ; DiFilippo, SD; Katz, IR; Oslin, DW; Streim, JE; Weintraub, D, 2003)	0.82
"Sertraline hydrochloride, mean dosage of 95 mg/d, or identical placebo, randomly assigned."	( Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Baker, AS; Brandt, J; DelCampo, L; Frangakis, C; Lyketsos, CG; Miles, Q; Munro, C; Rabins, PV; Sheppard, JM; Steele, CD; Steinberg, M, 2003)	2
" Medication dosage was started at 50 mg/day, increased to 100 mg/day after 1 week, and then increased up to 200 mg/day if subjects had not remitted."	( Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. El Sheshai, A; Fayek, M; Kingsbury, SJ; Rady, A; Simpson, GM, 2003)	1.76
"Patients were randomly assigned to receive a flexible dosage (50-200 mg/d) of sertraline (n = 189) or matching placebo tablets (n = 187) for 10 weeks."	( Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Ambrosini, P; Childress, A; Deas, D; Donnelly, C; Greenbaum, MS; Rynn, M; Wagner, KD; Wohlberg, C; Yang, R, 2003)	0.93
" Due to the cyclic luteal occurrence of PMDD, luteal phase dosing of SSRIs has been suggested and proven effective for sertraline as well as several other SSRIs."	( Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline. Halbreich, U; Kahn, LS, 2003)	0.76
" Subjects with higher postmenstrual symptoms before treatment remained more symptomatic regardless of the dosing regimen."	( Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Freeman, EW; Polansky, M; Rickels, K; Sondheimer, SJ; Xiao, S, 2004)	0.59
"Premenstrual dosing does not differ from continuous dosing with sertraline in premenstrual syndrome treatment."	( Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Freeman, EW; Polansky, M; Rickels, K; Sondheimer, SJ; Xiao, S, 2004)	0.83
" The mean levodopa equivalent dosage (LED) was 1010+/-318 mg before surgery and 116+/-93 mg 3 months after surgery."	( Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Bergamasco, B; Cicolin, A; Fattori, E; Guastamacchia, G; Lanotte, MM; Lopiano, L; Makrydakis, G; Mutani, R; Tavella, A; Terreni, A; Torre, E; Zibetti, M, 2004)	0.32
" Multiple SSRI dosing ranges were evaluated in autistic patients of different ages with various functional impairments."	( Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Eichner, SF; Jones, JR; Moore, ML, 2004)	0.32
" Two weeks after the increase of the dosage of sertraline, the patient developed a full-blown SS, which resolved completely after the discontinuation of the drug."	( Repetition of serotonin syndrome after reexposure to SSRI--a case report. Modestin, J; Tomaselli, G, 2004)	0.58
" The mean daily dosage was 34."	( Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Chung, MY; Jun, EM; Jun, YJ; Kim, SS; Kim, WC; Min, KH, 2004)	0.58
" In consecutive dosing periods separated by washout periods of > or = 3 weeks, healthy volunteers received either oral donepezil HCI 5 mg once daily for 15 days, oral sertraline HCl 50 mg once daily for 5 days followed by 10 days of once-daily sertraline HCl 100 mg, or the simultaneous administration of oral donepezil HCl and sertraline HCl."	( Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Cullen, EI; Kumar, D; Nagy, CF; Perdomo, CA; Pratt, RD; Wason, S, 2004)	0.78
" After 4 weeks of treatment with sertraline at a standard dosage of 50 mg/day, both the single TRH test and the combined T3/TRH test were repeated in the depressed patients."	( The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. Alajbegovic, L; Baghai, TC; Eser, D; Möller, HJ; Rupprecht, R; Schaaf, L; Schüle, C; Schwarz, M; Zwanzger, P, 2005)	0.88
"Three simple and sensitive spectrophotometric methods were developed and validated for determination of the hydrochloride salts of fluoxetine, sertraline, and paroxetine in their pharmaceutical dosage forms."	( Development and validation of spectrophotometric methods for determination of fluoxetine, sertraline, and paroxetine in pharmaceutical dosage forms. Darwish, IA, )	0.55
"Use of intermittent dosing strategies for the treatment of premenstrual dysphoric disorder (PMDD) highlights the need for detailed empirical data on the onset, duration and pattern of symptom expression in women suffering from PMDD."	( Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Fayyad, R; Gillespie, JA; Pearlstein, T; Yonkers, KA, 2005)	0.33
"Despite the proven efficacy of luteal phase medication dosing for women with premenstrual dysphoric disorder (PMDD), it is not known whether this approach adequately treats symptoms that linger into the first 2-3 days of the follicular phase, a time when up to one-third of women diagnosed with PMDD report residual symptoms."	( Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. Fayyad, R; Gillespie, JA; Pearlstein, T; Yonkers, KA, 2005)	0.33
" The first study used continuous dosing of sertraline, 50-150 mg/day, throughout the menstrual cycle, while the second study used intermittent dosing with sertraline, 50-100 mg/day in the 14-16 days prior to onset of menses."	( Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. Fayyad, R; Gillespie, JA; Pearlstein, T; Yonkers, KA, 2005)	0.59
" luteal phase dosing on the first day of menses (0."	( Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. Fayyad, R; Gillespie, JA; Pearlstein, T; Yonkers, KA, 2005)	0.33
" All patients received sertraline in a dosage of 50 mg daily."	( Adjunctive bright light in non-seasonal major depression: results from patient-reported symptom and well-being scales. Bech, P; Dam, H; Lunde, M; Martiny, K; Undén, M, 2005)	0.64
"This prospective 6-week study examined the differences in dosage and steady state plasma concentrations of sertraline in Chinese versus Caucasian depressed patients."	( A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. Fan, A; Hong Ng, C; Klimidis, S; Kong Wai Ho, B; Naing, KO; Norman, TR; Schweitzer, I, 2006)	0.86
" Antidepressant medication costs, however, are significantly higher when fluoxetine is the initial SSRI rather than sertraline or paroxetine, reflecting the larger proportion of fluoxetine patients prescribed a daily dosage of two or more capsules."	( Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. Berndt, ER; Colucci, SV; Grudzinski, AN; Miceli, R; Russell, JM; Xu, Y, )	0.34
"Eighty-four patients 60 years of age and over with a principal diagnosis of generalized anxiety disorder, panic disorder, agoraphobia, or social phobia were randomly assigned to one of three conditions: 15 sessions of CBT, pharmacologic treatment with an SSRI (sertraline; maximum dosage 150 mg), or a waitlist control group."	( A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Comijs, H; Emmelkamp, PM; Gundy, CM; Schuurmans, J; van den Hout, M; van Dyck, R; Weijnen, I, 2006)	0.74
" Dosing strategies for the SSRIs sertraline and paroxetine are provided, and an algorithm for PTSD pharmacotherapy is discussed."	( Pharmacologic treatment of acute and chronic stress following trauma: 2006. Davidson, JR, 2006)	0.62
" Outpatients with DSM-IV GAD (N = 326) who satisfied inclusion/exclusion criteria and completed a 1-week screening phase were randomly assigned to 10-week double-blind treatment with flexible dosing of sertraline (50-200 mg/day) or placebo."	( Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Brawman-Mintzer, O; Carter, RE; Knapp, RG; Rickels, K; Rynn, M, 2006)	1.96
"To determine if voluntary prescription change forms for antidepressant drugs could induce dosing changes and reduce the cost of antidepressant therapy in a Medicaid population."	( Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. Hamer, AM; Hartung, DM; Haxby, DG; Ketchum, KL; Pollack, DA, )	0.13
" The objective of this study was to evaluate the safety and efficacy of sertraline in the treatment of moderate-to-severe PMS using 3 different dosing strategies: luteal phase (2 cycles), followed by continuous dosing throughout the month (1 cycle), followed by dosing begun at the first onset of PMS symptoms, or "symptom-onset" dosing (1 cycle)."	( Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. Farfel, GM; Fayyad, R; Gillespie, JA; Kornstein, SG; Pearlstein, TB, 2006)	0.98
"Intermittent luteal-phase dosing with low doses of sertraline (25 and 50 mg/day) produced significant improvement across 2 menstrual cycles, based on total DSR scores, compared with placebo."	( Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. Farfel, GM; Fayyad, R; Gillespie, JA; Kornstein, SG; Pearlstein, TB, 2006)	1
"This trial was conducted to compare the efficacy and tolerability of a fixed dose of escitalopram 10 mg/day with sertraline optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder."	( Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007)	0.87
" At week 8, the mean sertraline dosage was 144 mg/day (median = 150 mg/day)."	( Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007)	0.98
"No differences in efficacy were observed for fixed-dose escitalopram 10 mg/day and sertraline flexibly dosed from 50-200 mg/day."	( Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007)	0.89
" Patients recruited from 10 VA medical centers were randomly assigned to 12 weeks of flexibly dosed sertraline (25-200 mg/day) (N = 86; 70% with combat-related PTSD; 79% male) or placebo (N = 83; 72% combat-related PTSD; 81% male) between May 1994 and September 1996."	( Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Baker, DG; Farfel, GM; Friedman, MJ; Marmar, CR; Sikes, CR, 2007)	0.83
" The treatment response was assessed at baseline, week 4 and week 12, with hospital anxiety and depression scale (HADS) and Montgomery Asberg depression rating scale (MADRS), to rate depression and anxiety; mini mental adjustment to cancer scale (Mini-MAC), to assess the psychological response to the diagnosis of cancer; clinical global impression (CGI) to evaluate severity of illness; dosage record and treatment emergent symptom scale (DOTES), to assess the adverse effects of the clinical treatments and their possible relation with the drug used; and QL index to rate quality of life."	( Sertraline effectiveness and safety in depressed oncological patients. Caldera, P; Siri, I; Torta, R, 2008)	1.79
"Selective serotonin reuptake inhibitors were found to be effective in treating premenstrual symptoms, with continuous dosing regimens favored for effectiveness."	( Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R, 2008)	0.35
" This pilot study is designed to evaluate the effectiveness of variable dosing in PMED using the antidepressant sertraline."	( Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study. Ferslew, KE; Frizzell, PG; Kayser, RA; Miller, BE; Miller, MN; Newell, CL, )	0.67
"The use of variable dosing in PMED increases the effectiveness of treatment."	( Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study. Ferslew, KE; Frizzell, PG; Kayser, RA; Miller, BE; Miller, MN; Newell, CL, )	0.46
" Adverse effects were evaluated using the Dosage Record and Treatment Emergent Symptom Scale (DOTES)."	( Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Bellino, S; Bogetto, F; Paradiso, E, 2008)	0.59
"Insufficient data inform dosing of antidepressants and clinical monitoring for major depressive disorder (MDD) during the perinatal period."	( Pharmacokinetics of sertraline across pregnancy and postpartum. Anthony, M; Davis, MF; Fankhauser, M; Freeman, MP; Fried, K; Moreno, F; Nolan, PE; Woosley, RL, 2008)	0.67
"The objective of the current study was to develop a validated stability-indicating high-performance liquid chromatographic method for alprazolam and sertraline in combined dosage forms."	( Development of a stability-indicating high-performance liquid chromatographic method for the simultaneous determination of alprazolam and sertraline in combined dosage forms. Pathak, A; Rajput, SJ, )	0.53
" Greater clinical severity and low initial dosing may increase the risk of switching antidepressants."	( Antidepressant switching among adherent patients treated for depression. Hassan, M; Marcus, SC; Olfson, M, 2009)	0.35
" Also included are human pharmacokinetic studies with prototype CR dosage forms for CJ-13,610 and CP-424,391."	( The use of gastrointestinal intubation studies for controlled release development. Sutton, SC, 2009)	0.35
" Blood samples were collected before dosing and at frequent intervals for up to 96 h post dose."	( Bioequivalence study of 50 mg sertraline tablets in healthy Thai volunteers. Chatsiricharoenkul, S; Kongpatanakul, S; Niyomnaitham, S; Pongnarin, P; Sathirakul, K, 2009)	0.64
" Phase 1 was a 6-week lead-in with open-label sertraline flexibly dosed to 100 mg (or escitalopram equivalent) to prospectively define treatment refractoriness (lack of remission)."	( Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. Hoge, EA; Lebeau, RT; Moshier, SJ; Otto, MW; Pollack, MH; Simon, NM; Thompson, EH; Worthington, JJ; Zalta, AK, 2009)	0.61
"It is important that variations in drug metabolism during pregnancy be considered as these changes may necessitate a dosage adjustment to ensure that therapeutic failure does not occur during pregnancy."	( Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach. Baumer, C; Koren, G; O'Brien, L; Sachs, H; Thieme, D, 2010)	0.36
" medical centers with mild-to-moderate AD (Mini-Mental State Examination scores 10-26) and depression of AD were randomized to double-blinded treatment with sertraline (N = 67) or placebo (N = 64), with a target dosage of 100 mg daily."	( Sertraline for the treatment of depression in Alzheimer disease. Drye, LT; Frangakis, C; Lyketsos, CG; Martin, BK; Meinert, CL; Mintzer, JE; Munro, CA; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Weintraub, D, 2010)	2
" When managing a patient with nonpsychotic depression and inadequate response to the maximum dose of a single antidepressant, the physician should first identify factors that may contribute to the poor response, such as suboptimal dosage resulting from nonadherence, inadequate duration of therapy, and comorbid medical and psychiatric conditions."	( Clinical inquiries. What's best when a patient doesn't respond to the maximum dose of an antidepressant? Lo, V; Maggio, L, 2010)	0.36
" The applicability of the proposed method was shown by the successful analysis of sertraline in tablet dosage forms."	( Electrochemical behaviour of sertraline hydrochloride at a glassy carbon electrode and its determination in pharmaceutical products using osteryoung square wave voltammetry. Cay, HY; Dermiş, S, 2010)	0.88
" Patients were treated with torin (sertraline) in dosage 25-50 mg daily during 4 weeks."	( [Torin (sertraline) in the treatment of depressive and obsessive-compulsive disorders in children]. Malinina, EV; Zabozlaeva, IV, 2010)	1.07
"we related medication choice and dosage range to outcomes of treatment as reflected by discharge rates and suicidality."	( Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. Agius, M; Gardner, J; Liu, K; Zaman, R, 2010)	0.36
" Regarding Dose Ranges, we note that wheras many patients had their dosage titrated upwards from the starting dose, most did not have the dosage titrated to the highest dose of the relevant medication."	( Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. Agius, M; Gardner, J; Liu, K; Zaman, R, 2010)	0.36
" Important issues related to adherence included parental and child attitudes, complex dosing schedules, and barriers to communication between parents and providers."	( Promoting adherence to psychotropic medication for youth-part 2. McGuinness, TM; Worley, J, 2010)	0.36
"Seventy Iranian veterans of the Iran-Iraq war who met the DSM-IV criteria for diagnosis of PTSD were randomized to receive either flexibly dosed sertraline (50-200 mg/day) (n=35, completers=32) or placebo (n=35, completers=30) for 10 weeks."	( A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Beiraghdar, F; Karami, G; Moghaddam, BR; Nazari, MA; Panahi, Y; Saadat, AR; Sahebkar, A, 2011)	0.79
" Second we do not know which dosage we should be aiming at with that antidepressant."	( Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Akechi, T; Furukawa, TA; Inagaki, M; Miki, K; Shimodera, S; Watanabe, N; Yamada, M; Yonemoto, N, 2011)	0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Each child received either flexibly dosed sertraline between 25-150 mg/day or placebo."	( A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. Chang, Y; Chedekel, DS; Drake, J; Levine, JB; Luthra, R; Saxe, GN; Sheridan, RL; Sorrentino, EA; Stoddard, FJ, 2011)	0.91
" No subject discontinued dosing due to adverse events."	( Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. Altmeyer, R; Cheng, CW; Chopra, N; Lawitz, E; Lim, SG; McHutchison, JG; Patel, K; Randle, JC; Tillmann, HL, 2011)	0.59
" We undertook parallel studies in endothelial cells derived from brain microvessels to determine the dose-response and time-course of effects."	( Effects of sertraline and fluoxetine on p-glycoprotein at barrier sites: in vivo and in vitro approaches. Gibb, W; Ho, HL; Iqbal, M; Kapoor, A; Matthews, SG; Petropoulos, S, 2013)	0.78
" A dose-response relationship between active-sham differences with the long allele was also suggested."	( Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system. Benseñor, IM; Brunoni, AR; Brunoni, D; Coprerski, B; Cordeiro, Q; Fregni, F; Goulart, AC; Kemp, AH; Lotufo, PA; Perez, AB; Shiozawa, P; Valiengo, LC, 2013)	0.64
" Cox regression models, adjusted for demographic and clinical characteristics, were used to examine associations of antidepressant dosing with ventricular arrhythmia and cardiac, noncardiac, and all-cause mortality."	( Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Blow, FC; Bohnert, AS; Ganoczy, D; Kales, HC; Nallamothu, BK; Pfeiffer, PN; Zivin, K, 2013)	0.39
" Sertraline was initiated at 25 mg daily orally for the first month, with dosage increment of 25 mg monthly according to clinical response up to a maximum of 200 mg daily as necessary."	( Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients. Chan, KY; Chan, ML; Cheng, HW; Li, CW; Sham, MK; Wong, H; Yip, T, 2013)	1.76
"Twenty-one adult female cynomolgus monkeys were housed in small, stable social groups, trained to participate in oral dosing, and began a 5-week cumulative dose-response study."	( Sertraline effects on cerebrospinal fluid monoamines and species-typical socioemotional behavior of female cynomolgus monkeys. Higley, JD; Register, TC; Shively, CA; Willard, SL, 2014)	1.85
" Depressed patients were administered sertraline 50mg at 8:00am on the first day, and the dosage was subsequently titrated up to a maximum of 200mg daily during the 8-week trial."	( Sertraline and periodic limb movements during sleep: an 8-week open-label study in depressed patients with insomnia. Hao, Y; Jia, F; Li, X; Liu, W; Ren, Y; Wing, YK; Zhang, B; Zhou, P, 2013)	2.1
" This effect of sertraline on PLMS might be dosage dependent."	( Sertraline and periodic limb movements during sleep: an 8-week open-label study in depressed patients with insomnia. Hao, Y; Jia, F; Li, X; Liu, W; Ren, Y; Wing, YK; Zhang, B; Zhou, P, 2013)	2.18
"This study aimed at evaluating the safety and efficacy of an improved dosage regimen of sertraline in patients with premature ejaculation (PE) and to examine whether the premature ejaculation diagnostic tool (PEDT) can be used as a measure of treatment response in these patients."	( An improved dosage regimen of sertraline hydrochloride in the treatment for premature ejaculation: an 8-week, single-blind, randomized controlled study followed by a 4-week, open-label extension study. Ding, Q; Fang, J; Gu, B; Jiang, HW; Liu, J; Wen, H; Xu, G; Zhang, LM; Zhang, YF, 2014)	0.91
"Oxidation of active pharmaceutical ingredients is a common chemical degradation process occurring in solid dosage forms."	( Impact of sertraline salt form on the oxidative stability in powder blends. Hsieh, YL; Pan, W; Shalaev, EY; Shamblin, SL; Taylor, LS; Waterman, KC; Xiang, Y; Yu, W, 2014)	0.8
" However, therapeutic efficacy and treatment success is often variable, requiring changes in dosing regimens or drug selection."	( The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clarke, W; Jannetto, PJ; Johnson-Davis, KL; Langman, LJ; Marzinke, MA; Moskowitz, J; Petrides, AK, 2014)	0.6
" However, both single and multiple dosing treatments of SC alcoholic extract remarkably decreased the in vivo metabolism of tacrolimus indicated by the enhanced AUC (7-12 fold) and elevated Cmax (10 fold)."	( Multifaceted interaction of the traditional Chinese medicinal herb Schisandra chinensis with cytochrome P450-mediated drug metabolism in rats. Hu, J; Li, Y; Wang, B; Yang, S, 2014)	0.4
" The patient was known to suffer from depression and was treated with sertraline (Zoloft®) for 6 months at the dosage of 100 mg/day."	( [Thrombopathy induced by selective serotonin reuptake inhibitors: a case report]. Amar, L; Ben Said, M; Bertil, S; Fischer, AM; Gaussem, P; Helley, D; Rivet, N; Smadja, D, )	0.37
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."	( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)	0.42
" In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34."	( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)	0.42
"To determine the efficacy of symptom-onset dosing with the SRI sertraline hydrochloride for treatment of PMDD."	( Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. Altemus, M; Gueorguieva, R; Kornstein, SG; Merry, B; Van Steenburgh, K; Yonkers, KA, 2015)	0.96
" Step I randomization compares the minimum and the maximum dosing strategy for the first-line antidepressant."	( Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis plan. Akechi, T; Furukawa, TA; Guyatt, GH; Hayasaka, Y; Inagaki, M; Kato, T; Mantani, A; Miki, K; Ogawa, Y; Shimodera, S; Shinohara, K; Tajika, A; Takeshima, N; Tanaka, S; Watanabe, N; Yamada, M; Yonemoto, N, 2015)	0.42
" The observed results were unchanged with the addition of SSRI dosage as a covariate."	( Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. Bussing, R; Geffken, GR; Goodman, WK; Guzick, AG; McNamara, JP; Murphy, TK; Reid, AM; Storch, EA, 2015)	0.42
" These findings suggest that dosage changes due to AS do not explain why those with higher AS had worse multimodal outcome."	( Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. Bussing, R; Geffken, GR; Goodman, WK; Guzick, AG; McNamara, JP; Murphy, TK; Reid, AM; Storch, EA, 2015)	0.42
" The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder."	( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016)	0.43
" Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder."	( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016)	0.43
" Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated."	( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016)	0.43
"The proportion of commercially insured children initiating an SSRI with a low dose was higher after the 2004 FDA warning on the risk of suicidality among children, suggesting improved prescribing practices surrounding SSRI dosing among children."	( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016)	0.43
"We observed a 60-year-old man who experienced resting tremors, dyskinesia and dysgraphia 2 months after a stepwise increase in sertraline dosing from 50 to 200 mg/day."	( A case of dysgraphia induced by sertraline and a review of official spontaneous adverse reaction databases. Antoniazzi, S; Carnovale, C; Clementi, E; Galimberti, C; Gentili, M; Marinaccio, PM; Pozzi, M; Radice, S; Viganò, C, 2016)	0.92
" Grade 4 or 5 adverse event risk did not differ between current US Food and Drug Administration-approved dosing of 100-200 mg/day and higher doses of 300-400 mg/day (hazard ratio 1·27, 95% CI 0·69-2·32; p=0·45)."	( Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Abassi, M; Akampurira, A; Alhadab, A; Bahr, NC; Boulware, DR; Fisher, J; Hullsiek, KH; Kiggundu, R; Meya, DB; Morawski, BM; Musubire, A; Nabeta, HW; Nielsen, K; Rhein, J; Smith, KD; Tugume, L; Velamakanni, SS; Williams, DA, 2016)	0.74
" The mean dosage of duloxetine was 55 mg/day (range 40-60 mg/day) and the mean dosage of sertraline was 146 mg/day (range 50-200 mg/day)."	( Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial. Dastgheib, SA; Mowla, A; Razeghian Jahromi, L, 2016)	0.96
" All drugs showed maximum occupancy at 4h after dosing and then decreasing occupancies with time."	( Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB. Arakawa, R; Kim, W; Ogawa, K; Okubo, Y; Sakayori, T; Tateno, A, 2016)	0.43
" In contrast, among doses above these, there was no indication of a dose-response relationship."	( A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Eriksson, E; Hieronymus, F; Nilsson, S, 2016)	0.43
" The mean dosage of duloxetine was 44."	( Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial. Boostani, S; Dastgheib, SA; Mowla, A, 2016)	0.43
" In addition there is no need to adjust sertraline dosage in patients with ESRD."	( Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hashemi, N; Malekmakan, L; Pakfetrat, M; Tadayon, T, 2018)	2.19
" Using a blinded dosing strategy, we demonstrated that high dose sertraline monotherapy provided no benefit for the prevention of Ebola virus disease in rhesus macaques with regards to reduction of viral load, morbidity, or survival highlighting the challenges of translating results between in vitro and in vivo models."	( High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. Adams, RD; Bennett, RS; Hensley, LE; Honko, AN; Huzella, L; Jahrling, PB; Johnson, JC; Marchand, JS; Oberlander, N; Olinger, GG; Torzewski, LM, 2017)	1.1
"Regression analyses indicated a dose-response relationship between therapist-reported quantity of exposure and independent evaluations of treatment outcome, with more time devoted to exposure linked to better outcomes."	( Therapist-Reported Features of Exposure Tasks That Predict Differential Treatment Outcomes for Youth With Anxiety. Albano, AM; Bergman, RL; Birmaher, B; Caporino, NE; Compton, SN; Ginsburg, GS; Kendall, PC; McCracken, JT; O'Rourke, S; Peris, TS; Piacentini, J; Sakolsky, D; Walkup, JT, 2017)	0.46
" All subjects began open-label sertraline treatment and were followed over 12 weeks with clinically indicated flexible dosing and an option to switch antidepressants."	( Presence of neuroticism and antidepressant remission rates in late-life depression: results from the Neurobiology of Late-Life Depression (NBOLD) study. Grady, JJ; Manning, KJ; Steffens, DC; Wu, R, 2018)	0.77
" Serum concentration of citalopram and daily dosage correlated positively while daily dosage and mother milk concentration did not (rho = 0."	( Antidepressants in breast milk; comparative analysis of excretion ratios. Augustin, M; Franz, C; Gründer, G; Paulzen, M; Saßmannshausen, H; Schoretsanitis, G, 2019)	0.51
"The present study involved segmental testing of hair in two clinical cases with known dosage histories."	( Segmental Hair Analysis-Interpretation of the Time of Drug Intake in Two Patients Undergoing Drug Treatment. Johansen, SS; Linnet, K; Nielsen, MKK; Wang, X, 2019)	0.51
" Sertraline dosage was titrated during a 10-week period and continued until week 24; medication management was manualized."	( Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. Acierno, R; Allard, CB; Hoge, CW; Kim, HM; King, AP; Liberzon, I; Martis, B; Norman, SB; Phan, KL; Porter, K; Powell, C; Rauch, SAM; Rothbaum, BO; Simon, NM; Stein, MB; Tuerk, PW; Venners, MR, 2019)	1.69
" Subjects were evaluated every 2 weeks up to 12 weeks by the study psychiatrist, who followed a flexible, clinically based medication dosing schedule."	( Functional connectivity predictors of acute depression treatment outcome. Pearlson, GD; Steffens, DC; Wang, L, 2019)	0.51
" Monitoring the body levels of this drug and its active metabolite, N-desmethylsertraline (DSRT), permits optimizing the dosage and personalizing the treatment, especially in the case of severe adverse reactions or lack of response to the applied therapy."	( Sertraline - isolation methods and quantitation in biological material. Dziurkowska, E; Wesolowski, M, 2018)	2.15
"Using patient-derived glioblastoma stem cell (GSC) cultures from 15 GBM patients, we described stem cell properties of individual cultures, determined the dose-response relationships of the drugs in the CUSP9, and assessed the efficacy the CUSP9 combination with TMZ in concentrations clinically achievable."	( The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019)	0.51
" This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray."	( Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E, 2019)	0.51
" At the time of randomization, the median dosage of sertraline was 150 mg/d (interquartile range [IQR], 150-200 mg/d) and the median dosage of olanzapine was 15 mg/d (IQR, 10-20 mg/d)."	( Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. Alexopoulos, GS; Banerjee, S; Flint, AJ; Marino, P; Meyers, BS; Mulsant, BH; Pollari, CD; Rothschild, AJ; Rudorfer, MV; Voineskos, AN; Whyte, EM; Wu, Y, 2019)	0.76
" A 12-lead electrocardiogram was recorded in triplicate before dosing and at selected time points up to 72 hours after dosing."	( A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects. Abbas, R; Bachinsky, M; Chappell, PB; Crownover, PH; Damle, B; LaBadie, RR; Riley, S, 2020)	0.79
" Uncertainty in drug dosing in pregnancy can lead to suboptimal therapy, which can contribute to disease exacerbation."	( Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. Beitz, J; Crentsil, V; George, B; Lumen, A; Nguyen, C; Wang, J; Wesley, B, 2020)	0.8
" Donepezil (3 mg/kg; po) and sertraline (10 mg/kg; po) dosing was started from D-8 and continued up to D-32."	( Development and treatment of cognitive inflexibility in sub-chronic stress-re-stress (SRS) model of PTSD. Krishnamurthy, S; Prajapati, SK, 2021)	0.91
"Since several recent meta-analyses report a dose-response relationship for the antidepressant effect of the selective serotonin reuptake inhibitors (SSRIs), we investigated how these drugs are dosed in clinical practice."	( Low SSRI dosing in clinical practice-a register-based longitudinal study. Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021)	0.62
" The lack of consensus regarding effective dosing of SSRIs may have contributed to this state of affairs."	( Low SSRI dosing in clinical practice-a register-based longitudinal study. Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021)	0.62
" In addition, since each antidepressant possesses a different dosage range from the other, overdoses of these antidepressants might also be the causes of these differences."	( Antidepressant Screening Demonstrated Non-Monotonic Responses to Amitriptyline, Amoxapine and Sertraline in Locomotor Activity Assay in Larval Zebrafish. Audira, G; Chen, KH; Hsiao, CD; Hussain, A; Saputra, F; Siregar, P; Suryanto, ME; Uapipatanakul, B, 2021)	0.84
" After experiencing a major Covid-19-related personal trauma, patients showed clinical worsening which required dosage adjustment (20 mg/day vortioxetine; 600 mg/day trazodone, and 200 mg/day sertraline) and, for some of them, hospitalisation."	( Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma. Amici, E; De Filippis, S; Di Giovanni, A; Giovanetti, V; Kotzalidis, GD; Lombardozzi, G; Matrone, M; Perrini, F; Trovini, G, 2022)	0.91
" Knowing the CYP2B6 and CYP2C19 genotype, including the CYP2C:TG haplotype status, can prospectively be useful to clinicians in making more appropriate sertraline dosing decisions."	( Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population. Bråten, LS; Ingelman-Sundberg, M; Jukic, MM; Kringen, MK; Molden, E, 2022)	1.16
" Sixty-one patients suffering from OCD who were resistant to sertraline monotherapy were randomly allocated to receive mirtazapine (mean dosage = 39."	( Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial. Baniasadipour, H; Mowla, A, 2023)	1.36
" This case report is novel is several aspects: the tics emergence was immediate whereas previous cases were delayed; the tics symptoms were measured and quantified by a validated scale; a dose-response relationship was observed; to our knowledge, our case was the first adolescent female reported; and finally, paroxetine was well-tolerated as a substitute, although it is unclear whether the observed tics-sparing effect is co-incidental, ideocratic or can be replicated."	( Sertraline-Induced Tics: A Case Report and Narrative Review. Arasu, R; Badeshae, S; Chen, W; Furlong, Y, 2023)	2.35
" The steroid structure was chemically altered to improve bioavailability and create an oral dosage form."	( Neuroactive steroids - new possibilities in the treatment of postpartum depression. Adamičková, A; Gažová, A; Hrubá, O; Massarová, P; Vranecová, K; Žigová, L, 2022)	0.72
" Another interesting aspect of antidepressants is that they have shown to induce non-monotonic dose-response (NMDR) curves."	( Contrasting dose response relationships of neuroactive antidepressants on the behavior of C. elegans. Estruch, IM; van den Brink, NW; van der Most, MA, 2023)	0.91
" Scatter plots revealed a complex relationship between the dosage of clozapine and dose-adjusted sertraline concentrations composed of an initial decrease at clozapine doses below 300 mg, an increase between 300 and 600 mg and a final decrease at 800 mg which was best modeled by a third order polynomial term."	( Lower sertraline plasma concentration in patients co-medicated with clozapine-Implications for pharmacological augmentation strategies in schizophrenia. Endres, K; Gaebler, AJ; Haen, E; Hiemke, C; Omar, NB; Paulzen, M; Schoretsanitis, G, 2023)	1.61
" This finding can serve to inform sertraline dosing optimization, especially when changes in kidney function occur in treated individuals, to prevent adverse drug reactions and maximize therapeutic benefits."	( Population Pharmacokinetic Modeling to Inform Sertraline Dosing Optimization in Patients with Depression. Ilic, N; Jankovic, SM; Milovanovic, J; Nikolic, VN; Popovic, D; Stoiljkovic, M; Vujovic, M, 2023)	1.45
" However, the relationship between the dosage of sertraline and its efficacy and safety are unclear."	( Selection of the optimal dose of sertraline for depression: A dose-response meta-analysis of randomized controlled trials. Chen, Y; Li, J; Liu, Y; Luo, X; Ren, M; Si, T; Zhu, D, 2023)	1.45

Role	Description
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
serotonin uptake inhibitor	A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
tetralins	Compounds containing a tetralin skeleton.
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
dichlorobenzene	Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	28.1838	0.0447	17.8581	100.0000	AID485294
glp-1 receptor, partial	Homo sapiens (human)	Potency	2.8184	0.0184	6.8060	14.1254	AID624417
phosphopantetheinyl transferase	Bacillus subtilis	Potency	25.1189	0.1413	37.9142	100.0000	AID1490
ATAD5 protein, partial	Homo sapiens (human)	Potency	30.8552	0.0041	10.8903	31.5287	AID493106; AID493107
Fumarate hydratase	Homo sapiens (human)	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
USP1 protein, partial	Homo sapiens (human)	Potency	56.2341	0.0316	37.5844	354.8130	AID504865
PPM1D protein	Homo sapiens (human)	Potency	26.2123	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	26.1011	0.0008	11.3822	44.6684	AID686978; AID686979
Smad3	Homo sapiens (human)	Potency	35.4813	0.0052	7.8098	29.0929	AID588855
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	29.9349	0.5318	15.4358	37.6858	AID504845
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	11.2202	0.2818	9.7212	35.4813	AID2326
polyprotein	Zika virus	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	10.6101	0.0001	8.4406	100.0000	AID720579; AID720580
IDH1	Homo sapiens (human)	Potency	10.3225	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	26.6795	0.0355	20.9770	89.1251	AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	46.4515	0.0165	25.3078	41.3999	AID602332
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	58.0479	0.0126	2.4518	25.0177	AID485313
D(1A) dopamine receptor	Homo sapiens (human)	Potency	8.2942	0.0224	5.9449	22.3872	AID488981; AID488982; AID488983
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	89.1251	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	5.0119	0.0060	26.1688	89.1251	AID488953
atrial natriuretic peptide receptor 2 precursor	Homo sapiens (human)	Potency	14.6892	0.0066	9.8094	18.4927	AID1347050
ras-related protein Rab-9A	Homo sapiens (human)	Potency	58.0479	0.0002	2.6215	31.4954	AID485297
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	24.2144	0.0037	8.6189	23.2809	AID2660; AID2666; AID2667; AID2668
histone-lysine N-methyltransferase 2A isoform 2 precursor	Homo sapiens (human)	Potency	7.9433	0.0103	23.8567	63.0957	AID2662
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	16.3508	0.0046	11.3741	33.4983	AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	36.1254	0.0056	12.3677	36.1254	AID624032
Rap guanine nucleotide exchange factor 3	Homo sapiens (human)	Potency	35.4813	6.3096	60.2008	112.2020	AID720709
Interferon beta	Homo sapiens (human)	Potency	26.2123	0.0033	9.1582	39.8107	AID1347411
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	26.1216	0.0037	8.1081	23.2809	AID2667
Ataxin-2	Homo sapiens (human)	Potency	14.1254	0.0119	12.2221	68.7989	AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	1.0830	0.0001	1.0076	8.7800	AID625218
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	Ki	0.5673	0.0000	0.8871	10.0000	AID625218
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	29.3400	0.1100	7.1903	10.0000	AID1449628
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.9848	0.0004	1.8773	10.0000	AID625207
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	Ki	0.9766	0.0032	2.2887	9.3160	AID625207
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	IC50 (µMol)	2.7675	0.0000	1.2326	7.7930	AID625152
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	0.9840	0.0000	0.6902	10.0000	AID625152
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	IC50 (µMol)	2.6309	0.0000	1.1546	7.5858	AID625154
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	Ki	0.3669	0.0000	0.7951	9.1201	AID625154
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	31.8000	0.0002	2.3185	10.0000	AID681144
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	0.8000	0.0001	1.7536	10.0000	AID550788
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	IC50 (µMol)	0.5073	0.0001	0.9917	8.0000	AID625155
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	Ki	0.3645	0.0000	0.7292	6.9183	AID625155
Alpha-2A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.2888	0.0000	1.4421	7.3470	AID625201
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	0.1083	0.0001	0.8074	10.0000	AID625201
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	1.4000	0.0000	2.0151	10.0000	AID550787
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	1.2882	0.0000	1.4039	10.0000	AID625151
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	Ki	0.3102	0.0000	0.5972	9.1201	AID625151
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	14.2500	0.0000	2.8005	10.0000	AID1210069; AID550785
Transcriptional activator protein LuxR	Aliivibrio fischeri	IC50 (µMol)	27.0000	1.3600	3.2533	7.0000	AID493958
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	8.3173	0.0000	1.6129	10.0000	AID625171
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	Ki	6.8141	0.0004	2.0337	8.6606	AID625171
Alpha-2B adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.1814	0.0000	1.2380	8.1590	AID625202
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	0.0828	0.0002	0.7257	10.0000	AID625202
Alpha-2C adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	4.4770	0.0000	1.4725	7.8980	AID625203
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.6505	0.0003	0.4834	10.0000	AID625203
D	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2600	0.0003	0.5026	7.7625	AID179927
D(3) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2600	0.0003	0.3907	5.4000	AID179927
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	0.8783	0.0008	1.5416	20.0000	AID262048; AID550777; AID625207
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	0.9766	0.0003	1.4656	10.0000	AID625207
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8250	0.0007	0.9774	9.7000	AID550777
D(1B) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2600	0.0003	0.3563	5.4000	AID179927
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	2.7409	0.0001	0.8801	8.8500	AID625192
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	0.7831	0.0000	0.3855	10.0000	AID625192
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	1.0830	0.0001	1.0302	9.0000	AID625218
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	0.5673	0.0001	0.9549	10.0000	AID625218
D(4) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2600	0.0003	0.3871	5.4000	AID179927
3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)	IC50 (µMol)	0.8000	0.0001	0.5267	10.0000	AID550788
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	0.0016	0.0001	0.8645	8.7096	AID1718178; AID262046; AID550776; AID625222
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.0001	0.0000	0.7048	8.1930	AID625222
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1743	0.0003	0.8197	8.4900	AID179927; AID550776
Melanocortin receptor 5	Homo sapiens (human)	IC50 (µMol)	4.5980	0.0009	1.2566	9.5180	AID625149
Melanocortin receptor 5	Homo sapiens (human)	Ki	4.3132	0.0005	3.5265	8.9290	AID625149
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	0.6550	0.0000	2.3983	10.0000	AID550786; AID625247
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	IC50 (µMol)	3.3935	0.0001	1.1873	8.9125	AID625217
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	2.1595	0.0003	0.7693	10.0000	AID625217
Cytochrome P450 2J2	Homo sapiens (human)	IC50 (µMol)	18.5000	0.0120	2.5312	9.4700	AID1210069
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2600	0.0001	0.5494	8.4000	AID179927
Sodium-dependent dopamine transporter	Homo sapiens (human)	IC50 (µMol)	0.2175	0.0007	1.8419	46.0000	AID262047; AID550778; AID625256
Sodium-dependent dopamine transporter	Homo sapiens (human)	Ki	0.0258	0.0002	1.1115	8.0280	AID625256
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	8.3173	0.0009	1.9014	10.0000	AID625171
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	6.8141	0.0021	1.8407	10.0000	AID625171
Sigma intracellular receptor 2	Rattus norvegicus (Norway rat)	Ki	5.2970	0.0024	1.1050	9.3000	AID1718151
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	IC50 (µMol)	8.3173	0.1048	2.8398	8.3173	AID625171
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	Ki	6.8141	0.0858	2.9542	8.6606	AID625171
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0697	0.0003	0.7028	5.3660	AID625223
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	0.0432	0.0000	0.4901	10.0000	AID625223; AID712773
Sigma non-opioid intracellular receptor 1	Rattus norvegicus (Norway rat)	Ki	0.0570	0.0003	0.2671	5.0700	AID1718165
Transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2600	0.0008	1.9562	8.8000	AID179927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Kd	0.4200	0.0008	0.2533	1.0600	AID145563
Sodium-dependent serotonin transporter	Homo sapiens (human)	Kd	0.0003	0.0001	0.0317	0.2000	AID204080
Sodium-dependent dopamine transporter	Homo sapiens (human)	Kd	0.0250	0.0250	2.1443	9.3000	AID64372
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adaptive immune response	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
associative learning	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Rap protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
intracellular signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of GTPase activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of protein export from nucleus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of stress fiber assembly	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
establishment of endothelial barrier	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cellular response to cAMP	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Ras protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of insulin secretion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cell surface receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
gastric acid secretion	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dopamine transport	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
transmission of nerve impulse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylation	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of blood pressure	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
temperature homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytokine production involved in immune response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
activation of phospholipase C activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
memory	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
response to xenobiotic stimulus	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
regulation of dopamine secretion	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
artery smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
urinary bladder smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of heat generation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of potassium ion transport	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of neuron apoptotic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein localization to cytoskeleton	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of vasoconstriction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
symbiont entry into host cell	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
sensitization	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral response to cocaine	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of inflammatory response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of execution phase of apoptosis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of platelet aggregation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of DNA biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
locomotory behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
feeding behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of nervous system process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of appetite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of corticotropin-releasing hormone secretion	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of calcium-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
androgen biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
steroid catabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
cell-cell signaling	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
androgen metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
male gonad development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to xenobiotic stimulus	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
biphenyl metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
phthalate metabolic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
hippocampus development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
hypothalamus development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
cell differentiation	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
male genitalia development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
female genitalia development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to nutrient levels	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to follicle-stimulating hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to testosterone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to peptide hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
response to steroid hormone	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
bone development	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
testosterone biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
steroid biosynthetic process	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Melanocortin receptor 5	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Melanocortin receptor 5	Homo sapiens (human)
regulation of metabolic process	Melanocortin receptor 5	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
neural crest cell migration	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cytokine production	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of endothelial cell proliferation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor internalization	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
heart morphogenesis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cardiac muscle hypertrophy	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
activation of phospholipase C activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
response to xenobiotic stimulus	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neural crest cell differentiation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
intestine smooth muscle contraction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phosphorylation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
calcium-mediated signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
negative regulation of apoptotic process	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of MAP kinase activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
embryonic morphogenesis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cell division	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein kinase C signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cellular response to temperature stimulus	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
fatty acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
icosanoid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
regulation of heart contraction	Cytochrome P450 2J2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
monoamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
lactation	Sodium-dependent dopamine transporter	Homo sapiens (human)
sensory perception of smell	Sodium-dependent dopamine transporter	Homo sapiens (human)
locomotory behavior	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to iron ion	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
adenohypophysis development	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to nicotine	Sodium-dependent dopamine transporter	Homo sapiens (human)
positive regulation of multicellular organism growth	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of dopamine metabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cocaine	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine biosynthetic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine catabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to ethanol	Sodium-dependent dopamine transporter	Homo sapiens (human)
cognition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cAMP	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
prepulse inhibition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
hyaloid vascular plexus regression	Sodium-dependent dopamine transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
lipid transport	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nervous system development	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
regulation of neuron apoptotic process	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein homotrimerization	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein domain specific binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
3-oxo-5-alpha-steroid 4-dehydrogenase activity	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
protein binding	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
amide binding	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) activity	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Melanocortin receptor 5	Homo sapiens (human)
hormone binding	Melanocortin receptor 5	Homo sapiens (human)
melanocortin receptor activity	Melanocortin receptor 5	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
iron ion binding	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
heme binding	Cytochrome P450 2J2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2J2	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cortical actin cytoskeleton	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
microvillus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
endomembrane system	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
lamellipodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
filopodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular exosome	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
endoplasmic reticulum membrane	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
neuronal cell body	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
cell body fiber	3-oxo-5-alpha-steroid 4-dehydrogenase 2	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Melanocortin receptor 5	Homo sapiens (human)
plasma membrane	Melanocortin receptor 5	Homo sapiens (human)
cytoplasm	Melanocortin receptor 5	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2J2	Homo sapiens (human)
extracellular exosome	Cytochrome P450 2J2	Homo sapiens (human)
cytoplasm	Cytochrome P450 2J2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2J2	Homo sapiens (human)
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID503332	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1904255	Anti-cryptococcal activity against Cryptococcus neoformans H99 assessed as inhibition of fungal growth incubated for 72 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1210073	Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1904260	Antifungal activity against Candida glabrata 9073 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1759282	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as reduction in phosphorylated mTOR expression at 3 to 6 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID262068	Tmax in rat at 1 mg/kg, iv or 1 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID503339	Inhibition of HSP90 expressed in HEK293 cells assessed as effect on HSP90-Cdc37 by EYFP and/or YFP Venus fragment based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID144700	Noncompetitive inhibition of N-methyl-D-aspartate (NMDA) Receptor, by the displacement of [3H]MK-801 in rat brain membranes; nd means not determined	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1220556	Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID700107	Antidepressant activity in BALB/cJ mouse assessed as reduction in immobility at 20 mg/kg, po measured after 30 mins post drug administration by forced swim test	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.
AID262066	Oral bioavailability in rat at 1 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID712773	Binding affinity to sigma 1 receptor	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.
AID1705389	Cytotoxicity against human HEK293T cells incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
AID1759262	Induction of apoptosis in human SGC-7901 cells assessed as upregulation of cleaved caspase 3 expression level by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID179747	In vitro inhibition of serotonin (5-HT) uptake in crude rat brain synaptosomes	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
AID186980	Inhibition of [3H]- NE reuptake into rat hippocampal synaptosomes	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID1904256	Antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1210074	Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1904258	Antifungal activity against Candida albicans 0304103 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID196062	Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID550788	Inhibition of CYP3A4	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID1533457	Antiviral activity against Ebolavirus infected in mouse assessed as protection against viral infection at 20 mg/kg/day relative to control	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID262047	Inhibition of dopamine re-uptake at human dopamine transporter expressed in HEK293 cells	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID1904280	Inhibition of Cryptococcus neoformans H99 delta5,6-desaturase assessed as accumulation of ergosta-7,22-dien-3-ol at 16 ug/ml incubated for 24 hrs by GC-MS analysis	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID262058	Blood clearance in rat in CNS penetration assay at 1 mg/kg, iv or 1 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID262051	Distribution coefficient of the compound, log D	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID330665	Effect on life span of Caenorhabditis elegans at 250 uM	2007	Nature, Nov-22, Volume: 450, Issue:7169	An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID710152	Antidepressant activity in BALB/cJ mouse assessed as reduction of immobility time at 20 mg/kg, ip administered 30 mins before test measured over 6 mins trial by forced swim test	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Discovery of highly potent and selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II.
AID700132	Antidepressant activity in BALB/cJ mouse assessed as reduction in immobility at 10 mg/kg, ip measured after 30 mins post drug administration by forced swim test	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID1863562	Antiviral activity against pseudotyped Ebola virus assessed as inhibition of viral entry	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1759266	Induction of apoptosis in human SGC-7901 cells assessed as early apoptotic cells at 8 uM by FITC/PI staining based flow cytometry analysis (Rvb = 3.06 %)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID50341	Maximal activatory effect against human carbonic anhydrase I (hCA I)	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID1472910	Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein by SYPRO orange dye-based fluorescence assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID1759285	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as change in total AKT expression at 8 to 16 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID1759264	Antiproliferative activity against cisplatin resistant human SGC-7901 cells assessed as sensitizing activity in presence of cisplatin	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID196063	Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1759275	Induction of cell cycle arrest in human SGC-7901 cells assessed as accumulation at G0/G1 phase at 8 to 16 uM by flow cytometry analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID1220559	Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1904259	Antifungal activity against Candida tropicalis 10186 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID262062	Unbound volume of distribution in rat at 1 mg/kg, iv or 1 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID1904242	Inhibition of Cryptococcus neoformans H99 delta5,6-desaturase assessed as change in sterol content at < 8 ug/ml incubated for 24 hrs by GC-MS analysis	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1759268	Induction of apoptosis in human SGC-7901 cells assessed as necrotic cells at 8 uM by FITC/PI staining based flow cytometry analysis (Rvb = 0.068 %)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID262050	Selectivity for inhibition of serotonin re-uptake at human serotonin transporter over inhibition of noradrenaline re-uptake at human noradrenaline transporter	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID262056	Half life in human liver microsome	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID1759273	Induction of apoptosis in human SGC-7901 cells assessed as total caspase 3 expression level at 8 to 16 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID503338	Inhibition of HSP90 expressed in HEK293 cells assessed as reduction of HSP90-eEF2K signaling complex by EYFP and/or YFP Venus fragment based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1904243	Anti-cryptococcal activity against Cryptococcus neoformans H99 assessed as fungal growth inhibition	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1472913	Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein assessed as change in melting temperature at 500 uM by SYPRO orange dye-based fluorescence assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID179744	In vitro inhibition of norepinephrine (NE) uptake in crude rat brain synaptosomes	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1207702	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1904266	Antifungal activity against Aspergillus fumigatus 023-2 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311933	Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID550776	Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1705387	Inhibition of glycoprotein in VSV-G pseudotyped EBOV Mayinga infected in human HEK293T cells assessed as reduction in virus entry preincubated with pseudotyped virus for 1 hr followed by cell infection and measured after 48 hrs by luciferase reporter gene	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID493958	Inhibition of LuxR-dependent quorum sensing in Vibrio fischeri assessed as reduction of 3-oxo-C6-HSL-induced bioluminescence intensity	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID503335	Inhibition of of c-Jun expressed in HEK293 cells assessed as induction of protein interaction in presence of camptothecin with Pin1 by EYFP based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID539464	Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID761146	Antidepressant-like activity in BALB/cJ mouse assessed as decrease in immobility time at 20 mg/kg, ip administered 30 mins before test measured for 6 mins by forced swimming test	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Chemistry, pharmacology, and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. Part II.
AID1904257	Antifungal activity against Candida albicans 904 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID616837	Anti-depressant activity in mouse assessed as immobility effect at 10 mg/kg, po after 60 mins by forced swimming test	2011	Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18	Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
AID196059	Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID64372	Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID250135	Inhibition of compound against MES-SA/DX5 cell line was determined using P-glycoprotein assay	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
AID1759279	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as reduction in phosphorylated AKT expression at 8 to 16 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID503337	Inhibition of cofilin1 expressed in HEK293 cells assessed as effect on cofilin1; Limk2 interaction complexes by EYFP and/or YFP Venus fragment based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1904279	Inhibition of Cryptococcus neoformans H99 delta5,6-desaturase assessed as accumulation of ergosta-7,22-dien-3-ol at < 8 ug/ml incubated for 24 hrs by GC-MS analysis	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID179927	Inhibition of 5-HT uptake in synaptosomal preparation from rat corpus striatum, using [3H]5-HT	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID262046	Inhibition of serotonin re-uptake at human serotonin transporter expressed in HEK293 cells	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID1904263	Antifungal activity against Candida auris 0029 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1220560	Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1904269	Cytotoxicity against HUVEC cells	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1210070	Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID262053	Permeability from apical to basolateral in Caco-2 cell membrane	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID311935	Partition coefficient, log P of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID550786	Inhibition of CYP2C19	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID1705409	Antiviral activity against eGFP-EBOV infected in African green monkey Vero E6 cells	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
AID262054	Permeability from basolateral to apical in Caco-2 cell membrane	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID262048	Inhibition of noradrenaline re-uptake at human noradrenaline transporter expressed in HEK293 cells	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID1759267	Induction of apoptosis in human SGC-7901 cells assessed as late apoptotic cells at 8 uM by FITC/PI staining based flow cytometry analysis (Rvb = 2.56 %)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID262052	Dissociation constant, pKa of the compound	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID1220554	Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID179973	Inhibition of norepinephrine uptake in synaptosomal preparation fro rat hypothalamus, using [3H]norepinephrine	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID550778	Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID503333	Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1759265	Induction of apoptosis in human SGC-7901 cells assessed as viable cells at 8 uM by FITC/PI staining based flow cytometry analysis (Rvb = 94.3 %)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID550785	Inhibition of CYP2C9	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID1718151	Displacement of [3H]DTG from sigma 2 receptor in Sprague-Dawley rat brain membranes in presence of (+)-pentazocine by scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1904271	Anti-cryptococcal activity against Cryptococcus neoformans H99 infected Cryptococcal meningitis ICR mouse model of assessed as reduction in fungal burden in brain at 15 mg/kg, IG administered daily measured after 5 days	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID681144	TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells	2003	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 305, Issue:1	Inhibition of P-glycoprotein by newer antidepressants.
AID1220557	Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1904252	Inhibition of biofilm formation in Cryptococcus neoformans H99 at 8 ug/ml incubated for 24 hrs by XTT reduction assay	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1186830	Fraction unbound in mouse brain	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Rational use of plasma protein and tissue binding data in drug design.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID262064	Half life in rat at 1 mg/kg, iv or 1 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID1718178	Inhibition of SERT (unknown origin)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1904297	Anti-cryptococcal activity against Cryptococcus assessed as inhibition of fungal growth incubated for 72 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1759278	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as reduction in phosphorylated PI3K expression at 3 to 6 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1904267	Metabolic stability in mouse liver microsomes assessed as half life	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1904254	Antifungal activity against Candida auris 0030 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID186979	Inhibition of [3H]- DA reuptake into rat striatal synaptosomes	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID1904262	Antifungal activity against Candida krusei 10153 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1904261	Antifungal activity against Candida glabrata 9025 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1472912	Antiviral activity against Ebolavirus infected in human HepG2 cells assessed as reduction in virus entry after 48 hrs by Celltiter-Glo luminescent assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID1220558	Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1759281	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as reduction in phosphorylated mTOR expression at 8 to 16 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID493961	Induction of of LuxR-dependent quorum sensing in Vibrio fischeri assessed as induction of bioluminescence intensity up to 200 uM	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1759277	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as reduction in phosphorylated PI3K expression at 8 to 16 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID1705388	Inhibition of glycoprotein in VSV-G infected in human HEK293T cells assessed as reduction in virus entry preincubated with virus for 1 hr followed by cell infection and measured after 48 hrs by luciferase reporter gene assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
AID515780	Intrinsic solubility of the compound in water	2010	Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19	QSAR-based solubility model for drug-like compounds.
AID712772	Binding affinity to sigma 2 receptor	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.
AID550787	Inhibition of CYP2D6	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID418843	Antidepressant activity in C57BL/6J mouse assessed as decrease in immobility time at 10 mg/kg, ip administered 30 mins prior to testing measured every 1 min for 6 mins by forced swim test relative to control	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.
AID1210071	Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1904273	Anti-cryptococcal activity against Cryptococcus neoformans H99 assessed as cell membrane damage at 4 ug/ml incubated for 8 hrs by transmission electron microscopy	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID503336	Effect on cofilin1 expressed in HEK293 cells assessed as effect on cofilin1; Limk2 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1220555	Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1847246	Antiviral activity against Ebola virus infected in African green monkey assessed as reduction in viral infection incubated for 48 hrs by CellTiter-Glo Luminescent Cell Viability Assay	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID50343	Maximal activatory effect against human carbonic anhydrase I (hCA I) at a concentration of 1 uM	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID186981	Inhibition of [3H]5-HT reuptake into rat frontal cortex synaptosomes	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID330659	Effect on life span of Caenorhabditis elegans at 50 uM	2007	Nature, Nov-22, Volume: 450, Issue:7169	An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1904245	Anti-cryptococcal activity against Cryptococcus neoformans H99 assessed as inhibition of fungal growth at 8 ug/ml incubated upto 72 hrs by time-growth curve assay	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1210072	Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID204080	Equilibrium dissociation constant (KD) for Competitive binding between [3H]- imipramine and the compound at human transporter-hSERT	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1904272	Toxicity in ICR mouse model of Cryptococcal meningitis infected with Cryptococcus neoformans H99 assessed as median survival time at 15 mg/kg, IG administered daily (Rvb = 11 day)	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1904264	Antifungal activity against Candida auris 15448 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID550789	Inhibition of human ERG	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID179960	Inhibition of dopamine uptake in synaptosomal preparation in rat corpus striatum, using [3H]dopamine	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1904268	Metabolic stability in mouse liver microsomes assessed as clearance	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1759287	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as change in total mTOR expression at 8 to 16 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID1210069	Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1759280	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as reduction in phosphorylated AKT expression at 3 to 6 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID229635	Selectivity ratio measured as the ratio of IC50 of NE/IC50 of 5-HT	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
AID1904251	Fungicidal activity against Cryptococcus neoformans H99 assessed as fungal growth inhibition incubated upto 72 hrs by time-fungicidal curve assay	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID550784	Inhibition of CYP1A	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID1759283	Effect on PI3K/AKT/mTOR signaling pathway in human SGC-7901 cells assessed as change in total PI3K expression at 8 to 16 uM by Western blotting analysis	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID262060	Volume of distribution in rat at 1 mg/kg, iv or 1 mg/kg, po	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID503334	Effect on p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1705408	Antiviral activity against eGFP-MARV infected in African green monkey Vero E6 cells	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
AID1472911	Antiviral activity against Ebolavirus infected in african green monkey Vero E6 cells assessed as reduction in virus entry after 48 hrs by by Celltiter-Glo luminescent assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID1705390	Selectivity index, ratio of CC50 for human HEK293T cells to IC50 for glycoprotein in VSV-G pseudotyped EBOV Mayinga infected in human HEK293T cells	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
AID1718165	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Sprague-Dawley rat brain membranes by scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID311934	Dissociation constant, pKa of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID262049	Selectivity for inhibition of serotonin re-uptake at human serotonin transporter over inhibition of dopamine re-uptake at human dopamine transporter	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID262055	Ratio of permeability from apical to basolateral over basolateral to apical in Caco-2 cell membrane	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID550783	Half life in mouse liver microsome	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID688847	Octanol-phosphate buffered saline partition coefficient, log K of the compound	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Fluorescent reporters of monoamine transporter distribution and function.
AID1904265	Antifungal activity against Aspergillus fumigatus 7544 assessed as inhibition of fungal growth incubated for 48 hrs by microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Discovery of Novel Sertraline Derivatives as Potent Anti-
AID503311	Antiproliferative activity against human PC3 cells at 10 uM after 120 hrs by MTT assay relative to DMSO	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID550777	Inhibition of [3H]norepinephrine reuptake at human NET expressed in MDCK cells by scintillation counting	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID145563	Equilibrium dissociation constant (KD) for Competitive binding between [3H]- nisoxatine and the compound at human Norepinephrine transporter	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID262057	Half life in rat liver microsome	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
AID550782	Half life in human liver microsome	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155	Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150	Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1801851	LoxA HTP Assay from Article 10.1021/acs.biochem.6b00338: \\Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase.\\	2016	Biochemistry, 06-14, Volume: 55, Issue:23	Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	29 (0.90)	18.7374
1990's	647 (20.17)	18.2507
2000's	1074 (33.49)	29.6817
2010's	1082 (33.74)	24.3611
2020's	375 (11.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,028 (29.54%)	5.53%
Reviews	293 (8.42%)	6.00%
Case Studies	686 (19.71%)	4.05%
Observational	12 (0.34%)	0.25%
Other	1,461 (41.98%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (300)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression [NCT03126188]		105 participants (Actual)	Observational	2017-04-05	Completed
Cognitive Processing Therapy Versus Sertraline for the Treatment of Post-traumatic Stress Disorder & Substance Use Disorder Egyptian Patients [NCT03469128]	Phase 1	150 participants (Actual)	Interventional	2016-01-01	Completed
Efficacy of Dynamic Therapy Versus Selective Serotonin Reuptake Inhibitor for Depression [NCT00043550]	Phase 3	156 participants (Actual)	Interventional	2001-11-30	Completed
Matching Genotypes and Serotonergic Medications for Alcoholism [NCT01113164]	Phase 1	79 participants (Actual)	Interventional	2008-09-30	Completed
The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study [NCT01114100]	Phase 4	210 participants (Actual)	Interventional	2000-01-31	Completed
Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents [NCT01160588]		156 participants (Actual)	Observational	2010-07-31	Completed
Collaborative Care for Depressed Elders in China [NCT01287494]	Phase 4	320 participants (Anticipated)	Interventional	2010-08-31	Recruiting
Combined Treatment for Alcohol-Dependent Individuals With PTSD [NCT00262223]	Phase 2	69 participants (Actual)	Interventional	2006-05-31	Completed
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients [NCT01352572]		300 participants (Anticipated)	Interventional	2002-01-31	Active, not recruiting
A Prospective, Longitudinal Comparison of the Pharmacokinetic Properties of Sertraline Before and After Roux-en-Y Gastric Bypass [NCT01214382]	Phase 3	31 participants (Actual)	Interventional	2010-10-31	Completed
Z 31801 - A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women [NCT04094870]	Phase 4	80 participants (Actual)	Interventional	2019-10-30	Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
An Investigation of the Role of Inflammatory Processes in the Development and Treatment of Idiopathic Unipolar and Bipolar Depression in Patients With Moderate to Severe Depressive Symptoms. [NCT03920475]		104 participants (Actual)	Observational	2015-08-05	Completed
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients [NCT01237275]		300 participants (Anticipated)	Interventional	1999-10-31	Active, not recruiting
SS1: Pilot Study of Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (MDS) [NCT02452983]	Phase 1	14 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to This protocol is closed to further enrollment due to lack of study progress.)
Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg [NCT01267383]	Phase 1	32 participants (Actual)	Interventional	2006-09-30	Completed
Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety [NCT05683223]		240 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype [NCT01352559]		1,000 participants (Anticipated)	Interventional	2001-11-30	Active, not recruiting
Effects of Sertraline on Brain Connectivity in Adolescents With OCD (Obsessive-Compulsive Disorder) [NCT02797808]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2013-08-31	Completed
Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of Selective Serotonin Reuptake Inhibitors in Healthy Subjects [NCT02175602]	Phase 1	41 participants (Actual)	Interventional	2014-06-30	Completed
International Committee of Medical Journal Editors [NCT02179268]	Phase 3	203 participants (Actual)	Interventional	2012-03-31	Completed
Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg [NCT01267396]	Phase 1	32 participants (Actual)	Interventional	2006-09-30	Completed
A Randomized, Double-Blind, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly-dosed Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New S [NCT03852160]	Phase 3	0 participants (Actual)	Interventional	2019-12-01	Withdrawn(stopped due to New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study)
The Changes in Functional Recovery and Brain Neurotrophic Factor Six Months After Percutaneous Coronary Intervention in Cardiovascular Patients With Depression [NCT03841474]		150 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Phenotype Predictors of Cognitive Outcomes in Geriatric Depression [NCT05273996]	Phase 4	75 participants (Anticipated)	Interventional	2021-09-28	Recruiting
Psychiatric Orders in Psychoanalytic Treatment of ASD [NCT05930912]		1 participants (Actual)	Observational	2023-06-01	Active, not recruiting
Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin: The ANDROS Study [NCT02463110]	Phase 4	2 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Investigator's decision)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole (1 - 3 mg/Day) as Monotherapy or as Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder [NCT03033069]	Phase 2	336 participants (Actual)	Interventional	2017-01-26	Completed
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression [NCT02493868]	Phase 3	719 participants (Actual)	Interventional	2015-10-01	Completed
Efficacy and Safety of Aripiprazole 2.5mg Combine Sertraline 50mg in Major Depression [NCT00873795]		41 participants (Actual)	Interventional	2007-04-30	Completed
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]		1,600 participants (Anticipated)	Observational	2018-10-04	Recruiting
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene [NCT02237937]	Phase 4	80 participants (Anticipated)	Interventional	2011-09-30	Recruiting
A Randomized Controlled Study of Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder [NCT04977544]		200 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder [NCT03279471]	Phase 2	68 participants (Actual)	Interventional	2017-10-01	Completed
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients [NCT00581009]	Phase 1/Phase 2	96 participants (Actual)	Interventional	2001-05-30	Completed
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment [NCT05537584]	Phase 4	183 participants (Anticipated)	Interventional	2022-09-30	Recruiting
A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A) [NCT02269540]	Early Phase 1	10 participants (Actual)	Interventional	2014-10-31	Completed
Pharmacologic Treatment of PTSD in Sexually Abused Children [NCT00078767]	Phase 3	24 participants (Actual)	Interventional	2001-04-30	Completed
A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders [NCT06081348]	Phase 2	130 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Predict Antidepressant Responsiveness Using Pharmacogenomics [NCT01228357]		1,000 participants (Anticipated)	Interventional	2003-02-28	Recruiting
Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder [NCT03514810]	Phase 1	28 participants (Actual)	Interventional	2017-01-10	Completed
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]		3,255,526 participants (Actual)	Observational	2013-06-30	Completed
A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF ZOLOFT (REGISTERED) ORAL SOLUTION (20 MG/ML; FARMASIERRA MANUFACTURING, S.L.) COMPARED TO ZOLOFT (REGISTERED) TABLETS (50 MG; WYETH INDÚSTR [NCT03711708]	Phase 4	36 participants (Actual)	Interventional	2018-11-06	Completed
Strategic Use of New Generation Antidepressants for Depression [NCT01109693]	Phase 4	2,011 participants (Actual)	Interventional	2010-12-31	Completed
A Single-center, Open-label, Randomized, Two-treatment, Two-period Crossover Trial to Investigate Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and S [NCT03342963]	Phase 1	74 participants (Actual)	Interventional	2017-11-21	Completed
Utility of Plasma Drug Level Monitoring and CYP2C19 Genotyping in Dose Personalization of Sertraline [NCT05210153]		148 participants (Anticipated)	Observational	2020-07-16	Recruiting
Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT. [NCT00594269]	Phase 4	149 participants (Actual)	Interventional	2008-08-31	Completed
SPRITES: SERTRALINE PEDIATRIC REGISTRY FOR THE EVALUATION OF SAFETY A NON-INTERVENTIONAL, LONGITUDINAL, COHORT STUDY TO EVALUATE THE EFFECTS OF LONG-TERM SERTRALINE TREATMENT IN CHILDREN AND ADOLESCENTS [NCT01302080]		941 participants (Actual)	Observational	2012-04-04	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Sertraline Hydrochloride Tablets (100 mg; Mylan) and Zoloft® Tablets (100 mg; Pfizer) in Healthy Volunteers [NCT00650325]	Phase 1	49 participants (Actual)	Interventional	2002-11-30	Completed
Postpartum Depression: Transdermal Estradiol Versus Sertraline [NCT00744328]	Phase 4	85 participants (Actual)	Interventional	2008-08-31	Terminated(stopped due to Recruitment Issues)
TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode [NCT00666757]	Phase 4	750 participants (Actual)	Interventional	2008-05-31	Completed
Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression [NCT00787501]	Phase 1	98 participants (Actual)	Interventional	2008-06-30	Completed
Assessment of the Inter-patient Variability in Clinical Response and Correlated Genetic Variations in Substance Use Disorders [NCT05833399]		200 participants (Anticipated)	Observational	2022-11-28	Recruiting
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients [NCT00817375]		1,000 participants (Anticipated)	Interventional	2003-02-28	Recruiting
Medication and Psychotherapy Treatment Trial for Psychogenic Nonepileptic Seizures [NCT00835627]	Phase 4	38 participants (Actual)	Interventional	2008-09-30	Completed
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fed Conditions [NCT00864019]	Phase 1	30 participants (Actual)	Interventional	2004-08-31	Completed
Neuro-Genetic Markers of SSRI Treatment Response in Social Anxiety Disorder [NCT00872131]		200 participants (Actual)	Observational	2008-03-31	Completed
The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults [NCT02228005]	Phase 4	25 participants (Actual)	Interventional	2014-07-31	Completed
THE AIUNI - Integral Assessment in Unipolar Depression [NCT02268487]	Phase 4	100 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Effects and Consequences for Mother and Child From Treatment for Depression, A Prospective Randomized, Placebo- Controlled, Trial With Internet-based Cognitive Behavior Therapy and Sertraline or Placebo for Moderate Depression in Pregnancy [NCT02185547]	Phase 4	17 participants (Actual)	Interventional	2016-02-21	Terminated(stopped due to Difficulties in recruiting participants.)
A Randomised, Controlled Evaluation of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression [NCT02122393]	Phase 3	45 participants (Actual)	Interventional	2002-04-30	Completed
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression [NCT02422186]	Phase 3	139 participants (Actual)	Interventional	2015-08-20	Completed
Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study [NCT04806230]		81 participants (Actual)	Observational	2011-04-01	Completed
Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline [NCT01028482]		42 participants (Actual)	Interventional	2008-03-31	Completed
Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression [NCT00944996]		100 participants (Actual)	Interventional	2009-06-30	Completed
Treatment Refractory Panic Disorder [NCT00118417]	Phase 2/Phase 3	46 participants (Actual)	Interventional	1999-03-31	Completed
[11C] Sertraline PET Imaging Study That Investigates Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration [NCT00969852]	Phase 4	10 participants (Anticipated)	Interventional	2009-07-31	Completed
A Factorial, Double-blinded, Randomized Clinical Trial on Major Depressive Disorder Using Transcranial Direct Current Stimulation [NCT01033084]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2009-12-31	Completed
Symptom Onset Antidepressant Treatment for PMDD [NCT00536198]	Phase 4	252 participants (Actual)	Interventional	2007-11-06	Completed
A Study to Compare the Relative Bioavailability of Ranbaxy and Pfizer Formulation of Sertraline 100 mg Tablets in Healthy Adult Volunteers Under Fed Conditions. [NCT00778973]		36 participants (Actual)	Interventional	2005-08-31	Completed
A Study of Sertraline to Prevent PTSD [NCT00182078]	Phase 4	26 participants (Actual)	Interventional	2002-11-30	Completed
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fasting Conditions [NCT00602849]		38 participants (Actual)	Interventional	2003-06-30	Completed
Special Investigation Of J Zoloft For Panic Disorder Patients [NCT00605917]		997 participants (Actual)	Observational	2007-04-30	Completed
Sertraline/[S,S]-Reboxetine Combination Versus Sertraline And [S,S]-Reboxetine Monotherapy In Major Depressive Disorder (MDD) In A Double-Blind, Placebo-Controlled, Eight Week Study. [NCT00636246]	Phase 2	510 participants (Actual)	Interventional	2004-06-30	Completed
The Outcome of Treatment of Traumatised Refugees With Trauma-Focused Cognitive Behavioural Therapy and / or Antidepressants - a Randomised Controlled Trial [NCT00917397]	Phase 4	280 participants (Actual)	Interventional	2009-06-30	Completed
A Multicenter Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder [NCT00644982]	Phase 4	163 participants (Actual)	Interventional	2002-10-31	Completed
International Study to Predict Optimised Treatment - in Depression [NCT00693849]	Phase 4	2,688 participants (Anticipated)	Interventional	2008-09-30	Active, not recruiting
Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT00836849]	Phase 1	24 participants (Actual)	Interventional	2002-03-31	Completed
A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder [NCT04476030]	Phase 3	440 participants (Actual)	Interventional	2020-11-09	Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]		5,000 participants (Anticipated)	Observational	2020-03-05	Recruiting
Treatment of Orthostatic Intolerance [NCT00262470]	Phase 1/Phase 2	150 participants (Anticipated)	Interventional	1997-04-30	Active, not recruiting
Special Investigation Of Long Term Use Of J ZOLOFT. [NCT00605813]		542 participants (Actual)	Observational	2007-09-30	Completed
Vortioxetine Versus Sertraline in Control Metabolic, Distress and Depression in Mexican Patients With Type 2 Diabetes [NCT03978286]	Phase 4	21 participants (Actual)	Interventional	2016-06-30	Completed
Efficacy of Nepeta Menthoides Boiss & Bohse Freeze Dried Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial [NCT02565316]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2014-11-30	Completed
Optimizing PTSD Treatment: PE Versus PE Plus Sertraline [NCT01600456]	Phase 3	150 participants (Actual)	Interventional	2011-03-31	Completed
Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent in Treatment Resistant Depression Patients : Proof of Concept [NCT04171193]	Phase 2	30 participants (Anticipated)	Interventional	2019-12-31	Not yet recruiting
Patient Dimensions as Predictors of Response, Relapse and Recurrence Following Cognitive-Behavioral Therapy, Interpersonal Psychotherapy and Pharmacotherapy Treatment of Patients With Major Depression. [NCT00744406]	Phase 2	72 participants (Actual)	Interventional	2003-07-31	Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder [NCT00797966]	Phase 2	850 participants (Actual)	Interventional	2009-05-31	Completed
A Study to Compare the Relative Bioavailability of Ranbaxy and Pfizer Formulations of Sertraline 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions. [NCT00779350]		36 participants (Actual)	Interventional	2005-08-31	Completed
Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients [NCT04071639]	Phase 1	60 participants (Anticipated)	Interventional	2020-03-12	Recruiting
Shanghai Mental Health Center in China [NCT02739061]		142 participants (Actual)	Interventional	2014-06-12	Completed
A Phase 1, Single Center Randomized, Three-way Crossover, Double-blinded, Placebo- And Moxifloxacin-controlled Thorough Qt (Tqt) Study To Determine The Effects Of Sertraline (Zoloft (Registered)) On The Cardiac Repolarization In Healthy Subjects [NCT02651623]	Phase 1	54 participants (Actual)	Interventional	2016-01-31	Completed
The Clinical Application of Tumor Reversion: A Phase I Study of Sertraline (Zoloft) in Combination With Timed-sequential Cytosine Arabinoside (Ara-C) in Adults With Relapsed and Refractory Acute Myeloid Leukemia (AML) [NCT02891278]	Phase 1	6 participants (Actual)	Interventional	2016-08-11	Completed
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]		1,000 participants (Anticipated)	Interventional	2006-04-30	Recruiting
Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fed Conditions. [NCT00836667]	Phase 1	18 participants (Actual)	Interventional	2002-03-31	Completed
[NCT00946036]	Phase 1	0 participants	Interventional		Completed
[NCT00944242]	Phase 1	0 participants	Interventional		Completed
A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder [NCT00677352]	Phase 4	321 participants (Actual)	Interventional	2008-05-31	Completed
Adapting Marital Therapy in Older Adults With Depression [NCT00612807]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2006-07-31	Completed
A Double-Blind Augmentation Study of LEvetiracetam in Obsessive Compulsive Disorder [NCT00299611]	Phase 2/Phase 3	12 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to Sponsor decided to terminate the study due to budget consideration)
Drug Use Investigation of Jzoloft. [NCT00605865]		2,272 participants (Actual)	Observational	2007-04-30	Completed
Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory in Patients With Chronic Subjective Endotic Tinnitus [NCT05646693]	Phase 2	58 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A Phase 3, Multicenter, Randomized, Double-blind Trial of Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder [NCT04124614]	Phase 3	450 participants (Actual)	Interventional	2019-10-17	Completed
Rhodiola Rosea Therapy of Major Depressive Disorder [NCT01098318]	Phase 3	58 participants (Actual)	Interventional	2010-06-30	Completed
Antidepressant Treatment of Melancholia in Late :Ife [NCT00000378]	Phase 4	110 participants (Actual)	Interventional	1997-07-31	Completed
The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder [NCT00157547]	Phase 4	95 participants (Actual)	Interventional	2003-04-30	Completed
An 8-week, Open-label Study to Evaluate the Effect of Sertraline on Polysomnogram in Depressive Patients With Insomnia [NCT01032434]		31 participants (Actual)	Interventional	2009-12-31	Completed
Sertraline Pharmacotherapy for Alcoholism Subtypes [NCT00368550]	Phase 4	134 participants (Actual)	Interventional	2004-02-29	Completed
Cognitive Behavioral Therapy vs. Sertraline in the Treatment of Post Traumatic Stress Disorder [NCT00391430]	Phase 4	39 participants (Actual)	Interventional	2005-05-31	Terminated(stopped due to Difficulty enrolling subjects)
An Integrated Pharmacological and Psychological Approach to Young People With Comorbid Depression and Substance Abuse [NCT00232284]	Phase 2	60 participants (Actual)	Interventional	2004-09-30	Completed
Establishing Multimodal Brain Biomarkers Using Data-driven Analytics for Treatment Selection in Depression [NCT05892744]	Phase 4	50 participants (Anticipated)	Interventional	2023-09-30	Recruiting
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Tolerability Of Indiplon Therapy Initiated With Sertraline Versus Sertraline Monotherapy In Subjects With Insomnia And Co-Existing Major Depressive Disorder [NCT00232167]	Phase 3	380 participants	Interventional	2005-11-30	Terminated(stopped due to Please see Detailed Description below for termination reason.)
[NCT00229476]	Phase 4	60 participants	Interventional	2003-12-31	Completed
Escitalopram vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression [NCT00234312]	Phase 4	40 participants	Interventional	2005-09-30	Completed
A Phase I, Single Center, Open Label, Intra Subject, Dose Escalation Study to Evaluate Safety and Tolerability of Sertraline Plus Telenzepine in Overweight Healthy Subjects [NCT01155531]	Phase 1	40 participants (Actual)	Interventional	2010-05-31	Completed
Nuclear Magnetic Resonance Imaging Study of Treatment With Sertraline in Geriatric Depression [NCT00245557]		43 participants (Actual)	Interventional	2004-11-30	Completed
TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression [NCT02042573]	Phase 4	60 participants (Anticipated)	Interventional	2013-11-30	Recruiting
An Eight-Week, Double-Blind, Group-Sequential Design, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of The Co- Administration Of Sertraline And Elzasonan (CP-448,187) In Outpatients With Major Depressive Disorder [NCT00275197]	Phase 2	262 participants (Actual)	Interventional	2005-12-31	Completed
A Controlled, Randomized, Double-Blind Trial of Sertraline in Patients With Frontal Lobe Dementia (FLD) [NCT00001777]	Phase 1	30 participants	Interventional	1997-12-31	Completed
Effects of Chronic Sertraline Hydrochloride Administration on Vascular Endothelial and Autonomic Function in Patients With Chronic Heart Failure [NCT00585455]		4 participants (Actual)	Observational	2006-01-31	Terminated(stopped due to PI change in institution)
Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) [NCT01178671]	Phase 4	38 participants (Actual)	Interventional	2010-07-31	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension (ATRAX Trial) [NCT02641652]	Phase 4	136 participants (Anticipated)	Interventional	2017-11-30	Not yet recruiting
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma [NCT02770378]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2016-11-30	Completed
Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS) [NCT01032018]	Phase 1/Phase 2	150 participants (Actual)	Interventional	2010-01-31	Completed
Single-Dose Food In Vivo Bioequivalence Study of Sertraline Hydrochloride Tablets (100 mg; Mylan) and Zoloft® Tablets (100 mg; Pfizer) in Healthy Volunteers [NCT00648856]	Phase 1	21 participants (Actual)	Interventional	2002-12-31	Completed
A Double-Blind Placebo-Controlled Randomized Clinical Trial of Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood? [NCT00655174]	Phase 3	108 participants (Actual)	Interventional	1999-06-30	Completed
LY2216684 and Sertraline Pharmacokinetic Interaction Study in Healthy Subjects [NCT01250873]	Phase 1	20 participants (Actual)	Interventional	2010-11-30	Completed
Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. [NCT00680602]	Phase 4	158 participants (Actual)	Interventional	2006-01-31	Completed
Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease [NCT00946998]	Phase 3	201 participants (Actual)	Interventional	2010-02-08	Completed
The Efficacy and Tolerability of Seroquel XR Combined With a Selective Serotonin Re-Uptake Inhibitor Versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder With Psychotic Features [NCT00955474]	Phase 4	32 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012)
Determining the Impact of Dementia and Executive Impairment on Antidepressant Treatment Response in Older Persons [NCT01477268]	Phase 4	30 participants (Actual)	Interventional	2007-06-30	Completed
A Randomized Controlled Study on the Treatment of Moderate Depressive Disorder With Cheek Acupuncture [NCT05923021]		126 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
Clinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's Disease [NCT01437189]		35 participants (Anticipated)	Interventional	2011-08-31	Recruiting
SSRI Treatment of Dual Diagnosis PTSD and Alcohol Dependence: A Test of the Serotonergic Hypothesis [NCT02504931]	Phase 4	49 participants (Actual)	Interventional	2011-04-30	Completed
Pharmacotherapy in Depression With Panic Spectrum [NCT00177996]	Phase 4	30 participants (Actual)	Interventional	2001-10-31	Completed
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fasting Conditions [NCT00864344]	Phase 1	30 participants (Actual)	Interventional	2004-08-31	Completed
Effectiveness of Quetiapine XR Versus Sertraline in Acute Depression as add-on Therapy to Previous Mood Stabilizer Treatment: a Pilot Study [NCT00857584]	Phase 3	27 participants (Actual)	Interventional	2009-05-31	Completed
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia [NCT04076371]		1,640 participants (Actual)	Interventional	2012-01-31	Completed
A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD) [NCT00150306]	Phase 3	160 participants	Interventional	2002-11-30	Terminated(stopped due to Please see Detailed Description below for termination reason.)
A Randomized, Double-Blind, Active Controlled Clinical Trial of Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction [NCT01856127]	Phase 4	4 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to PI left institution)
Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD [NCT00215241]	Phase 2/Phase 3	80 participants	Interventional	2004-04-30	Completed
A Phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-Dose Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder [NCT04174170]	Phase 3	591 participants (Actual)	Interventional	2019-10-30	Completed
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study [NCT01488266]		90 participants (Anticipated)	Interventional	2011-11-30	Active, not recruiting
Treatment of Pediatric Obsessive-Compulsive Disorder [NCT00000384]	Phase 3	0 participants	Interventional	1997-05-31	Completed
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fed Conditions [NCT00601588]		43 participants (Actual)	Interventional	2003-06-30	Completed
Noradrenergic Augmentation of SSRI Therapy in Patients With Depression Unresponsive or Incompletely Responsive to SSRI Monotherapy [NCT00485862]	Phase 4	214 participants (Actual)	Interventional	2003-06-30	Completed
Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 [NCT00519012]	Phase 4	200 participants (Anticipated)	Interventional	2007-08-31	Recruiting
Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression [NCT00056472]	Phase 3	259 participants (Actual)	Interventional	2003-01-31	Completed
[NCT00508859]	Phase 4	93 participants (Actual)	Interventional	1997-07-31	Completed
Comparative Evaluation of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Treatment-resistant Burning Mouth Syndrome: a Prospective Longitudinal Clinical Trial With Treatment Response Prediction [NCT06025474]	Phase 3	203 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Assessing Bioequivalence Of Zoloft ODT 50 Mg Under Fasting Condition With And Without Water To Jzoloft Tablet 50 Mg Under Fasting Condition With Water In Healthy Japanese Subjects [NCT01699724]	Phase 1	30 participants (Actual)	Interventional	2012-09-30	Completed
fMRI Studies of Emotional Circuitry in Major Depression: Treatment Changes [NCT01027559]		97 participants (Actual)	Interventional	2009-02-28	Completed
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial [NCT01360866]	Phase 3	2,944 participants (Actual)	Interventional	2011-10-31	Completed
The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease [NCT02917122]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to Funding is insufficient.)
Sertraline for Alcohol Dependence and Depression [NCT00004554]	Phase 4	171 participants (Actual)	Interventional	2000-01-31	Completed
Safety and Efficacy of Sertraline for Depression CHF [NCT00078286]	Phase 2/Phase 3	469 participants (Actual)	Interventional	2003-11-30	Completed
Omega-3 for Depression and Other Cardiac Risk Factors [NCT00116857]	Phase 3	122 participants (Actual)	Interventional	2005-02-28	Completed
A Randomized, Double-Blinded, Placebo Controlled, Trial of the Effect of Sertraline Vs. Placebo in Reducing the Incidence and Severity of Hot Flashes in Healthy Women [NCT00283192]		100 participants	Interventional	2003-07-31	Completed
Lamotrigine Use in Treatment Refractory Depression in Adolescents [NCT00284791]		50 participants	Interventional	2006-01-31	Terminated
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]		73,336 participants (Actual)	Observational	2022-10-01	Completed
An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Severely Depressed Inpatients [NCT00325000]		0 participants	Interventional	2000-11-30	Terminated
A Six-Week, Fixed Dose, Double-Blind, Double-Dummy, Placebo and Sertraline Controlled, Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Outpatients With Major Depressive Disorder [NCT00143091]	Phase 2	200 participants	Interventional	2005-04-30	Terminated(stopped due to See Detailed Description for termination reason.)
Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. [NCT00421369]		35 participants (Actual)	Interventional	2007-09-30	Completed
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00351910]	Phase 3	494 participants (Actual)	Interventional	2006-05-31	Completed
Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania [NCT00118014]	Phase 4	75 participants (Actual)	Interventional	2000-01-31	Completed
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram (LEAP-SE): A Multicenter, Randomized, Blinded Outcome Study of EEG-guided Treatment With Sertraline Versus Escitalopram in Adults With Major Depressive Disorder [NCT04388202]	Phase 4	0 participants (Actual)	Interventional	2020-10-15	Withdrawn(stopped due to No participants enrolled)
Treatment Response Study of Sertraline to Treat Japanese Major Depressive Disorder [NCT01454635]		96 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 4 Randomized, Double-Blind, Placebo Controlled Methodology Study to Evaluate the Time of Onset of AntiDepressant Response in Subjects With Major Depressive Disorder [NCT00406952]		165 participants (Actual)	Interventional	2006-11-30	Completed
Triiodothyronine (T3) Supplementation in Bipolar and Unipolar Depression: A Random Assignment, Double Blind, Placebo-Controlled Study. [NCT00158990]	Phase 3	220 participants	Interventional	2002-10-31	Completed
Sertraline Alone vs. in Combination With Risperidone in the Treatment of Attenuated Positive and Negative Symptoms [NCT00169988]		8 participants (Actual)	Interventional	2004-03-31	Completed
A Multi-center, Randomized, Double-blind, Parallel-group Study of Sertraline vs. Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder [NCT00179283]	Phase 3	20 participants	Interventional	2002-04-30	Completed
Cognitive and Physical Impairment in Frail Older Adults [NCT04962841]		485 participants (Anticipated)	Observational	2020-04-01	Recruiting
Acute Efficacy of Bupropion, Sertraline, and Venlafaxine as Adjuvant Treatment to Mood Stabilizers in Bipolar Depression: A Randomized, Double-Blind, Comparative Study [NCT00001483]	Phase 2	75 participants	Interventional	1995-06-30	Completed
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder [NCT01254305]	Phase 2	262 participants (Actual)	Interventional	2011-04-30	Completed
Stereotypies and Mental Retardation: Neurobiological Basis [NCT00491478]	Phase 3	0 participants	Interventional	1992-09-30	Recruiting
CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia: Depression, Anxiety, and Mild Cognitive Impairment [NCT02955719]		145 participants (Actual)	Interventional	2016-03-30	Completed
A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05973786]	Phase 4	418 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study [NCT00667121]		85 participants (Anticipated)	Observational	2011-03-16	Active, not recruiting
Sertraline and Cognitive Therapy in Depressed Alcoholics [NCT00000458]	Phase 2	100 participants	Interventional		Completed
CREST-II: Tiagabine, Sertraline, or Donepezil vs. Unmatched Placebo [NCT00015132]	Phase 2	0 participants	Interventional	1999-03-31	Completed
Treatment of Cholestatic Pruritus With Sertraline [NCT00058903]	Phase 2	40 participants (Anticipated)	Interventional	2003-04-30	Completed
A Phase III Double-Blind Randomized Trial Comparing Sertraline (Zoloft) And Hypericum Perforatum (St. John's Wort) In Cancer Patients With Mild To Moderate Depression [NCT00066859]	Phase 3	2 participants (Actual)	Interventional	2004-03-01	Completed
[NCT00080158]	Phase 2/Phase 3	120 participants	Interventional	2004-03-31	Completed
[NCT00009191]	Phase 4	0 participants	Interventional	2005-11-30	Completed
Prevention of Recurrent Postpartum Depression [NCT00276900]	Phase 3	300 participants	Interventional	2003-12-31	Completed
Sequenced Treatment Alternatives to Relieve Depression [NCT00021528]	Phase 4	4,000 participants	Interventional	2001-07-31	Completed
Depression and Health Outcomes in Refractory Epilepsy [NCT00026637]	Phase 3	140 participants (Actual)	Interventional	2001-08-31	Completed
Comparing the Safety and Effectiveness of a Mood Stabilizing Medication, an Antidepressant Medication, and a Combination of Both Medications to Treat Symptoms of Bipolar Type II Depression [NCT00276965]	Phase 3	139 participants (Actual)	Interventional	2006-09-30	Completed
Improving Hispanic Retention in Antidepressant Therapy [NCT00057642]		50 participants (Actual)	Interventional	2002-09-30	Completed
A Randomized Controlled Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease [NCT00208117]	Phase 1	7 participants (Actual)	Interventional	2005-04-30	Terminated(stopped due to Unable to enroll subjects)
A Randomized Placebo-Controlled Trial of Sertraline for the Neurobehavioral Sequelae of Traumatic Brain Injury [NCT00208585]		100 participants (Anticipated)	Interventional	2000-02-29	Recruiting
Thyroid Axis in Major Depression [NCT00208702]	Phase 4	153 participants (Actual)	Interventional	1996-09-30	Completed
Treatment Outcome of Vascular Depression [NCT00045773]		208 participants (Actual)	Observational	2001-04-30	Completed
Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD [NCT00133822]	Phase 1/Phase 2	65 participants	Interventional	2004-04-30	Completed
Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder [NCT00048854]	Phase 1/Phase 2	66 participants (Actual)	Interventional	2001-09-30	Completed
Efficacy of an SSRI in Acute Stress Disorder and PTSD [NCT00050804]	Phase 4	80 participants	Interventional	2002-12-31	Completed
Intervention to Prevent Post-Stroke Major Depression. [NCT00177424]	Phase 4	154 participants (Anticipated)	Interventional	2004-07-31	Terminated(stopped due to Recruitment goals could not be met.)
Dynamic Measures of Neurochemistry in Mood Disorders [NCT00178828]	Phase 4	42 participants (Actual)	Interventional	2002-10-31	Completed
The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to [NCT00179257]	Phase 3	20 participants	Interventional	2004-06-30	Completed
Sertraline in the Treatment of Generalized Social Phobia With Comorbidity [NCT00182533]	Phase 4	170 participants (Anticipated)	Interventional	2002-07-31	Terminated(stopped due to Study drug could not be re-supplied)
A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients [NCT00198094]	Phase 4	150 participants (Anticipated)	Interventional	2003-12-31	Completed
An Electrophysiological Predictor of SSRI Response in Veterans With PTSD [NCT04183205]	Phase 4	94 participants (Anticipated)	Interventional	2019-09-11	Recruiting
A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol [NCT00340379]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2003-04-30	Completed
Ziprasidone for the Treatment of Refractory Social Anxiety Disorder [NCT00215150]	Phase 2	51 participants (Actual)	Interventional	2004-11-30	Completed
Effect of Pharmacological Treatment of Depression on A1C and Quality of Life in Underserved Hispanics and African Americans With Diabetes: A Randomized, Placebo Controlled Trial. [NCT00624013]	Phase 4	89 participants (Actual)	Interventional	2006-09-30	Completed
The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor in Depressed Elders [NCT01305889]		19 participants (Actual)	Interventional	2011-03-31	Completed
Sertraline Augmented With GABA Agents for Cocaine Dependence [NCT00654953]	Phase 2	102 participants (Actual)	Interventional	2006-01-31	Completed
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury [NCT00704379]	Phase 2/Phase 3	94 participants (Actual)	Interventional	2008-06-30	Completed
Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline [NCT01309074]	Phase 4	0 participants (Actual)	Interventional	2009-11-30	Withdrawn(stopped due to No subjects could be enrolled and therefore we decided to withdraw/stop the study.)
[NCT02655354]		635 participants (Actual)	Interventional	2015-10-31	Completed
A Randomized, Double-blind, Placebo-controlled Pilot Study of Sertraline for the Prevention of PTSD in Burn Victims [NCT02520726]	Phase 4	5 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to Insufficient enrollment)
Child/Adolescent Anxiety Multimodal Treatment Study [NCT00052078]	Phase 3	488 participants (Actual)	Interventional	2003-01-31	Completed
NMDA Modulation in Major Depressive Disorder in Late- Life [NCT03414931]	Phase 2	136 participants (Actual)	Interventional	2016-01-31	Completed
Modulation of Visually Evoked Potentials by an Antidepressant [NCT00263133]		12 participants	Interventional	2005-12-31	Completed
Effects of Ziprasidone vs. Placebo During the First Four Weeks of Eight Weeks Sertraline Treatment in Patients With Post-traumatic Stress Disorder (PTSD) [NCT00248261]		7 participants (Actual)	Observational	2005-11-30	Terminated(stopped due to High rate of early drop-outs)
A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence [NCT00249431]	Phase 2	9 participants (Actual)	Interventional	2001-12-31	Terminated(stopped due to Inability to recruit patients.)
Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly [NCT00701675]	Phase 4	42 participants (Actual)	Interventional	2005-10-31	Completed
A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis [NCT01943435]		259 participants (Actual)	Interventional	2013-11-20	Completed
Treatment Outcomes of Vascular Depression [NCT00339066]		131 participants (Actual)	Interventional	2001-08-31	Completed
Pharmacologic Dissection of Vestibular Migraine and Chronic Subjective Dizziness: A Double-Blind Parallel Group Trial Comparing Response to Verapamil Versus Sertraline [NCT01669304]	Phase 1	32 participants (Actual)	Interventional	2012-08-31	Completed
Early Detection and Intervention for the Prevention of Psychosis Project [NCT00531518]		292 participants (Actual)	Interventional	2007-10-31	Completed
Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis [NCT02908334]	Phase 2	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to failure to enroll)
Late-life Depression and Cerebral Perfusion [NCT01751828]		0 participants (Actual)	Interventional	2012-12-31	Withdrawn(stopped due to This was an initial unfunded pilot project stopped after similar studies were funded.)
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]	Phase 4	1,080 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child [NCT01796132]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Recruiting
The Efficacy and Safety of Sertraline in Maintenance Hemodialysis Patients With Depression: a Randomized Controlled Study [NCT06124417]	Phase 4	125 participants (Actual)	Interventional	2022-01-10	Completed
Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression [NCT01794455]	Phase 4	1 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Enrollment difficulties)
Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Major Depression Through Resources Available in Brazilian Public Health [NCT02901249]	Phase 4	68 participants (Actual)	Interventional	2010-05-31	Completed
Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode [NCT02918097]	Phase 4	78 participants (Actual)	Interventional	2010-05-31	Completed
"Response Variability in Treatment Resistant Depression - an Ancillary Study to Sequenced Treatment Alternatives to Relieve Depression (STAR*D)" [NCT00375843]	Phase 4	118 participants (Actual)	Interventional	2005-01-31	Completed
Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS [NCT01769027]	Phase 2	0 participants (Actual)	Interventional	2013-06-30	Withdrawn(stopped due to No participants enrolled)
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05603104]	Phase 3	1,254 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder [NCT01460212]	Phase 4	80 participants (Anticipated)	Interventional	2011-12-31	Recruiting
"Randomized Double Blinding Controlled Study on Jia Wei Xiao Yao Jiaonang Treating Mild to Moderate Major Depressive Disorder" [NCT01467804]		180 participants (Anticipated)	Interventional	2011-11-30	Not yet recruiting
Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease [NCT02813447]		15 participants (Actual)	Interventional	2016-08-31	Terminated(stopped due to COVID-19 hold)
Depression in Alzheimer's Disease (DIADS-2) [NCT00086138]	Phase 2/Phase 3	131 participants (Actual)	Interventional	2004-07-31	Completed
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis [NCT00004300]	Phase 2	40 participants	Interventional		Suspended
Study on the Brain Hippocampal Volume, Cortisol and C-reactive Protein Levels Relationship With Anxious Symptoms in Major Depressive Patients [NCT04430556]		30 participants (Anticipated)	Interventional	2018-07-01	Active, not recruiting
Efficacy of Exposure and Response Prevention（ERP） and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder [NCT02022709]	Phase 4	78 participants (Actual)	Interventional	2014-01-31	Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]		74 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Treatment of Pediatric OCD for SRI Partial Responders [NCT00074815]	Phase 3	124 participants (Actual)	Interventional	2003-09-30	Completed
NMDA Modulation in Major Depressive Disorder [NCT04637620]	Phase 2	90 participants (Anticipated)	Interventional	2017-06-01	Recruiting
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression [NCT02418585]	Phase 3	236 participants (Actual)	Interventional	2015-08-07	Completed
Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES [NCT00159965]	Phase 4	38 participants (Actual)	Interventional	2003-12-31	Completed
Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder: A Double-blind, Parallel, Randomized Controlled Trial [NCT05950061]	Phase 3	744 participants (Actual)	Interventional	2022-06-01	Completed
Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial [NCT03779789]	Phase 4	362 participants (Actual)	Interventional	2019-02-01	Completed
The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study [NCT01569685]	Phase 4	207 participants (Actual)	Interventional	2012-04-30	Completed
Improving Outcomes in Pharmacotherapy of Social Phobia [NCT00282828]	Phase 4	397 participants (Actual)	Interventional	2006-03-31	Completed
Short-Term Versus Long-Term Treatment for Severe PMS [NCT00318773]	Phase 4	174 participants (Actual)	Interventional	2002-02-28	Completed
Exercise Training and Depression in Older Adults II [NCT00331305]	Phase 3	457 participants (Actual)	Interventional	1999-08-31	Completed
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) for Depression [NCT01407094]	Phase 2	296 participants (Actual)	Interventional	2011-07-29	Completed
Sertraline and Naltrexone for Alcohol Dependents [NCT00000440]	Phase 2	124 participants	Interventional		Completed
Sertraline Treatment in Comorbid Post-Traumatic Stress Disorder and Alcoholism [NCT00000446]	Phase 2	0 participants	Interventional		Completed
Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives [NCT00000451]	Phase 2	198 participants (Actual)	Interventional	2003-01-31	Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]		405,349 participants (Actual)	Observational	2022-07-04	Completed
ASCEND: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression [NCT02358343]	Phase 3	184 participants (Actual)	Interventional	2015-03-23	Completed
Effectiveness of Sertraline in Alleviating Uremic Pruritis in Hemodialysis Patients [NCT05341843]	Phase 2	60 participants (Actual)	Interventional	2022-05-01	Completed
Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline [NCT01977729]	Phase 2	1 participants (Actual)	Interventional	2013-10-31	Terminated(stopped due to funding)
Extracellular Vesicles as Predictors of Antidepressant Outcomes in Pediatric Anxiety (EV-SOPRANO) [NCT04221997]	Phase 4	150 participants (Anticipated)	Interventional	2019-11-01	Recruiting
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol [NCT05814640]	Phase 1/Phase 2	520 participants (Anticipated)	Interventional	2023-02-20	Recruiting
A Placebo Controlled Clinical Trial of a Standardized Extract of Hypericum Perforatum in Major Depressive Disorder [NCT00005013]		0 participants	Interventional	1998-12-31	Completed
An I-123-ADAM SPECT Imaging Study to Evaluate the Serotonin Transporter (SERT) Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Assisting in Detecting MDD [NCT02473783]	Phase 2	37 participants (Actual)	Interventional	2011-10-31	Completed
Research on Standardized Electronic Cognitive Training Technique in Early Stage of Senile Depression With Cognitive Impairment [NCT05588102]		128 participants (Anticipated)	Interventional	2021-05-18	Recruiting
Cryptococcal Antigen Screening Plus Sertraline [NCT03002012]	Phase 3	22 participants (Actual)	Interventional	2017-11-15	Terminated(stopped due to SAEs with n=1 serotonin syndrome, n=2 SAEs after sertraline interruption.)
Preventing Depression Recurrence in Diabetes [NCT00374426]	Phase 4	262 participants	Interventional	1998-03-31	Completed
A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients [NCT01607593]		123 participants (Actual)	Observational	2012-08-31	Completed
Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). [NCT01524133]	Phase 4	223 participants (Actual)	Interventional	2011-11-30	Completed
Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment [NCT02469545]	Phase 2	60 participants (Actual)	Interventional	2014-06-30	Completed
A Randomized Controlled Trial of Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder [NCT04963257]	Phase 4	400 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]	Phase 4	80 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
The Study of Mindfulness Based Cognitive Therapy and Obsessive-Compulsive Disorder [NCT03179839]		123 participants (Actual)	Interventional	2017-01-20	Completed
Effectiveness of PTSD Treatment: CBT Versus Sertraline [NCT00127673]	Phase 3	200 participants (Actual)	Interventional	2004-09-30	Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
RCT of Sertraline Versus Cognitive Behavioural Therapy for Anxiety Symptoms in People With Generalised Anxiety Disorder Who Have Failed to Respond to Low Intensity Psychological Interventions as Defined by the NICE GAD Guidelines [NCT02347033]	Phase 4	5 participants (Actual)	Interventional	2014-08-31	Terminated(stopped due to Difficulties with recruitment during the internal pilot phase)
A Controlled Trial of Sertraline in Young Children With Fragile X Syndrome [NCT01474746]	Phase 2	57 participants (Actual)	Interventional	2012-01-31	Completed
Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline. [NCT03068429]	Phase 4	69 participants (Actual)	Interventional	2016-12-01	Completed
Placebo Controlled Trial of Sertraline and Interpersonal Psycho-Therapy for Postpartum Depression [NCT00602355]	Phase 2	162 participants (Actual)	Interventional	2008-02-29	Completed
Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep [NCT02189213]		14 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Insufficient funding)
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression [NCT02497287]	Phase 3	802 participants (Actual)	Interventional	2015-09-30	Completed
Riluzole Augmentation Pilot in Depression (RAPID) Trial [NCT01703039]	Phase 2	21 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to PI departure, slow recruitment)
Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder [NCT02777372]	Phase 4	84 participants (Actual)	Interventional	2016-04-01	Completed
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression [NCT02417064]	Phase 3	346 participants (Actual)	Interventional	2015-08-10	Completed
Understanding the Prognostic Benefits of Exercise and Anti-depressant Therapy (UPBEAT) [NCT00302068]	Phase 3	101 participants (Actual)	Interventional	2006-07-31	Completed
Improving Depression Treatment Outcomes With an Insulin-Sensitizing Agent [NCT00834652]	Phase 4	206 participants (Actual)	Interventional	2007-09-30	Completed
Effects of Treatment on Decision-making in Major Depression [NCT01916824]	Phase 4	53 participants (Actual)	Interventional	2013-08-31	Completed
Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioequivalence Study Comparing Sertraline Hydrochloride 50 mg Film-Coated Tablets To Sertraline Hydrochloride 50 mg Hard Capsules Under Fasted Conditions [NCT01235195]	Phase 1	30 participants (Actual)	Interventional	2010-11-30	Completed
Sustaining Remission of Psychotic Depression [NCT01427608]	Phase 4	269 participants (Actual)	Interventional	2011-10-31	Completed
Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial [NCT02235064]		2 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Low recruitment, completion of funding cycle)
Proof of Concept Study to Treat Negative Affect in Chronic Low Back Pain [NCT04747314]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2021-03-31	Recruiting
A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of Precise Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy Based on Neuroimaging in Depressed Adolescents With Anhedonia. [NCT05544071]		88 participants (Anticipated)	Interventional	2023-02-12	Recruiting
A Pilot Study Examining the Gut Microbiota in Patients With Obsessive-Compulsive Disorder vs. Healthy Controls and Following 12-weeks of Open-label Selective Serotonin Reuptake Inhibitors Treatment [NCT02285699]		43 participants (Anticipated)	Interventional	2014-11-01	Completed
A Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD [NCT04539951]	Phase 2	1,600 participants (Anticipated)	Interventional	2020-09-22	Recruiting
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis [NCT01802385]	Phase 3	460 participants (Actual)	Interventional	2015-03-09	Completed
A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depressio [NCT03434041]	Phase 3	252 participants (Actual)	Interventional	2018-05-25	Completed
Depression Screening RCT in ACS Patients: Quality of Life and Cost Outcomes [NCT01993017]		1,501 participants (Actual)	Interventional	2013-11-30	Completed
Treatment of Post-TBI Depression [NCT00233103]	Phase 2	52 participants (Actual)	Interventional	2003-06-30	Completed
A Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder [NCT02385799]	Phase 2	58 participants (Actual)	Interventional	2015-04-30	Completed
Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression (R21) [NCT01896934]	Phase 4	31 participants (Actual)	Interventional	2013-07-31	Completed
Testing an Imaging Biomarker for Treatment Stratification in Major Depression [NCT02137369]	Phase 4	77 participants (Actual)	Interventional	2014-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000378 (1) [back to overview]	HAMILTON Rating Scale for DEPRESSION Range
NCT00043550 (1) [back to overview]	Hamilton Rating Scale for Depression-17 Item
NCT00052078 (1) [back to overview]	Clinical Global Impression - Improvement Scale
NCT00056472 (3) [back to overview]	Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial
NCT00056472 (3) [back to overview]	Scores on CGI-S Compared to Baseline Over the Course of the Trial
NCT00056472 (3) [back to overview]	Mean Score Hamilton Depression Rating Scale (Ham-D) Over the Course of the Trial From Week to Week.
NCT00074815 (1) [back to overview]	Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00078286 (2) [back to overview]	Symptoms of Depression in Congestive Heart Failure Patients With Clinical Depression After Treatment With Sertraline or Placebo
NCT00078286 (2) [back to overview]	Percentage of Cardiac Events and Morbidity / Mortality, Including Rehospitalization, in Congestive Heart Failure Patients With Depression After Treatment With Sertraline or Placebo.
NCT00086138 (2) [back to overview]	Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC)
NCT00086138 (2) [back to overview]	Remission According to Cornell Scale for Depression in Dementia Scale
NCT00116857 (1) [back to overview]	Beck Depression Inventory-II
NCT00118417 (3) [back to overview]	Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6)
NCT00118417 (3) [back to overview]	Change in Panic Disorder Symptoms, Phase 3 (Week 12 - Week 24)
NCT00118417 (3) [back to overview]	Change in Panic Disorder Symptoms, Phase 2 (Week 6 - Week 12)
NCT00127673 (4) [back to overview]	Depression Symptoms
NCT00127673 (4) [back to overview]	PTSD Symptoms
NCT00127673 (4) [back to overview]	Quality of Life Functioning
NCT00127673 (4) [back to overview]	State Anxiety
NCT00159965 (14) [back to overview]	Davidson Trauma Scale (DTS)
NCT00159965 (14) [back to overview]	Dissociative Experiences Scale (DES)
NCT00159965 (14) [back to overview]	Global Assessment of Functioning (GAF)
NCT00159965 (14) [back to overview]	Longitudinal Interval Follow-Up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)
NCT00159965 (14) [back to overview]	Modified Hamilton Depression Scale (MHRS)
NCT00159965 (14) [back to overview]	Number of Nonepileptic Seizures (NES)
NCT00159965 (14) [back to overview]	Oxford Handicap Scale (OHS)
NCT00159965 (14) [back to overview]	Symptom Checklist 90 (SCL-90)
NCT00159965 (14) [back to overview]	Clinical Global Impressions - Improvement (CGI-I)
NCT00159965 (14) [back to overview]	Family Assessment Device (FAD)
NCT00159965 (14) [back to overview]	Barratt Impulsivity Scale (BIS)
NCT00159965 (14) [back to overview]	Beck Depression Inventory-II (BDI-II)
NCT00159965 (14) [back to overview]	Quality of Life in Epilepsy-31 (QOLIE-31)
NCT00159965 (14) [back to overview]	Clinical Global Impressions - Severity (CGI-S)
NCT00182078 (3) [back to overview]	Diagnostic Interview for Children and Adolescents (DICA) - Child
NCT00182078 (3) [back to overview]	The Child Depression Inventory (CDI)
NCT00182078 (3) [back to overview]	Diagnostic Interview Schedule for Children and Adolescents (DICA) - Parent
NCT00215150 (1) [back to overview]	Brief Social Phobia Scale(BSPS)
NCT00233103 (4) [back to overview]	BAI
NCT00233103 (4) [back to overview]	Life-3
NCT00233103 (4) [back to overview]	Depression at End of Treatment
NCT00233103 (4) [back to overview]	Depression at Baseline
NCT00245557 (3) [back to overview]	Geriatric Depression Scale
NCT00245557 (3) [back to overview]	Phosphorus Magnetic Resonance Spectroscopy (31P-MRS)
NCT00245557 (3) [back to overview]	HAM-D 17 (Hamilton Depression Rating Scale)
NCT00262223 (2) [back to overview]	Heavy Drinking Days/Week
NCT00262223 (2) [back to overview]	PTSD Symptom Severity / Clinician Administered PTSD Scale
NCT00282828 (2) [back to overview]	Post-treatment Social Phobia Severity as Defined by Endpoint LSAS Scores
NCT00282828 (2) [back to overview]	Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders
NCT00302068 (7) [back to overview]	Interleuken 6 (IL-6)
NCT00302068 (7) [back to overview]	Heart Rate Variability (HRV)
NCT00302068 (7) [back to overview]	C-reactive Protein (CRP)
NCT00302068 (7) [back to overview]	Percent Change in Flow Mediated Dilation (FMD)
NCT00302068 (7) [back to overview]	Hamilton Depression Rating Scale
NCT00302068 (7) [back to overview]	Baroreflex Sensitivity (BRS)
NCT00302068 (7) [back to overview]	Platelet Factor 4
NCT00340379 (3) [back to overview]	21 Item Hamilton Depression Rating Scale
NCT00340379 (3) [back to overview]	Clinical Global Impression Improvement Scale
NCT00340379 (3) [back to overview]	Brief Psychiatric Rating Scale at 12 Weeks
NCT00368550 (3) [back to overview]	Change in the Level of Alcohol-related Problems
NCT00368550 (3) [back to overview]	Number of Days of Heavy Drinking (Defined as Days on Which Women Drank >= 4 Drinks and Men Drank >= 5 Drinks)
NCT00368550 (3) [back to overview]	Number of Days on Which Subjects Drank
NCT00531518 (1) [back to overview]	Psychotic Symptoms
NCT00536198 (12) [back to overview]	Adverse Events
NCT00536198 (12) [back to overview]	Clinical Global Impressions-Improvement (CGI-I)
NCT00536198 (12) [back to overview]	Clinical Global Severity (CGI-S)
NCT00536198 (12) [back to overview]	DRSP
NCT00536198 (12) [back to overview]	DRSP Anger/Irritability Subscale
NCT00536198 (12) [back to overview]	DRSP Depression Subscale
NCT00536198 (12) [back to overview]	DRSP Physical Subscale
NCT00536198 (12) [back to overview]	Inventory of Depression Symptoms (IDS-C)
NCT00536198 (12) [back to overview]	Michelson SSRI Withdrawal Checklist
NCT00536198 (12) [back to overview]	Number of Days Pills Were Taken
NCT00536198 (12) [back to overview]	Premenstrual Tension Scale (PMTS)
NCT00536198 (12) [back to overview]	Number of Symptomatic Days Before Pills Were Taken
NCT00602355 (5) [back to overview]	Social Functioning Based on Postpartum Adjustment Questionnaire (PPAQ)
NCT00602355 (5) [back to overview]	Depression Illness Severity Based on Beck Depression Inventory (BDI)
NCT00602355 (5) [back to overview]	Global Illness Severity Based on Clinical Global Impression (CGI) Scale
NCT00602355 (5) [back to overview]	Hamilton Anxiety Rating Scale (HARS)
NCT00602355 (5) [back to overview]	Hamilton Depression Rating Scale (HAM-D)
NCT00605813 (6) [back to overview]	Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert
NCT00605813 (6) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction
NCT00605813 (6) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness
NCT00605813 (6) [back to overview]	Number of Participants of Treatment Related Adverse Events (TRAEs)
NCT00605813 (6) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Present or Past History of Intentional Suicidal Ideation (Including Suicide Attempt)
NCT00605813 (6) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Non-Pharmaceutical Therapies
NCT00605865 (16) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not
NCT00605865 (16) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments.
NCT00605865 (16) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Age
NCT00605865 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Suicidal Ideation (Including Suicide Attempt)
NCT00605865 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction
NCT00605865 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness
NCT00605865 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug
NCT00605865 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications
NCT00605865 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Average Daily Dose
NCT00605865 (16) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not
NCT00605865 (16) [back to overview]	Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert
NCT00605865 (16) [back to overview]	Number of Participants of Treatment Related Adverse Events (TRAEs)
NCT00605865 (16) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Target Disease Severity
NCT00605865 (16) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient
NCT00605865 (16) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: History of Treatment Prior to Administration of Sertraline Hydrochloride
NCT00605865 (16) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Suicidal Ideation (Including Suicide Attempt)
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Smoking Status
NCT00605917 (14) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Complication
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Average Daily Dose
NCT00605917 (14) [back to overview]	Number of Participants of Treatment Related Adverse Events (TRAEs)
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Non-Pharmaceutical Therapies
NCT00605917 (14) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Drinking Status
NCT00605917 (14) [back to overview]	Factors Considered to Affect the Efficacy of Sertraline: Concomitant Drug
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Family History of Psychiatric Disorder
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: History of Treatment Prior to Administration of Sertraline
NCT00605917 (14) [back to overview]	Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert
NCT00605917 (14) [back to overview]	Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Starting Dose
NCT00612807 (2) [back to overview]	Dyadic Adjustment Scale (DAS)
NCT00612807 (2) [back to overview]	Hamilton Depression Rating Scale (HDRS)
NCT00624013 (2) [back to overview]	HbA1C (%)
NCT00624013 (2) [back to overview]	Quality of Life
NCT00654953 (1) [back to overview]	Urine Toxicology Screens for the Presence of Cocaine/Cocaine Metabolites
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Presenteeism Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Absenteeism Score at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Absenteeism at 12-Week Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Presenteeism (WP)Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in Weight at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Pulse Rate at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)
NCT00677352 (7) [back to overview]	Mean Change From Baseline in Panic and Agoraphobia Scale (PAS) Total Score at the End of Treatment Phase
NCT00677352 (7) [back to overview]	Mean Change From Baseline in Panic Attack at the End of Treatment Phase
NCT00677352 (7) [back to overview]	Percentage of Participants of Responder in Clinical Global Impression (CGI) - Improvement
NCT00677352 (7) [back to overview]	Percentage of Participants With Deterioration in Antidepressant Discontinuation Scale During Tapering Phase
NCT00677352 (7) [back to overview]	Number of Participants With Summary of Adverse Events in Treatment Phase
NCT00677352 (7) [back to overview]	Summary of Adverse Events in Tapering Phase
NCT00677352 (7) [back to overview]	Mean Change From Baseline in Hamilton Anxiety Rating Scale Total Score at the End of Treatment Phase
NCT00701675 (1) [back to overview]	Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg
NCT00704379 (6) [back to overview]	Iowa Gambling Task Score
NCT00704379 (6) [back to overview]	Neuroimaging Variables (i.e., Fractional Anisotropy [FA] of Frontal White Matter Such as the Cingulate Gyrus)
NCT00704379 (6) [back to overview]	Social Functioning Examination Total Score
NCT00704379 (6) [back to overview]	Time to Onset of Diagnostic and Statistical Manual (DSM) IV Defined Mood and Anxiety Disorders Associated With Traumatic Brain Injury (TBI)
NCT00704379 (6) [back to overview]	Total Community Integration Questionnaire Scores
NCT00704379 (6) [back to overview]	Memory Function Composite
NCT00744328 (2) [back to overview]	To Test the Efficacy of Estradiol for the Treatment of Postpartum Depression - Percent Change in SIGH-ADS29
NCT00744328 (2) [back to overview]	Infant Serum Concentrations of Estradiol in 3 Treatment Arms
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).
NCT00797966 (14) [back to overview]	Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]	Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.
NCT00797966 (14) [back to overview]	Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]	Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.
NCT00797966 (14) [back to overview]	Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).
NCT00834652 (1) [back to overview]	Change of Beck Depression Inventory-II Scores Over 16 Weeks
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 2 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 8 in the Hamilton Anxiety Rating Scale (HARS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 4 in the Hamilton Anxiety Rating Scale (HARS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 4 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 2 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00857584 (18) [back to overview]	Number of Patients With Response at Week 4.
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 1 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 1 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857584 (18) [back to overview]	Number of Patients With Response at Week 8.
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 4 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00857584 (18) [back to overview]	Number of Patients With Response at Week 2
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 8.
NCT00857584 (18) [back to overview]	Number of Patients Response at Week 1
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 2.
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 4.
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 1.
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 8 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 8 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00946998 (5) [back to overview]	Change in Quality of Life From Baseline to Exit in the Kidney Disease Quality of Life -Short Form, Version 1.3, Patient-reported Overall Health.
NCT00946998 (5) [back to overview]	Change From Baseline to Exit in Overall Function as Assessed by the Work and Social Adjustment Scale
NCT00946998 (5) [back to overview]	Change From Baseline to Exit in Depression Symptom Severity as Measured by the QIDS-C-16 Score.
NCT00946998 (5) [back to overview]	Serious Adverse Events During the 12 Week Study Duration.
NCT00946998 (5) [back to overview]	Response to Treatment Defined as a Decline of 50% in the Baseline QIDS-C-16 Score and Remission of Depression Defined as a QIDS-C-16 Score of 5
NCT00955474 (15) [back to overview]	Blood Hemoglobin A1C at Baseline and Week 8.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Visuospatial/Constructional Sub-scale.
NCT00955474 (15) [back to overview]	Blood Level of Total Cholesterol Levels Were Collected at Baseline and Week 8.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Total Score
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Language Sub-scale Score.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Immediate Memory Sub-scale Score
NCT00955474 (15) [back to overview]	Depression
NCT00955474 (15) [back to overview]	Blood Level of Triglycerides at Baseline and Week 8.
NCT00955474 (15) [back to overview]	CPFQ (Cognitive and Psychological Functioning Questionnaire)
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Attention Sub-scale Scores at Baseline and Week 8.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Delayed Memory Subscale Scores at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Psychosis
NCT00955474 (15) [back to overview]	LDL Blood Levels at Baseline and Week 8.
NCT00955474 (15) [back to overview]	HDL Blood Levels at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Fasting Blood Glucose
NCT01027559 (2) [back to overview]	Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.
NCT01027559 (2) [back to overview]	Hamilton Depression Rating Scale Score at Baseline and 12 Weeks
NCT01032018 (2) [back to overview]	Cost for Healthcare Utilization (Psychiatric Medications, Hospitalizations, Cardiac Procedures, Outpatient Services)
NCT01032018 (2) [back to overview]	Depressive Symptom Reduction
NCT01098318 (6) [back to overview]	Number of Participants With Treatment Emergent Side Effects
NCT01098318 (6) [back to overview]	Change in Sexual Function
NCT01098318 (6) [back to overview]	Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (17-items) at Week 8 and Week 12.
NCT01098318 (6) [back to overview]	Number of Participants With Suicide Ideation as Determined by the Columbia Suicide Form
NCT01098318 (6) [back to overview]	The Clinical Global Impression (CGI) Severity and Change
NCT01098318 (6) [back to overview]	Change in Depressive Symptoms as Measured by the Beck Depression Inventory
NCT01155531 (3) [back to overview]	Changes in the Meal Calories Consumed
NCT01155531 (3) [back to overview]	Safety of Sertraline and Telenzepine Combination
NCT01155531 (3) [back to overview]	Changes in the VAS Score From Baseline.
NCT01178671 (10) [back to overview]	Time to Discontinuation of Study Treatment
NCT01178671 (10) [back to overview]	Sexual Functioning
NCT01178671 (10) [back to overview]	Sleep Quality
NCT01178671 (10) [back to overview]	Adverse Effects
NCT01178671 (10) [back to overview]	Alternative Measure of PTSD Severity
NCT01178671 (10) [back to overview]	Depression Severity
NCT01178671 (10) [back to overview]	PTSD Self-rated Severity
NCT01178671 (10) [back to overview]	PTSD Severity
NCT01178671 (10) [back to overview]	Remission Status
NCT01178671 (10) [back to overview]	Response Status
NCT01235195 (5) [back to overview]	Area Under the Curve From Time Zero to 72 Hours [AUC (0-72)]
NCT01235195 (5) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
NCT01235195 (5) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01235195 (5) [back to overview]	Plasma Decay Half-Life (t1/2)
NCT01235195 (5) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01250873 (6) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684
NCT01250873 (6) [back to overview]	Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of LY2216684
NCT01250873 (6) [back to overview]	Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Sertraline
NCT01250873 (6) [back to overview]	Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of LY2216684
NCT01250873 (6) [back to overview]	Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of Sertraline
NCT01250873 (6) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of Sertraline
NCT01254305 (3) [back to overview]	Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
NCT01254305 (3) [back to overview]	Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
NCT01254305 (3) [back to overview]	Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
NCT01302080 (48) [back to overview]	Change From Baseline in Child Global Assessment Scale (CGAS) at Month 3, 6, 12, 18, 24, 30 and 36
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Metacognition Index From Behavior Rating Inventory of Executive Function (BRIEF) at Month 3
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Trails B at Month 3
NCT01302080 (48) [back to overview]	Change From Baseline in General Health and Social Functioning Using the Health of the Nation Outcome Scale for Children and Adolescents (HoNOSCA) Total Score at Month 3, 6, 12, 18, 24, 30 and 36
NCT01302080 (48) [back to overview]	Number of Participants in Each Category of Clinical Global Impression-Severity (CGI-S) Scale at Baseline, Month 3, 6, 12, 18, 24, 30 and 36
NCT01302080 (48) [back to overview]	Change From Baseline in Height at Month 3
NCT01302080 (48) [back to overview]	Change From Baseline in Weight at Month 3
NCT01302080 (48) [back to overview]	Number of Participants in Each Category of Clinical Global Impression-Tolerability (CGI-T) Scale at Month 3, 6, 12, 18, 24, 30 and 36
NCT01302080 (48) [back to overview]	Number of Participants Who Were Responders According to Clinical Global Impression-Effectiveness (CGI-E) Scale at Month 3, 6, 12, 18, 24, 30 and 36
NCT01302080 (48) [back to overview]	Number of Participants in Each Category of Clinical Global Impression-Improvement (CGI-I) Scale at Month 3, 6, 12, 18, 24, 30 and 36
NCT01302080 (48) [back to overview]	Change From Baseline in Weight at Month 30
NCT01302080 (48) [back to overview]	Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF at Month 12
NCT01302080 (48) [back to overview]	Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF at Month 18
NCT01302080 (48) [back to overview]	Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF at Month 24
NCT01302080 (48) [back to overview]	Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF at Month 30
NCT01302080 (48) [back to overview]	Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF at Month 36
NCT01302080 (48) [back to overview]	Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF at Month 6
NCT01302080 (48) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Month 12
NCT01302080 (48) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Month 18
NCT01302080 (48) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Month 24
NCT01302080 (48) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Month 30
NCT01302080 (48) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Month 36
NCT01302080 (48) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Month 6
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Metacognition Index From Behavior Rating Inventory of Executive Function (BRIEF) at Month 12
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Metacognition Index From Behavior Rating Inventory of Executive Function (BRIEF) at Month 18
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Metacognition Index From Behavior Rating Inventory of Executive Function (BRIEF) at Month 24
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Metacognition Index From Behavior Rating Inventory of Executive Function (BRIEF) at Month 30
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Metacognition Index From Behavior Rating Inventory of Executive Function (BRIEF) at Month 36
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Trails B at Month 12
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Trails B at Month 18
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Trails B at Month 24
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Trails B at Month 30
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Trails B at Month 36
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Trails B at Month 6
NCT01302080 (48) [back to overview]	Change From Baseline in Height at Month 12
NCT01302080 (48) [back to overview]	Change From Baseline in Height at Month 18
NCT01302080 (48) [back to overview]	Change From Baseline in Height at Month 24
NCT01302080 (48) [back to overview]	Change From Baseline in Height at Month 30
NCT01302080 (48) [back to overview]	Change From Baseline in Height at Month 36
NCT01302080 (48) [back to overview]	Change From Baseline in Height at Month 6
NCT01302080 (48) [back to overview]	Change From Baseline in Weight at Month 12
NCT01302080 (48) [back to overview]	Change From Baseline in Weight at Month 18
NCT01302080 (48) [back to overview]	Change From Baseline in Weight at Month 24
NCT01302080 (48) [back to overview]	Change From Baseline in Weight at Month 36
NCT01302080 (48) [back to overview]	Change From Baseline in Cognitive Function Using Metacognition Index From Behavior Rating Inventory of Executive Function (BRIEF) at Month 6
NCT01302080 (48) [back to overview]	Change From Baseline in Weight at Month 6
NCT01302080 (48) [back to overview]	Change From Baseline in Behavioral/Emotional Regulation Using the Behavior Regulation Index From BRIEF at Month 3
NCT01302080 (48) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Month 3
NCT01360866 (5) [back to overview]	Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score
NCT01360866 (5) [back to overview]	Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score
NCT01360866 (5) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score
NCT01360866 (5) [back to overview]	Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score
NCT01360866 (5) [back to overview]	Adverse Events (AEs) - All Participants
NCT01407094 (1) [back to overview]	Hamilton Rating Scale for Depression
NCT01427608 (4) [back to overview]	Changes in Metabolic Measure: Cholesterol
NCT01427608 (4) [back to overview]	Changes in Metabolic Measures: Triglycerides
NCT01427608 (4) [back to overview]	Changes in Metabolic Measures: Weight
NCT01427608 (4) [back to overview]	Number of Subjects at Risk of Relapse During the Randomized Phase.
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Fine Motor Age-equivalent Score
NCT01474746 (28) [back to overview]	Clinical Global Impression - Improvement
NCT01474746 (28) [back to overview]	Eye Tracking
NCT01474746 (28) [back to overview]	Eye Tracking
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Cognitive T Score Sum
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Cognitive T Score Sum
NCT01474746 (28) [back to overview]	Preschool Language Scale-fifth Edition (PLS-5): AC+EC Total Raw Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Fine Motor Age-equivalent Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Fine Motor Raw Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Fine Motor Raw Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Summary Age-equivalent Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Summary Age-equivalent Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Visual Reception Age-equivalent Score
NCT01474746 (28) [back to overview]	Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) - Adaptive Behavior Composite Standard Score
NCT01474746 (28) [back to overview]	Sensory Processing Measure-Preschool (SPM-P) Social Participation: Raw Score
NCT01474746 (28) [back to overview]	Sensory Processing Measure - Preschool (SPM-P) Social Participation: Raw Score
NCT01474746 (28) [back to overview]	Preschool Language Scale-fifth Edition (PLS-5): AC+EC Total Raw Score
NCT01474746 (28) [back to overview]	Change in Mullen Scales of Early Learning - Expressive Language Standard T Score
NCT01474746 (28) [back to overview]	Change in Mullen Scales of Early Learning - Expressive Language Raw Score
NCT01474746 (28) [back to overview]	Visual Analog Scale
NCT01474746 (28) [back to overview]	Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Visual Reception Raw Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Visual Reception Raw Score
NCT01474746 (28) [back to overview]	Mullen Scales of Early Learning - Visual Reception Age-equivalent Score
NCT01474746 (28) [back to overview]	Sensory Profile - Sensation Seeking Subscale Raw Score
NCT01474746 (28) [back to overview]	The Autism Diagnostic Observation Schedule (ADOS-2)
NCT01474746 (28) [back to overview]	The Visual Analog Scale
NCT01474746 (28) [back to overview]	Autism Diagnostic Observation Schedule
NCT01524133 (2) [back to overview]	Posttraumatic Stress Disorder (PTSD) Symptoms as Measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)
NCT01524133 (2) [back to overview]	Patient Health Questionnaire-15
NCT01607593 (3) [back to overview]	Clinical Global Impression of Severity (CGI-S) at Start of Administration/Observation
NCT01607593 (3) [back to overview]	Clinical Global Impression of Severity (CGI-S) at End of Administration/Observation
NCT01607593 (3) [back to overview]	Clinical Global Impression - Improvement (CGI-I) at End of Administration/Observation
NCT01703039 (5) [back to overview]	Number of Patients Experiencing an Antidepressant Response (>50% Reduction in HDRS) at Endpoint of 8 Weeks
NCT01703039 (5) [back to overview]	Number of Patients Experiencing Remission From Depression (HDRS<7) at Endpoint of 8 Weeks
NCT01703039 (5) [back to overview]	Mean Change in Clinical Global Impression (CGI) Scale From Baseline (0 Weeks) to Endpoint at 8 Weeks
NCT01703039 (5) [back to overview]	Mean Change in Hamilton Anxiety Rating Scale (HARS) Score From Baseline (0 Weeks) to Endpoint at 8 Weeks
NCT01703039 (5) [back to overview]	Mean Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline (0 Weeks) to Endpoint at 8 Weeks
NCT01794455 (2) [back to overview]	Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)
NCT01794455 (2) [back to overview]	Montgomery-Asberg Depression Rating Scale
NCT01802385 (8) [back to overview]	Center for Epidemiologic Studies in Depression (CES-D) Scale
NCT01802385 (8) [back to overview]	Event Free Survival
NCT01802385 (8) [back to overview]	Safety (Occurence of Adverse Events)
NCT01802385 (8) [back to overview]	Survival
NCT01802385 (8) [back to overview]	Fungal Clearance as Determined by Early Fungicidal Activity of CDF
NCT01802385 (8) [back to overview]	Number of Participants Experiencing IRIS OR Relapse
NCT01802385 (8) [back to overview]	Count of Participants With Cerebrospinal Fluid Sterility
NCT01802385 (8) [back to overview]	Quantitative Neurocognitive Performance Score (QNPZ-8)
NCT01896934 (3) [back to overview]	Change in Clinician-rated Depression Severity
NCT01896934 (3) [back to overview]	Remission of Depression
NCT01896934 (3) [back to overview]	Change in Patient-rated Depression Severity
NCT01916824 (1) [back to overview]	Money Earned
NCT01943435 (3) [back to overview]	Self Paced Walking Test (SPWT)
NCT01943435 (3) [back to overview]	Sense Wear Armband
NCT01943435 (3) [back to overview]	Swiss Spinal Stenosis (SSS) Questionnaire Score
NCT01993017 (3) [back to overview]	Cost of Health Care Utilization
NCT01993017 (3) [back to overview]	Depression-free Days
NCT01993017 (3) [back to overview]	Quality-Adjusted Life Years (QALYs)
NCT02137369 (2) [back to overview]	Number of Remission From Major Depressive Episode Events
NCT02137369 (2) [back to overview]	Number of Response to Treatment Events
NCT02189213 (1) [back to overview]	Clinical Global Impression-Improvement (CGI-I) Score
NCT02235064 (11) [back to overview]	Reported Infant Weight at 12 Weeks Following Delivery
NCT02235064 (11) [back to overview]	Number of Participants With Adverse Reaction to Treatment Agent up to 12 Weeks Following Discharge From Hospital
NCT02235064 (11) [back to overview]	Number of Participants With Perceived Infant Feeding Difficulties 12 Weeks Postpartum
NCT02235064 (11) [back to overview]	Number of Participants With Perceived Infant Feeding Difficulties 4 Weeks Postpartum
NCT02235064 (11) [back to overview]	Number of Participants With Perceived Infant Feeding Difficulties 8 Weeks Postpartum
NCT02235064 (11) [back to overview]	Number of Participants With Perceived Infant Sleeping Difficulty at 12 Weeks Postpartum
NCT02235064 (11) [back to overview]	Number of Participants With Development of Postpartum Depression up to 12 Weeks Following Discharge From Hospital
NCT02235064 (11) [back to overview]	Reported Infant Weight at 4 Weeks Following Delivery
NCT02235064 (11) [back to overview]	Reported Infant Weight at 8 Weeks Following Delivery
NCT02235064 (11) [back to overview]	Number of Participants With Perceived Infant Sleeping Difficulty at 4 Weeks Postpartum
NCT02235064 (11) [back to overview]	Number of Participants With Perceived Infant Sleeping Difficulty at 8 Weeks Postpartum
NCT02358343 (15) [back to overview]	Serum Phosphorus Level
NCT02358343 (15) [back to overview]	Satisfaction With Life Scale
NCT02358343 (15) [back to overview]	GAD-7
NCT02358343 (15) [back to overview]	SF-36 Energy/Vitality
NCT02358343 (15) [back to overview]	Sheehan Disability Scale
NCT02358343 (15) [back to overview]	BDI-II
NCT02358343 (15) [back to overview]	Exercise
NCT02358343 (15) [back to overview]	Global Quality of Life Scale
NCT02358343 (15) [back to overview]	Number of Participants Who Accepted Depression Treatment
NCT02358343 (15) [back to overview]	Number of Participants Who Initiated Depression Treatment
NCT02358343 (15) [back to overview]	Perceived Social Support
NCT02358343 (15) [back to overview]	Percent Inter-dialytic Weight Gain
NCT02358343 (15) [back to overview]	Percentage of Dialysis Treatment Sessions Skipped and/or Shortened
NCT02358343 (15) [back to overview]	PSQI
NCT02358343 (15) [back to overview]	QIDS-C Score
NCT02385799 (15) [back to overview]	Change in Mullen Scales of Early Learning - Combined Age Equivalent Score
NCT02385799 (15) [back to overview]	Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score
NCT02385799 (15) [back to overview]	Change in Mullen Scales of Early Learning - Expressive Language Raw Score
NCT02385799 (15) [back to overview]	Visual Analog Scale - Language/Communication Score
NCT02385799 (15) [back to overview]	Visual Analog Scale - Language/Communication Score
NCT02385799 (15) [back to overview]	Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score
NCT02385799 (15) [back to overview]	Sensory Processing Measure-Preschool - Social Participation Raw Score
NCT02385799 (15) [back to overview]	Sensory Processing Measure-Preschool - Social Participation Raw Score
NCT02385799 (15) [back to overview]	Preschool Language Scale-Fifth Edition - Total Language Raw Score
NCT02385799 (15) [back to overview]	Preschool Language Scale-Fifth Edition - Total Language Raw Score
NCT02385799 (15) [back to overview]	Preschool Anxiety Scale-Revised - Total Score
NCT02385799 (15) [back to overview]	Preschool Anxiety Scale-Revised - Total Score
NCT02385799 (15) [back to overview]	Clinical Global Impression Scale-Severity (CGI-S)
NCT02385799 (15) [back to overview]	Clinical Global Impression Scale-Improvement (CGI-I)
NCT02385799 (15) [back to overview]	Clinical Global Impression Scale-Improvement (CGI-I)
NCT02417064 (16) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02417064 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Percentage of Participants With Onset of Clinical Response by Day 2 and Day 8
NCT02417064 (16) [back to overview]	Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02417064 (16) [back to overview]	Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)
NCT02417064 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)
NCT02417064 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)
NCT02417064 (16) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02417064 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index
NCT02417064 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score
NCT02418585 (16) [back to overview]	Change From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis
NCT02418585 (16) [back to overview]	Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Percentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02418585 (16) [back to overview]	Percentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
NCT02418585 (16) [back to overview]	Percentage of Participants With Onset of Clinical Response on Day 2 and Day 8
NCT02418585 (16) [back to overview]	Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
NCT02418585 (16) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)
NCT02418585 (16) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis
NCT02422186 (8) [back to overview]	Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02422186 (8) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis
NCT02422186 (8) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): Sum Score
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): EQ-VAS
NCT02422186 (8) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis on Ranks
NCT02422186 (8) [back to overview]	Percentage of Participants in Remission (MADRS<=12) at Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
NCT02422186 (8) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) to Endpoint (Double-blind Induction Phase [Day 28]): Health Status Index
NCT02473783 (3) [back to overview]	The SERT Binding Potential (BP) --(Only the Treatment Group Was Assessed)
NCT02473783 (3) [back to overview]	Hamilton Depression Rating Scale (HAM-D) Total Scores
NCT02473783 (3) [back to overview]	Safety Assessments - the Tolerability of Injection of I-123-ADAM Solution
NCT02493868 (18) [back to overview]	Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Sheehan Disability Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Time to Relapse in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Time to Relapse in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in PHQ-9 Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Clinical Global Impression-Severity Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Sum Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level Sum Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Items (GAD-7) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)
NCT02493868 (18) [back to overview]	Change From Baseline in Generalized Anxiety Disorder-7 Items Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)
NCT02497287 (34) [back to overview]	Percentage of Participants With Response as Assessed by PHQ-9 Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Sheehan Disability Scale Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled
NCT02497287 (34) [back to overview]	Percentage of Participants With an Increase Score From Predose at Any Time in Clinician-Administered Dissociative States Scale (CADSS) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02497287 (34) [back to overview]	Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders
NCT02497287 (34) [back to overview]	Percentage of Participants With Remission as Assessed by MADRS Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Remission as Assessed by PHQ-9 Total Score During IND Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Response as Assessed by MADRS Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in GAD-7 Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Percentage of Participants With Treatment-Emergent Acute Hypertension (Systolic and Diastolic) During IND and OP/MA Phases
NCT02497287 (34) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: One Back Test (ONB) Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Identification Test (IDN) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score
NCT02497287 (34) [back to overview]	Change From Baseline in Cognitive Test Battery: Detection Test (DET) Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in Generalized Anxiety Disorder (GAD-7) Total Score During IND Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During OP/MA Phase: Sum Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During IND Phase: Sum Score
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Score During OP/MA Phase: EQ-VAS
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Score During IND Phase: EQ-VAS
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Scale Score During OP/MA Phase: Health Status Index
NCT02497287 (34) [back to overview]	Percentage of Participants With an Increase Score From Predose at Any Time in CADSS Total Score During OP/MA Phase
NCT02497287 (34) [back to overview]	Change From Baseline to Endpoint in EQ-5D-5L Scale Score During IND Phase: Health Status Index
NCT02504931 (2) [back to overview]	Percent Heavy Drinking Days
NCT02504931 (2) [back to overview]	PTSD (Post Traumatic Stress Disorder) Symptom Score From PCL (Patient Monitoring Checklist)
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02655354 (13) [back to overview]	Cognitive Impairment Scale
NCT02655354 (13) [back to overview]	Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Brief Pain Inventory
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Overall Health Care
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]	SF-36 Quality of Life
NCT02655354 (13) [back to overview]	Number of Participants With Suicidal Ideation
NCT02777372 (4) [back to overview]	Acoustic Startle Response (ASR) Magnitude Based on Menstrual Cycle Phase
NCT02777372 (4) [back to overview]	Impact of Sertraline on ASR Magnitude
NCT02777372 (4) [back to overview]	Interleukin 6 (IL-6) Level
NCT02777372 (4) [back to overview]	Tumor Necrosis Factor Alpha (TNF-alpha) Level
NCT02797808 (2) [back to overview]	CY-BOCS Total Score at 12-weeks
NCT02797808 (2) [back to overview]	Longitudinal 2-Group Resting State Functional Conectivity (RSFC) Analyses
NCT02901249 (3) [back to overview]	Number of Participants With Response to Treatment
NCT02901249 (3) [back to overview]	Quality of Life -WHOQOL Intrument Scores
NCT02901249 (3) [back to overview]	Number of Participants With Remission to Treatment
NCT02917122 (3) [back to overview]	Change of Hamilton Rating Scale for Depression Among Different Weeks
NCT02917122 (3) [back to overview]	Change of Modified-Unified Parkinson's Disease Rating Scale Among Different Weeks
NCT02917122 (3) [back to overview]	Change of Taiwanese Depression Questionnaire Among Different Weeks
NCT02918097 (3) [back to overview]	Number of Participants With Remission to Treatment
NCT02918097 (3) [back to overview]	"Number of Participants With Response to Treatment"
NCT02918097 (3) [back to overview]	Quality of Life Instrument Scores
NCT03002012 (8) [back to overview]	Number of Laboratory Grade 3-5 Adverse Events
NCT03002012 (8) [back to overview]	Adherence to Study Drug
NCT03002012 (8) [back to overview]	Prevalence of Depression by Patient Health Questionnaire (PHQ-9) Over Time
NCT03002012 (8) [back to overview]	6-month Survival
NCT03002012 (8) [back to overview]	6 Month Meningitis-free Survival
NCT03002012 (8) [back to overview]	Cumulative Incidence of Symptomatic Cryptococcal Meningoencephalitis
NCT03002012 (8) [back to overview]	All-Cause Premature Study Drug/Placebo Discontinuation
NCT03002012 (8) [back to overview]	Number of Clinical Adverse Events (Grade 3-5)
NCT03033069 (1) [back to overview]	Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5) Total Score
NCT03342963 (4) [back to overview]	Cmax of Aripiprazole and Sertraline in Cohort 2
NCT03342963 (4) [back to overview]	AUC168h of Aripiprazole and Sertraline in Cohort 2
NCT03342963 (4) [back to overview]	Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1
NCT03342963 (4) [back to overview]	Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1
NCT03434041 (12) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Percentage of Participants With Onset of Clinical Response
NCT03434041 (12) [back to overview]	Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score
NCT03434041 (12) [back to overview]	Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
NCT03434041 (12) [back to overview]	Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)
NCT03434041 (12) [back to overview]	Percentage of Participants With Sustained Remission
NCT03434041 (12) [back to overview]	Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index
NCT03434041 (12) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)
NCT03434041 (12) [back to overview]	Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)
NCT03434041 (12) [back to overview]	Percentage of Responders at the End of Double-blind Treatment Phase (Day 28)
NCT04094870 (12) [back to overview]	Number of Women With Anxiety or Depression Based on the MINI Who Agree to Participate in the Study
NCT04094870 (12) [back to overview]	Percentage of Women Experiencing Anti Depressant Medication Toxicity
NCT04094870 (12) [back to overview]	Number of Women Pre-Screened Who Have an EPDS Score >/= 6
NCT04094870 (12) [back to overview]	Number of Women Retained in the Study
NCT04094870 (12) [back to overview]	Number of Women Approached Who Agreed to Pre-Screening With EPDS
NCT04094870 (12) [back to overview]	Acceptability of Trial Participation for Treatment of Postpartum Depression
NCT04094870 (12) [back to overview]	Percentage of Women Who Adhere to the Prescribed Antidepressant Medication (ADM)
NCT04094870 (12) [back to overview]	Changes in the Viral Load Between Study Entry and the Last Visit
NCT04094870 (12) [back to overview]	Number of Women Who Adhere to the Interpersonal Therapy Arm (IPT)
NCT04094870 (12) [back to overview]	Number of Women With a CGI Score Decline of One Point From Baseline
NCT04094870 (12) [back to overview]	Number of Women With an EPDS >/= to 6 Who Were Consented and Underwent Diagnostic Testing With MINI
NCT04094870 (12) [back to overview]	Number of Women With an EPDS Score Decline of 3 Points From Baseline
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Over the Double-Blind Treatment Period
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Remission at Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With TEAEs, Graded by Severity
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Response at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in HAM-A Total Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in Depressive Symptoms at Day 15, as Assessed by PHQ-9
NCT04476030 (16) [back to overview]	Change From Baseline in CGI-S Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Day 3
NCT04476030 (16) [back to overview]	Change From Baseline in MADRS Total Score at Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04476030 (16) [back to overview]	Time to First HAMD-17 Response
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Remission at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Days 15 and 42
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Response at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Percentage of Participants With CGI-I Response, at Day 3 and Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Around End of Blinded Treatment

HAMILTON Rating Scale for DEPRESSION Range

Hamilton scale range 0-40, values below 7 are considered normal. the higher the number the more severe the depression weekly assessments, The primary outcome is a comparison of the baseline Hamilton to the 12 week measurement (NCT00000378)
Timeframe: BASELINE COMPARED TO 12 WEEK MEASUREMENT

Intervention	units on a scale (Mean)
	BASELINE	12 WEEK DATA
Nortriptyline	27.1	8.4
Sertaline	27.3	10.7

Intervention	units on a scale (Mean)
	Initial HRSD-17	Mid-treatment HRSD-17	LOCF HRSD-17
1 Sertraline	19.0	13.9	14.2
2 Supportive-expressive Psychotherapy	19.9	12.5	14.5
3 Pill Placebo	19.4	12.7	14.3

Intervention	percentage of participants (Number)
1 Setraline	54.9
2 CBT	59.7
3 Combination Setraline and CBT	80.7
4 Placebo	23.7

Intervention	percentage of participants (Number)
	Cardiovascular Status Worsened	Cardiovascular Status Improved	Cardiovascular Status Unchanged
Placebo	31.1	43.8	25.1
Sertraline	29.9	40.6	29.5

Intervention	participants (Number)
	"much worse"	"worse"	"a bit worse"	"no change"	"a bit better"	"better"	"much better"
Placebo	0	2	9	11	18	21	3
Sertraline	1	5	6	10	18	18	9

Intervention	units on a scale (Mean)
Sertraline Plus Omega-3 Supplement	16.1
Sertraline/Corn Oil	14.8

Intervention	Points on a scale (Mean)
Medication Optimization	3.78
Augmented Cognitive Behavior Therapy	2.9

Intervention	units on a scale (Mean)
CBT no Choice	10.33
CBT Choice	12.13
Sertraline no Choice	15.24
Sertraline Choice	12.11

Intervention	units on a scale (Mean)
CBT no Choice	10.02
CBT Choice	10.87
Sertraline no Choice	15.12
Sertraline Choice	10.78

Intervention	units on a scale (Mean)
CBT no Choice	8.82
CBT Choice	11.68
Sertraline no Choice	14.06
Sertraline Choice	10.78

Intervention	units on a scale (Mean)
NoChoice_CBT	39.16
Choice_CBT	38.79
NoChoice_SER	46.89
Choice_SER	38.72

Intervention	seizures (Median)
	Baseline (retrospective 2 weeks prior)	Week 2 (prospectively collected from day 1-14)	Week 4	Week 6	Week 8	Week 10	Week 12
Placebo	6.0	6.0	5.0	3.0	3.0	7.0	6.0
Sertraline	5.0	3.0	2.0	1.0	1.0	2.5	0.0

Intervention	units on a scale (Mean)
	Beginning of Study Phase	End of Study Phase
Open Label Phase	44.0	31.2
Randomization Phase for Placebo Group	31.8	24.6
Randomization Phase for Ziprasidone Group	31.8	21.0

Intervention	Spectroscopic Index (Least Squares Mean)
	bNTP	PCr	Total NTP
Depressed (Baseline)	.0397	.0512	.1420
Healthy Controls (Baseline)	.0432	.0496	.1509
Post-treatment Depressed	.0410	.0515	.1396

Intervention	Days/Week (Mean)
	Baseline	End-of-treatment	6-month	12-month
1) Seeking Safety + Sertraline	3.13	1.05	.86	0.30
2) Seeking Safety + Placebo	2.89	0.48	0.75	0.24

Intervention	units on a scale (Mean)
Sertraline and Clonazepam	27
Venlafaxine	18
Sertraline and Placebo	16

Intervention	pg/ml (Mean)
	Baseline	16 Week
Placebo Control	1.95	1.85
Sertraline (Zoloft)	1.7	2.1
Supervised Aerobic Exercise	1.98	1.80

Intervention	millisecond (Mean)
	Baseline	16 Weeks
Placebo Control	123	112
Sertraline (Zoloft)	120	118
Supervised Aerobic Exercise	116	122

Intervention	Raw changes in Ham-D scores (Mean)
Supervised Aerobic Exercise	-7.5
Sertraline (Zoloft)	-6.1
Placebo Control	-4.5

Intervention	msec/mmHg (Mean)
	Baseline	Week 16
Placebo Control	4.9	4.1
Sertraline (Zoloft)	4.7	5.1
Supervised Aerobic Exercise	4.8	4.0

Intervention	participants (Number)
	Nausea	Diarrhea	Headache	Insomnia	Fatigue	Mouth dryness	Difficulty concentrating	Anxiety, agitation	Diaphoresis	Dizziness/lightheadedness
Placebo	35	22	14	22	15	13	8	10	6	9
Sertraline	15	14	19	9	14	5	9	6	10	6

sertraline

Description

Cross-References

Synonyms (98)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (3)

Protein Targets (73)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (348)

Molecular Functions (126)

Ceullar Components (72)

Bioassays (248)

Research

Studies (3,207)

Market Indicators

Research Demand Index: 133.13

Study Types

Clinical Trials (300)

Trial Overview

Trial Outcomes

HAMILTON Rating Scale for DEPRESSION Range

Hamilton Rating Scale for Depression-17 Item

Clinical Global Impression - Improvement Scale

Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial

Scores on CGI-S Compared to Baseline Over the Course of the Trial

Mean Score Hamilton Depression Rating Scale (Ham-D) Over the Course of the Trial From Week to Week.

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

Symptoms of Depression in Congestive Heart Failure Patients With Clinical Depression After Treatment With Sertraline or Placebo

Percentage of Cardiac Events and Morbidity / Mortality, Including Rehospitalization, in Congestive Heart Failure Patients With Depression After Treatment With Sertraline or Placebo.

Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC)

Remission According to Cornell Scale for Depression in Dementia Scale

Beck Depression Inventory-II

Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6)

Change in Panic Disorder Symptoms, Phase 3 (Week 12 - Week 24)

Change in Panic Disorder Symptoms, Phase 2 (Week 6 - Week 12)

Depression Symptoms

PTSD Symptoms

Quality of Life Functioning

State Anxiety

Davidson Trauma Scale (DTS)

Dissociative Experiences Scale (DES)

Global Assessment of Functioning (GAF)

Longitudinal Interval Follow-Up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)

Modified Hamilton Depression Scale (MHRS)

Number of Nonepileptic Seizures (NES)

Oxford Handicap Scale (OHS)

Symptom Checklist 90 (SCL-90)

Clinical Global Impressions - Improvement (CGI-I)

Family Assessment Device (FAD)

Barratt Impulsivity Scale (BIS)

Beck Depression Inventory-II (BDI-II)

Quality of Life in Epilepsy-31 (QOLIE-31)

Clinical Global Impressions - Severity (CGI-S)

Diagnostic Interview for Children and Adolescents (DICA) - Child

The Child Depression Inventory (CDI)

Diagnostic Interview Schedule for Children and Adolescents (DICA) - Parent

Brief Social Phobia Scale(BSPS)

BAI

Life-3

Depression at End of Treatment

Depression at Baseline

Geriatric Depression Scale

Phosphorus Magnetic Resonance Spectroscopy (31P-MRS)

HAM-D 17 (Hamilton Depression Rating Scale)

Heavy Drinking Days/Week

PTSD Symptom Severity / Clinician Administered PTSD Scale

Post-treatment Social Phobia Severity as Defined by Endpoint LSAS Scores

Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders

Intervention	units on a scale (Mean)
	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Average change from Cycle 1
Placebo	3.2	2.7	2.4	2.5	2.1	2.2	-0.8
Sertraline	2.7	2.4	2.3	2.1	2.0	1.8	-0.9

Intervention	units on a scale (Mean)
	Baseline	Post-Treatment	3-Month Follow-up	6-Month Follow-up
1 (Placebo)	2.7	2.4	2.3	2.3
2 (Sertraline)	2.7	2.2	2.1	2.1
3 (IPT)	2.6	2.3	2.3	2.2

Intervention	events (Number)
	Erectile dysfunction	Dissociative disorder	Completed suicide
Sertraline Hydrochloride	2	1	1

Intervention	participants (Number)
Without Past Medical History of Other Illness	28
With Past Medical History of Other Illness	16

Intervention	participants (Number)
Past History of Intentional Suicidal Ideation	29
Present History of Intentional Suicidal Ideation	63

Intervention	participants (Number)
With Non-pharmaceutical Therapies	141
Without Non-pharmaceutical Therapies	255

Intervention	participants (Number)
Under 18 Years of Age	23
18-44 Years of Age	829
45-64 Years of Age	412
Over 65 Years of Age	245

Intervention	participants (Number)
With Suicidal Ideation (Including Suicide Attempt)	73
Without Suicidal Ideation (Including Suicide Attempt)	182

Intervention	participants (Number)
<25mg	6
>=25mg, <50mg	175
>=50mg, <75mg	61
>=75mg, <100mg	20
>=100mg	1

Intervention	participants (Number)
With History of Treatment Prior to Sertraline	398
Without History of Treatment Prior to Sertraline	1046